research paper for blood cancer

Blood Cancers and Research Progress

LLS has invested over $1.5 billion in cancer research since our founding in 1949, leading to nearly every advancement in blood cancer treatment and breakthroughs in immunotherapy, genomics and personalized medicine.

Our support of pioneering research at nearly 100 medical institutions worldwide is breaking new ground in the fight against cancer.

Image source: the LLS Annual Report

See our impact across all the disease areas we fund:

Leukemia Research Funded by LLS

Nearly every breakthrough in cancer treatment has emerged from our support of leukemia research, from chemotherapy to groundbreaking CAR T-cell immunotherapy. With more than $65 million committed to leukemia research, we are leading the way to cures.

Lymphoma Research Funded by LLS

Our investment in lymphoma research has led to significant advances, such as rituximab (Rituxan®) and innovative immunotherapy, such as the first first chimeric antigen receptor (CAR) T-cell-therapy approved by the FDA for lymphoma patients: axicabtagene ciloleucel (Yescarta®). Our current lymphoma research commitment exceeds $73 million, so we can continue to bring promising new treatments to patients.

Multiple Myeloma Research Funded by LLS

LLS is a leading funder of visionary myeloma research, and this investment has led to many approved therapies for patients in recent years. While progress has been made, our work continues. We have committed more than $31 million to myeloma research to find cures.

Myelodysplastic Syndrome (MDS) Research Funded by LLS

We are supporting advanced genomics and molecular research to understand the causes of MDS and improve diagnosis and treatment. LLS is funding nearly 30 active grants in MDS research worldwide.

Myeloproliferative Neoplasms (MPN) Research Funded by LLS

LLS is collaborating with the MPN Research Foundation to develop therapies for polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) – the group of blood cancers collectively known as myeloproliferative neoplasms.

Leukemia Research Results and Study Updates

See Advances in Leukemia Research for an overview of recent findings and progress, plus ongoing projects supported by NCI.

Treatment options for people with acute myeloid leukemia (AML) have expanded yet again. On July 20, FDA approved quizartinib (Vanflyta) combined with chemotherapy as a first-line treatment for AML with a specific change in the FLT3 gene.

Giving the drug blinatumomab (Blincyto) after standard chemotherapy substantially increased survival for infants with an aggressive form of acute lymphoblastic leukemia (ALL), a recent study showed. If confirmed in larger studies, the treatment may become standard therapy for infants with ALL caused by KMT2A rearrangements.

Treatment with revumenib caused complete remission in about one-third of participants in an early-phase clinical trial involving patients who’d had many prior treatments. Revumenib is part of a new class of targeted drugs known as menin inhibitors.

An NCI-funded clinical trial has shown that treatment-related early deaths in people with a rare leukemia can be dramatically reduced. How did they do it? In part, by establishing a help desk staffed by experts in treating APL.

FDA has approved zanubrutinib (Brukinsa) for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) based on results from two clinical trials. In both trials, the drug, which blocks a protein called BTK, was more effective and caused fewer side effects than other treatments.

The immunotherapy drug blinatumomab (Blincyto) extends life for people with acute lymphoblastic leukemia who are in remission, even those with no signs of disease after initial treatment, a trial has found.

For some people with acute myeloid leukemia (AML) that has a mutation in the IDH1 gene, combining ivosidenib (Tibsovo) with the chemotherapy drug azacitidine may be a new treatment option, according to results from a large clinical trial.

Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.

A Children’s Oncology Group trial shows that the combination of all-trans retinoic acid and arsenic trioxide is highly effective in children with acute promyelocytic leukemia. The therapy avoids or minimizes the use of conventional chemotherapy.

The CAR T-cell therapy Tecartus has become the first such treatment approved by FDA to treat adults with acute lymphoblastic leukemia (ALL). The approval is for patients whose cancer has not responded to treatment or returned after treatment.

FDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.

FDA has approved a new form of asparaginase called Rylaze. The drug was developed to help alleviate shortages of Erwinia asparaginase, a key part of treatment for children and adults with acute lymphoblastic leukemia.

In a small study, vemurafenib (Zelboraf) and rituximab (Rituxan) helped 85% of participants stay in remission for nearly 3 years. The study involved 30 people with hairy cell leukemia that had come back after or had not responded to previous treatment.

People with blood cancers seem to be less protected by COVID-19 vaccines than those with other cancers and people without cancer, three new studies suggest. Experts believe this limited effectiveness is likely due to patients’ weakened immune systems.

For people with acute myeloid leukemia and related cancers, a new study shows whole-genome sequencing could replace a series of conventional tests used to help guide decisions about treatment.

The results of two trials establish blinatumomab (Blincyto) as a new standard treatment for children and young adults with high-risk relapsed B-cell acute lymphoblastic leukemia after remission has been achieved and before a stem cell transplant.

For adults with CML who are in a sustained deep molecular remission, stopping treatment with a tyrosine kinase inhibitor is safe and improves their quality of life, a study shows. But researchers cautioned that these patients must be closely monitored.

Two rediscovered drugs, bisantrene and brequinar, slowed the growth of acute myeloid leukemia in studies of mice. The drugs blocked the activity of a protein called FTO, killing cancer stem cells and helping the immune system attack the cancer.

Maintenance therapy with CC-486 extended overall survival of adults with the blood cancer acute myeloid leukemia (AML) in a large clinical trial. CC-486 is a pill form of another cancer therapy called azacitidine (Vidaza).

For children and young adults with certain relapsed B-cell acute lymphoblastic leukemia (B-ALL), the immunotherapy drug blinatumomab is superior to standard chemotherapy, an NCI-sponsored Children’s Oncology Group trial shows.

People with relapsed or refractory acute myeloid leukemia (AML) with FLT3 gene mutations treated with gilteritinib had improved survival, higher rates of remission, and fewer side effects than those treated with chemotherapy, a recent trial found.

Only 1.5% of children with acute lymphoblastic leukemia who skipped radiation had a recurrence in the central nervous system, according to a recent trial. The therapy, which is intended to prevent such a recurrence, can have devastating side effects.

The Food and Drug Administration has approved venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) for the initial treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.

New findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).

In this trial, patients with hairy cell leukemia who have disease-related symptoms that require treatment, and who have not been treated or have had only one prior treatment with cladribine, will be randomly assigned to receive cladribine with either concurrent rituximab or rituximab at least 6 months after completing cladribine therapy.

A clinical trial found that an intensive treatment regimen developed specifically for children with acute lymphoblastic leukemia is also effective for older adolescents and young adults with the disease.

FDA has approved venetoclax (Venclexta) and glasdegib (Daurismo) for use in people with acute myeloid leukemia aged 75 and older and those with health conditions that prevent them from receiving the intensive chemotherapy regimen that is the standard initial treatment.

Two new studies show how the drugs venetoclax (Venclexta) and azacitidine (Vidaza) team up to block the unique metabolism of leukemia stem cells and may explain why the drug combination is effective against acute myeloid leukemia.

A clinical trial showed that ibrutinib plus rituximab is superior to standard treatment for patients age 70 and younger with untreated chronic lymphocytic leukemia (CLL). Findings were announced at the American Society of Hematology annual meeting.

The FDA has approved moxetumomab pasudotox (Lumoxiti), a bacterial toxin–based drug, for the treatment of some patients with hairy cell leukemia (HCL). Moxetumomab is approved to treat patients with HCL who have already undergone at least two lines of standard treatments.

The FDA has approved ivosidenib (Tibsovo) for the treatment of adults with acute myeloid leukemia (AML) that has a specific mutation in a gene called IDH1. Ivosidenib becomes the first FDA-approved IDH1-targeted treatment.

FDA expanded the approval of venetoclax (Venclexta) for people with chronic lymphocytic leukemia (CLL) to include those whose cancer has progressed after previous treatment, regardless of whether their cancer cells have the deletion 17p gene alteration.

This NCI-funded Children’s Oncology Group trial tested the addition of nelarabine (Arranon) to standard treatment for children and young adults with T-cell acute lymphoblastic leukemia (T-ALL).

People diagnosed with hairy cell leukemia (HCL) may have an effective new treatment option, a type of drug called an immunotoxin. Read more about how this treatment, moxetumomab pasudotox, fared in a phase 3 clinical trial in patients with advanced HCL.

A new study has identified a possible strategy for improving the efficacy of a toxin-based cancer treatment, moxetumomab pasudotox, in some patients with acute lymphoblastic leukemia (ALL).

An NCI-funded study has found significant differences in the genetics of acute myeloid leukemia in younger and older patients. The findings could help guide the development of treatments tailored specifically for childhood AML.

On December 22, FDA approved an update to the label of nilotinib (Tasignia) that states that some patients with CML who are taking nilotinib and whose cancer has been in remission for an extended period can safely stop taking it.

Interim results from an ongoing clinical trial show that patients with relapsed or refractory chronic lymphocytic leukemia treated with rituximab plus venetoclax have longer progression-free survival compared with patients treated with chemotherapy.

In a unique clinical trial, a group of oncologists with experience treating acute promyelocytic leukemia are making themselves available around the clock to help clinicians at hospitals across the country treat their APL patients.

On November 9, the FDA approved dasatinib (Sprycel®) for the treatment of children with chronic myelogenous leukemia (CML) whose cancer cells express the Philadelphia chromosome and whose disease is in a relatively early stage, known as the chronic phase.

FDA has approved gemtuzumab ozogamicin (Mylotarg™) for adults with newly diagnosed CD33-positive AML and patients 2 years and older with CD33-positive AML who have experienced a relapse or whose disease has not responded to initial treatment.

FDA has approved inotuzumab (Besponsa®) for some adults with B-cell acute lymphoblastic leukemia (ALL). The approval covers patients with B-cell ALL whose disease has relapsed or is refractory to standard chemotherapy.

FDA has approved tisagenlecleucel (Kymriah™), a type of immunotherapy called CAR T-cell therapy, for some children and young adults with advanced acute lymphoblastic leukemia (ALL).

FDA has approved two new treatments for some adult patients with acute myeloid leukemia (AML): enasidenib (Idhifa®), which targets the IDH2 protein; and liposomal cytarabine-daunorubicin CPX-351 (Vyxeos®), a two-drug chemotherapy combination encapsulated in liposomes.

FDA changed its accelerated approval of blinatumomab (Blincyto) for some patients with acute lymphoblastic leukemia to a full approval and expanded the approved indications for its use.

The FDA has approved a new formulation of rituximab, Rituxan Hycela, that reduces treatment administration time for patients with several types of blood cancer.

The FDA has approved midostaurin for patients with newly diagnosed acute myeloid leukemia (AML) with mutations in the FLT3 gene. The approval also covers several rare conditions.

Results from a large phase III clinical trial suggest that a highly intensive preparatory regimen should be used for younger patients with acute myeloid leukemia or myelodysplastic syndromes preparing to undergo an allogeneic stem cell transplant.

Patients with previously treated acute lymphoblastic leukemia who received blinatumomab, which encourages the immune system to kill cancer cells, lived longer and experienced fewer side effects than patients given standard chemotherapy.

Blood Cancer Detection using Machine Learning

Ieee account.

• Change Username/Password
• Update Address

Purchase Details

• Payment Options
• Order History
• View Purchased Documents

Profile Information

• Communications Preferences
• Profession and Education
• Technical Interests
• US & Canada: +1 800 678 4333
• Worldwide: +1 732 981 0060
• Contact & Support
• About IEEE Xplore
• Accessibility
• Terms of Use
• Nondiscrimination Policy
• Privacy & Opting Out of Cookies

A not-for-profit organization, IEEE is the world's largest technical professional organization dedicated to advancing technology for the benefit of humanity. © Copyright 2024 IEEE - All rights reserved. Use of this web site signifies your agreement to the terms and conditions.

• Alzheimer's disease & dementia
• Arthritis & Rheumatism
• Attention deficit disorders
• Autism spectrum disorders
• Biomedical technology
• Diseases, Conditions, Syndromes
• Endocrinology & Metabolism
• Gastroenterology
• Gerontology & Geriatrics
• Health informatics
• Inflammatory disorders
• Medical economics
• Medical research
• Medications
• Neuroscience
• Obstetrics & gynaecology
• Oncology & Cancer
• Ophthalmology
• Overweight & Obesity
• Parkinson's & Movement disorders
• Psychology & Psychiatry
• Radiology & Imaging
• Sleep disorders
• Sports medicine & Kinesiology
• Vaccination
• Breast cancer
• Cardiovascular disease
• Chronic obstructive pulmonary disease
• Colon cancer
• Coronary artery disease
• Heart attack
• Heart disease
• High blood pressure
• Kidney disease
• Lung cancer
• Multiple sclerosis
• Myocardial infarction
• Ovarian cancer
• Post traumatic stress disorder
• Rheumatoid arthritis
• Schizophrenia
• Skin cancer
• Type 2 diabetes
• Full List »

share this!

May 15, 2024

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

Scientists discover blood proteins that may give cancer warning seven years before diagnosis

by Cancer Research UK

Two studies from Oxford Population Health have discovered proteins in the blood that could warn people of cancer more than seven years before it is diagnosed.

Scientists identified 618 proteins linked to 19 different types of cancer , including 107 proteins in a group of people who blood was collected at least seven years before diagnosis. The team has discovered that these proteins could be involved at the very earliest stages of cancer, where it could be prevented.

They believe that some of these proteins could be used to detect cancer much earlier than is currently possible. In the future, this could help treat the disease at a much earlier stage or prevent it altogether.

The papers, titled "Identifying proteomic risk factors for cancer using prospective and exome analyses of 1,463 circulating proteins and risk of 19 cancers in the UK Biobank" and "Identifying therapeutic targets for cancer among 2,074 circulating proteins and risk of nine cancers," are published in Nature Communications .

In these studies, the team used a powerful technique called proteomics. Proteomics allows scientists to analyze a large set of proteins in tissue samples at a single point in time, to see how they interact with each other and find any important differences in proteins between different tissue samples.

In the first study, scientists analyzed blood samples from UK Biobank that had been taken from more than 44,000 people, including over 4,900 people who subsequently had a cancer diagnosis.

Using proteomics, the team analyzed a set of 1,463 proteins from a single sample of blood from each person. They compared the proteins of people who did and did not go on to be diagnosed with cancer to look for important differences between them and find out which ones were linked to cancer risk. The scientists also identified 182 proteins that differed in the blood three years before a cancer diagnosis took place.

In the second study, the scientists looked at genetic data from over 300,000 cancer cases to do a deep dive into which blood proteins were involved in cancer development and could be targeted by new treatments.

The scientists found 40 proteins in the blood that influenced someone's risk of getting 9 different types of cancer. While altering these proteins may increase or decrease the chances of someone developing cancer, the scientists also found that in some cases this may lead to unintended side effects.

However, the team stressed that they will need to do further research to find out the exact role these proteins play in cancer development, which of the proteins are the most reliable ones to test for, which tests could be developed to detect the proteins in the clinic, and which drugs could target these proteins.

Dr. Keren Papier, Senior Nutritional Epidemiologist at Oxford Population Health and joint first author of the first study, said, "To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease. Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer. Now we need to study these proteins in depth to see which ones could be reliably used for prevention."

Dr. Joshua Atkins, Senior Genomic Epidemiologist at Oxford Population Health and joint first author of the first study, added, "The genes we are born with, and the proteins made from them, are hugely influential in how cancer starts and grows. Thanks to the thousands of people who gave blood samples to UK BioBank, we are building a much more comprehensive picture of how genes influence cancer development over many years."

"We've predicted how the body might respond to drugs that target specific proteins, including many potential side effects. Before any clinical trials take place, we have some early indications of which proteins we might avoid targeting because of unintended side effects," continued Dr. Karl Smith-Byrne, Senior Molecular Epidemiologist at Oxford Population Health and a senior author of the first paper and first author of the second study. "This research brings us closer to being able to prevent cancer with targeted drugs—once thought impossible but now much more attainable."

Professor Ruth Travis, Senior Molecular Epidemiologist at Oxford Population Health and a senior author of both studies, observed, "To be able to prevent cancer, we need to understand the factors driving the earliest stages of its development. These studies are important because they provide many new clues about the causes and biology of multiple cancers, including insights into what's happening years before a cancer is diagnosed.

"We now have technology that can look at thousands of proteins across thousands of cancer cases, identifying which proteins have a role in the development of specific cancers, and which might have effects that are common to multiple cancer types."

"Preventing cancer means looking out for the earliest warning signs of the disease. That means intensive, painstaking research to find the molecular signals we should pay closest attention to," noted Dr. Iain Foulkes, Executive Director of Research and Innovation at Cancer Research UK. "Discoveries from this research are the crucial first step towards offering preventative therapies which is the ultimate route for giving people longer, better lives, free from the fear of cancer."

Karl Smith-Byrne et al, Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers, Nature Communications (2024). DOI: 10.1038/s41467-024-46834-3

Explore further

Feedback to editors

Modular communicative leadless ICD found to be safe and exceeds performance expectations

20 hours ago

Creativity and humor shown to promote well-being in older adults via similar mechanisms

Sweet taste receptor affects how glucose is handled metabolically by humans

22 hours ago

Better medical record-keeping needed to fight antibiotic overuse, studies suggest

May 18, 2024

Repeat COVID-19 vaccinations elicit antibodies that neutralize variants, other viruses

A long-term ketogenic diet accumulates aged cells in normal tissues, new study shows

May 17, 2024

Gut bacteria enhance cancer immunotherapy in mouse study

Research finds the protein VISTA directly blocks T cells from functioning in immunotherapy

Study opens the door to designing therapies to improve lung development in growth-restricted fetuses

Researchers make strides in microbiome-based cancer therapies via iron deprivation in the tumor microenvironment

Related stories.

New potential avenues for cancer therapies through RNA-binding proteins

Apr 24, 2024

Proteins in milk and blood could one day let doctors detect breast cancer earlier, and save lives

Mar 16, 2024

Researchers identify biomarkers in blood to predict liver cancer

May 1, 2024

Weight loss intervention in people with type 2 diabetes influences cancer-associated proteins

Jan 30, 2024

Sex-specific panel of 10 proteins can detect 18 different early-stage cancers

Jan 9, 2024

Study identifies new way to study proteins involved in breast cancer

Feb 13, 2024

Recommended for you

Novel genetic mechanisms may serve as therapeutic target against glioma

Research team develops new AI tool to help classify brain tumors

Researchers discover new pathway to cancer cell death from chemotherapy

May 16, 2024

Let us know if there is a problem with our content

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form . For general feedback, use the public comments section below (please adhere to guidelines ).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

E-mail the story

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Newsletter sign up

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

More information Privacy policy

Donate and enjoy an ad-free experience

We keep our content available to everyone. Consider supporting Science X's mission by getting a premium account.

E-mail newsletter

We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Cancer Research

Stay up to date on the topics that matter to you

Blood Proteins Could Give Cancer Warning Seven Years Before Diagnosis

These proteins could be involved at the very earliest stages of cancer..

Complete the form below to unlock access to ALL audio articles.

Proteins linked to cancer can start appearing in people’s blood more than seven years before they’re diagnosed, our funded researchers have found. In the future, it’s possible doctors could use these early warning signs to find and treat cancer much earlier than they’re able to today.   

Across two studies, researchers at  Oxford Population Health  identified 618 proteins linked to 19 different types of cancer, including 107 proteins in a group of people whose blood was collected at least seven years before they were diagnosed.  

The findings suggest that these proteins could be involved at the very earliest stages of cancer. Intercepting them could give us a way to stop the disease developing altogether.  

Want more breaking news?

Subscribe to Technology Networks ’ daily newsletter, delivering breaking science news straight to your inbox every day.

For now, though, we need to do further research. The team want to find out more about the roles these proteins play in cancer development, how we can use tests to spot the most important ones, and which drugs we can use to stop them driving cancer.

Comparing blood samples with proteomics

B oth studies, published today in  Nature Communications , used a powerful technique called proteomics to  find  important differences  in blood samples between people  who did and did not go on to develop cancer.  

To be able to prevent cancer, we need to understand the factors driving the earliest stages of its development. These studies are important because they provide many new clues about the causes and biology of multiple cancers, including insights into what’s happening years before a cancer is diagnosed. We now have technology that can look at thousands of proteins across thousands of cancer cases, identifying which proteins have a role in the development of specific cancers, and which might have effects that are common to multiple cancer types.

Their analysis of 1,463 proteins in each sample revealed 107 that changed at least seven years before a cancer diagnosis and 182 that changed at least three years before a cancer diagnosis.  

In the  second study , the scientists looked at genetic data from over 300,000 cancer cases to do a deep dive into which blood proteins were involved in cancer development and could be targeted by new treatments.    

This time, they found 40 proteins in the blood that influence someone’s risk of getting nine different types of cancer. While altering these proteins may increase or decrease the chances of someone developing cancer, more research is needed to make sure targeting them with drugs doesn’t cause unintended side effects.   

Preventing cancer means looking out for the earliest warning signs of the disease. That means intensive, painstaking research to find the molecular signals we should pay closest attention to. Discoveries from this research are the crucial first step towards offering preventive therapies, which is the ultimate route for giving people longer, better lives, free from the fear of cancer.

References:

1. Papier K, Atkins JR, Tong TYN, et al. Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank. Nat Comm . 2024;15(1):4010. doi:  10.1038/s41467-024-48017-6

2. Smith-Byrne K, Hedman Å, Dimitriou M, et al. Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers. Nat Comm . 2024;15(1):3621. doi:  10.1038/s41467-024-46834-3

This article has been republished from the following materials . Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here .

Blood test spots cancer seven years earlier – and could help prevent it

A major breakthrough could allow cancer to be detected seven years earlier than it is today using a simple blood test.

Researchers hope in future it could not only allow earlier detection and treatment , but could help prevent the disease altogether.

Two Cancer Research UK-funded studies have discovered proteins in the blood that could warn people of cancer long before current diagnosis allows.

Oxford University scientists identified 618 proteins linked to 19 different types of cancer, including 107 proteins in a group of people whose blood was collected at least seven years before diagnosis.

The research team have discovered the proteins could be involved at the very earliest stages of cancer, where it could be prevented and could be used to detect cancer much earlier than is currently possible. 

The team say the breakthrough could help treat the disease at a much earlier stage – or even prevent it altogether. 

The researchers used a powerful technique called proteomics which allows them to analyse a large set of proteins in tissue samples at a single point in time. 

This provides an insight into how they interact with each other and find any important differences in proteins between different tissue samples.

In the first study, scientists analysed blood samples taken from more than 44,000 British people, including more than 4,900 people who were afterwards diagnosed with cancer.

Using proteomics, the researchers analysed a set of 1,463 proteins from a single sample of blood from each person. 

The team compared the proteins of people who did and did not go on to develop cancer to look for differences between them and find out which ones were linked to the risk of cancer. 

The researchers also identified 182 proteins that differed in the blood three years before a cancer diagnosis took place.

Senior author of both studies Professor Ruth Travis said: ‘We now have technology that can look at thousands of proteins across thousands of cancer cases, identifying which proteins have a role in the development of specific cancers, and which might have effects that are common to multiple cancer types.’

In the second study, the team looked at genetic data from more than 300,000 cancer cases to do a ‘deep dive’ into which blood proteins were involved in cancer development and could be targeted by new treatments.

They found 40 proteins in the blood that influenced someone’s risk of getting nine different types of cancer. 

While altering the proteins may increase or decrease the chances of someone developing cancer, the researchers also found that in some cases this may lead to unintended side-effects.

Dr Keren Papier, joint first author of the first study, said: ‘To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease. 

‘Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer. 

‘Now we need to study these proteins in depth to see which ones could be reliably used for prevention.’

However, the team says further research is needed to find out the exact role the proteins are the most reliable ones to test for, what tests could be developed to detect the proteins, and which drugs could target the proteins.

Dr Karl Smith-Byrne, senior author of the first paper and first author of the second study, said: ‘We’ve predicted how the body might respond to drugs that target specific proteins, including many potential side-effects. 

‘Before any clinical trials take place, we have some early indications of which proteins we might avoid targeting because of unintended side-effects.’

‘This research brings us closer to being able to prevent cancer with targeted drugs – once thought impossible but now much more attainable.’

Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: ‘That means intensive, painstaking research to find the molecular signals we should pay closest attention to.

‘Discoveries from this research are the crucial first step towards offering preventative therapies which is the ultimate route for giving people longer, better lives, free from the fear of cancer.’

The findings were published in the journal Nature Communications.

Get your need-to-know latest news, feel-good stories, analysis and more by signing up to Metro's News Updates newsletter

More From Forbes

Blood test could detect cancer up to seven years earlier.

• Share to Facebook
• Share to Twitter
• Share to Linkedin

Cancer could be detected up to seven years before it is currently diagnosed, according to new ... [+] research.

A cocktail of proteins in the blood could indicate the presence of cancer several years before it can currently be diagnosed, according to newly published research.

The presence of these proteins might enable earlier detection of multiple different types of cancer and even eventually lead to targeted treatments to prevent cancer from developing, suggest two studies published in the journal Nature Communications , both led by researchers from the University of Oxford's population health department.

In the first study , the researchers analyzed blood samples from over 44,000 participants from the U.K. Biobank cohort, including from almost 5,000 people later diagnosed with cancer. They used an analysis technique called proteomics, which generates vast quantities of data and uses machine learning to detect changes in proteins in biological samples.

The team compared blood proteins in people who did and did not go on to develop cancer. They focused on 19 types of cancer and scrutinized 1,461 proteins, discovering that 618 of these proteins showed significant association with cancer presence.

Strikingly, 107 of these proteins were detectable in blood samples collected from individuals up to seven years before their cancer diagnoses and 182 proteins had changed at least three years before a cancer diagnosis, leading to the possibility of detecting the disease much earlier than current, traditional methods.

"To be able to prevent cancer, we need to understand the factors driving the earliest stages of its development," said Professor Ruth Travis, a senior molecular epidemiologist at the University of Oxford, who worked on both studies. "These studies are important because they provide many new clues about the causes and biology of multiple cancers, including insights into what’s happening years before a cancer is diagnosed.”

When Does ‘Bridgerton’ Season 3, Part 2 Come Out On Netflix? See The Release Schedule

A storm of 3 000 ukrainian bomblets blew up four russian jets at their base in crimea, samsung galaxy s24 series users really want to turn off one of its best features.

The second study looked at a database of genetic data from 300,000 cancers to find out more about which specific proteins are associated with cancer development and found 40 proteins which were associated with the development of at least one of nine types of cancer, including 21 proteins that were associated with a higher risk of breast cancer development.

Of the 40 proteins found to be associated with at least one type of cancer, 18 of these are already targeted by existing drugs, raising the possibility of being able to not only detect, but treat cancers earlier, sometimes several years before they are traditionally diagnosed.

"Preventing cancer means looking out for the earliest warning signs of the disease. That means intensive, painstaking research to find the molecular signals we should pay closest attention to," said Iain Foulkes, Ph.D., executive director of research and innovation at Cancer Research U.K., who funded the work. "Discoveries from this research are the crucial first step towards offering preventive therapies, which is the ultimate route for giving people longer, better lives, free from the fear of cancer."

However, the researchers urge caution, noting that targeting these proteins with drugs in otherwise seemingly healthy individuals could cause side-effects and that more research is needed to evaluate this.

• Editorial Standards
• Reprints & Permissions

Join The Conversation

One Community. Many Voices. Create a free account to share your thoughts. 

Forbes Community Guidelines

Our community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.

In order to do so, please follow the posting rules in our site's  Terms of Service.   We've summarized some of those key rules below. Simply put, keep it civil.

Your post will be rejected if we notice that it seems to contain:

• False or intentionally out-of-context or misleading information
• Insults, profanity, incoherent, obscene or inflammatory language or threats of any kind
• Attacks on the identity of other commenters or the article's author
• Content that otherwise violates our site's  terms.

User accounts will be blocked if we notice or believe that users are engaged in:

• Continuous attempts to re-post comments that have been previously moderated/rejected
• Racist, sexist, homophobic or other discriminatory comments
• Attempts or tactics that put the site security at risk
• Actions that otherwise violate our site's  terms.

So, how can you be a power user?

• Stay on topic and share your insights
• Feel free to be clear and thoughtful to get your point across
• ‘Like’ or ‘Dislike’ to show your point of view.
• Protect your community.
• Use the report tool to alert us when someone breaks the rules.

Thanks for reading our community guidelines. Please read the full list of posting rules found in our site's  Terms of Service.

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

• View all journals
• My Account Login
• Explore content
• About the journal
• Publish with us
• Sign up for alerts
• Review Article
• Open access
• Published: 18 August 2023

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects

• Lu Tang 1 , 2 , 3   na1 ,
• Zhongpei Huang 1 , 2 , 3   na1 ,
• Heng Mei 1 , 2 , 3 , 4 &
• Yu Hu   ORCID: orcid.org/0000-0002-2815-4568 1 , 2 , 3 , 4  

Signal Transduction and Targeted Therapy volume  8 , Article number:  306 ( 2023 ) Cite this article

8594 Accesses

10 Citations

3 Altmetric

Metrics details

• Cancer therapy
• Immunotherapy

The immune-cell origin of hematologic malignancies provides a unique avenue for the understanding of both the mechanisms of immune responsiveness and immune escape, which has accelerated the progress of immunotherapy. Several categories of immunotherapies have been developed and are being further evaluated in clinical trials for the treatment of blood cancers, including stem cell transplantation, immune checkpoint inhibitors, antigen-targeted antibodies, antibody-drug conjugates, tumor vaccines, and adoptive cell therapies. These immunotherapies have shown the potential to induce long-term remission in refractory or relapsed patients and have led to a paradigm shift in cancer treatment with great clinical success. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. To provide clinicians with timely information on these revolutionary therapeutic approaches, the comprehensive review provides historical perspectives on the applications and clinical considerations of the immunotherapy. Here, we first outline the recent advances that have been made in the understanding of the various categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects and toxicity management and then provide novel insights into challenges and future directions.

Similar content being viewed by others

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Introduction.

Cancer immunosurveillance is a process in which multiple innate and adaptive immune effector cells and molecules are involved in the recognition and killing of cancer cells. 1 Extrinsic immune stress can either prevent tumor growth, development and survival or promote tumor growth by both sculpting the immunogenicity of the tumor or inhibiting the anti-tumor immune response. 1 , 2 Immune editing is considered one of the key parts of why tumors could evade the surveillance and lie dormant in the host body for years before re-emerging through the “equilibrium” and “senescence”. 3 With the growth of poorly-immunogenic variants and the destruction of the host immune system, cancer cells ultimately evade immunosurveillance. 4 Cancer cells employ many strategies to suppress the immune system of the human body, so that they can survive in every stage of the anti-tumor immune responses. 5 The generation of anti-tumor immune response is a complicated and multi-step process and Chen et al. refer to these steps as the “Cancer-Immunity Cycle”. 6 As for cancer patients, the “Cancer-Immunity Cycle” does not perform optimally. Any abnormality in these steps can lead to the failure of the “Cancer-Immunity Cycle” and consequent cancer immune evasion. 7 Immunotherapies could fight against cancer by harnessing the immune system and restoring anti-tumor immunity. 8 Constructed over decades, immunotherapies have begun to demonstrate such promising results in treating cancer patients and have been selected as the “Breakthrough of the Year for 2013”. 8 , 9 , 10

Hematologic malignancies refer to malignant diseases originating from the lymphohematopoietic system and may involve all systems and organs throughout the body. Hematologic malignancies mainly include acute leukemia, chronic leukemia, lymphoma, multiple myeloma (MM), myelodysplastic syndrome (MDS), and myeloproliferative neoplasm (MPN). Acute lymphoblastic leukemia (ALL) is characterized by the abnormal proliferation of a huge number of immature lymphocytes. 11 Acute myeloid leukemia (AML) is the most commonly occurring acute leukemia in adults and its incidence increases with age. As a result of genetical mutations in hematopoietic stem/progenitor cells, AML is a highly heterogeneous disease. 12 , 13 Lymphomas are typically divided into two categories, Hodgkin lymphoma (HL, which accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma (NHL). 14 NHL is the most prevalent kind of lymphoma arising from lymphocytes that are at various stages of development and the characteristics of the specific lymphoma subtype reflect those of the cell from which they originated. 14 Diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) represent the most common types of NHL. HL, also known as Hodgkin’s disease, is a rare type of lymphoma with unique histologic, immunophenotypic and clinical features. 15 , 16 HL consists of two discrete disease entities: classical HL (cHL), which accounts for the majority of HL cases and nodular lymphocyte predominant HL. 16 MM, MDS and MPN are most common in elderly patients. MM accounts for about 10% of hematologic malignancies and cannot currently be cured. It typically begins as an asymptomatic precursor, either a monoclonal gammopathy of undetermined significance or smoldering multiple myeloma. 17 MDS is a clonal disorder characterized by ineffective hematopoiesis and a tendency to evolve into AML. 18 With increasing advances in chemotherapy, radiotherapy and targeted therapy, the overall response rate (ORR) of cancer patients has improved significantly. Historically, multi-drug chemotherapy has been the cornerstone of the treatment of both pediatric and adult patients with hematologic malignancies. However, over the past decade, many patients still face treatment failure due to relapse and resistance. The molecular characteristics of hematologic malignancies are highly heterogeneous, leading to considerable challenges in precision medicine and individualized treatment.

With the potential to induce long-term remission in patients with refractory or relapsed (R/R) hematologic malignancies, immunotherapy has already led to a paradigm shift in cancer therapy and tremendous success in the clinic. Furthermore, hematologic malignancies in this setting have some unique characteristics that make these cancers well-suited as targets for immunotherapy. 19 Immune cells and cancer cells are in constant interconnection with each other within the hematopoietic system, enabling an environment that is conducive to immune surveillance. Since the cellular origins of malignancies are the same as that of the immune system, the nature of these cancer cells is immunostimulatory. However, this may meanwhile lead to deficit and hindered immune responses. There has been accelerating advancement of cancer immunotherapies based on various strategies to harness the host immune system. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed. This review will provide perspectives on the applications and clinical considerations of immunotherapies so that clinicians can acquire timely information about such revolutionary therapeutic options. Here, we first outline the recent advances made toward understanding multiple categories of immunotherapies in the treatment of hematologic malignancies. We further discuss the specific mechanisms of action, summarize the clinical trials and outcomes of immunotherapies in hematologic malignancies, as well as the adverse effects (AEs) and toxicity management and then provide insights into future directions.

The history of immunotherapy in hematologic malignancies

As for the field of treating hematologic malignancies, immunotherapy mainly involves targeted antibodies, immune checkpoint inhibitors (ICIs), tumor vaccines, adoptive cell therapy (ACT), and stem cell transplantation (Fig. 1a ). The journey of the history of immunotherapy for hematologic malignancies is summarized in (Fig. 1b ). The allogeneic hematopoietic stem cell transplantation (allo-HSCT) is one of the oldest forms of cancer immunotherapy. 20 The allo-HSCT was first applied to disease treatment in 1968 by E. Donnall Thomas, who would later win the Nobel Prize for being a pioneer in this technology and is praised as “the father of stem cell transplantation”. 20 The allo-HSCT was primarily performed for treating leukemia in 1975 and lymphoma in 1978. Since then, HSCT has been used worldwide to treat serious blood disorders. Although it has been referred to as “the bluntest weapon of chemotherapists”, as it indeed aims to eradicate and restore the hematopoietic and immune systems, it still occupies a pivotal position and gives patients the possibility of a cure. It wasn’t until the end of the 20th century that new immunotherapy approaches emerged. Rituximab, a kind of anti-CD20 monoclonal antibody (mAb), was the first to be approved by the United States Food and Drug Administration (FDA) for the treatment of cancer in 1997 and since then has become the prototype for anti-CD20 mAbs and the backbone treatment regimen for B-cell malignancies, such as DLBCL, CLL (chronic lymphoblastic leukemia) and FL. 21 As well, the rituximab, combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen, has become the first-line therapy for patients with NHL. 22 Meanwhile, more types of mAbs have been developed, such as tafasitamab (anti-CD19 mAb) for DLBCL, 23 daratumumab (anti-CD38 mAb) for MM, 24 and lintuzumab (anti-CD33 mAb) for AML. 25 However, for R/R patients, mAbs often lose their clinical effectiveness and the development of bispecific antibodies (bsAbs) may allow for the continuation of treatment. Blinatumomab, an anti-CD3/CD19 BiTE (bispecific T cell engager), was the first FDA-approved BiTE for the treatment of R/R precursor B-cell ALL (pre-B-ALL) and has also achieved remarkable curative effects. 26 Over the past several decades, antibody-drug conjugates (ADCs) have been evaluated in a variety of clinical trials of hematologic malignancies. The brentuximab vedotin was approved by the FDA in 2011 for treating relapsed HL and systemic anaplastic large cell lymphoma (SALCL). 27 , 28 WT1 (Wilms’ tumor gene 1) peptide-based tumor vaccine was first used in patients with overt leukemia from MDS or MDS with myelofibrosis in the year 2002. 29 , 30 As another rising star in immunotherapy, ICIs have entered the field of treatment for hematologic malignancies due to their great success in solid tumors. PD-1/PD-L1 (programmed death receptor 1, programmed death receptor ligand 1) inhibitors play a notable clinical role in B-cell lymphoma, especially in HL. 31 CTLA-4 (cytotoxic T-lymphocyte antigen number 4) inhibitor also demonstrates certain curative effects in patients with HL and AML. 32 There’re lots of clinical trials of these drugs applied to different kinds of hematologic malignancies to overcome resistance and relapse. ACT is the most popular immunotherapy for patients with R/R hematologic malignancies, such as TCR-T (T cell receptor-engineered T) cell, γ/δ-T (gamma/delta T) cell, NK (nature killer) cell and CAR-NK (chimeric antigen receptor nature killer) cell and especially CAR-T (chimeric antigen receptor T) cell therapy. 33 , 34 , 35 Fred Hutchison Cancer Institute used CAR-T cells for the first time to treat B-cell lymphoma and proved its safety in the year 2008. And in the year 2010, two patients with CLL first received CAR-T transfusion and achieved CR (complete remission) and the CAR-T cells were still detected in vivo after 10 years of follow-up. 36 In 2012, Emily, an American patient with B-ALL, received CAR-T therapy and was cured. She has been disease-free for almost 11 years up to now. The development of CAR-T therapy has been greatly boosted due to the launch of large clinical trials, such as axicabtagene ciloleucel and tisagenlecleucel, as well as the FDA’s approval of the first commercialized CAR-T cell product in 2017. At present, CAR-T therapy has achieved remarkable results in R/R ALL, CLL, NHL, and MM. 37 There are many CAR targets for each malignant disease and the number of treatment lines is gradually advancing. In summary, immunotherapy has achieved rapid development in recent years, which provides more possibilities and hopes for the cure of hematologic malignancies.

The development of immunotherapy for hematologic malignancies. a Types of immunotherapies for treating hematologic malignancies. b The journey of the history of immunotherapy for hematologic malignancies

Overview of immunotherapies in hematologic malignancies

HSCT is an effective means of curing a range of hematologic diseases. It is done by harvesting functional hematopoietic stem cells from the patients or a healthy donor and transplanting them to the patients to replace their dysfunctional blood system. Initially, bone marrow was considered as a source of stem cells for transplantation. However, within the last two decades, peripheral blood stem cells have replaced bone marrow stem cells and become the main stream. 38 The replacement indicates no impact on overall survival (OS) except a greater risk of graft-versus-host disease (GVHD). 38 Fortunately, the management of GVHD is strict and upgraded continuously. 39 The allo-HSCT is usually considered as a preferred choice for hematologic malignancies. 40 , 41 But due to the greater risk of GVHD, allo-HSCT is still restrictive to the patient’s own status. This led to the emergence of reduced-intensity stem cell transplantation (RIST), which is associated with less morbidity and mortality and can be performed in a wider range of patients. 42 , 43 Meanwhile, cord blood transplantation with a low relapse rate and chronic GVHD was also promoted but was later hampered by a high incidence of infection and transplant-related mortality. However, the safety and feasibility of HSCT using single UM171-expanded cord blood were validated in patients with malignant hematologic diseases who did not have a suitable HLA (human leukocyte antigen)-matched donor, indicating the potential to overcome the disadvantages of other cord blood transplantation while maintaining the benefits of low risk of chronic GVHD and relapse. 44 Haploidentical family donors, such as parents, children, or haploidentical siblings, offer the advantage of rapid donor availability. Currently, two methods are most commonly used for haploidentical hematopoietic stem cell transplantation (haplo-HSCT): (i) granulocyte colony-stimulating factor (G-CSF) plus anti-thymocyte globulin-based regimen with non-manipulated T-cell enriched grafts, which was originated by the Peking group in China; (ii) post-transplantation cyclophosphamide-based regimens with non-manipulated T-cell enriched grafts, which was initiated by the Baltimore group in the United States. 35 , 45 , 46 , 47 With the development of haplo-HSCT, strategies to address the associated side effects have become a research trend. A substantial improvement in non-relapse mortality and supportive care (e.g., treatment and prevention of infections or GVHD) has contributed to improved OS of allogeneic transplantation over the past decades. 48 , 49 In addition, to overcome barriers such as donor availability, novel transplantation strategies have been refined. For example, post-transplant cyclophosphamide for GVHD prevention after haploidentical donor transplants has shown similar outcomes with a reduced risk of GVHD. 50 , 51 The recurrence of the malignancy remains the most prevalent cause of post-transplant failure or even death, emphasizing the importance of enhancing the immune system in the treatment of hematologic malignancies and how far we have yet to go to achieve a cure. Although much is still being discovered, we have learned a great deal about how the host immune system affects the treatment of hematologic malignancies from the growing and evolving field of allogeneic transplantation, which is helping to advance the field of novel immunotherapies. 20

The mAbs are highly homogeneous IgG antibodies produced from a single B cell clone and directed against only specific antigenic epitopes. The first-generation mAbs are derived from mice and typically prepared using the hybridoma technique, which is based on cell fusion technology that fuses sensitized murine B cells with the capacity to secrete specific antibodies and myeloma cells with the capacity to multiply indefinitely into B cell hybrids. 52 Through culturing individual hybridoma cells with such properties into cell populations, it is possible to generate antibodies against corresponding antigenic epitopes. However, murine mAbs can be recognized by the immune system and result in human anti-mouse antibody reactions, particularly human anti-mouse antibody (HAMA), 53 , 54 , 55 resulting in limited efficacy of mAbs and potentially serious AEs. Since then, mAbs have gradually evolved toward the trend of humanization. The second generation is human/mouse chimeric mAbs (with the suffix -ximab, e.g., rituximab), 21 using chimeric antibody or humanized modified monoclonal antibody technology. 56 , 57 Both approaches greatly reduce the human anti-mouse immune response, but a certain degree of immunogenicity still exists because they contain mouse-derived sequence fragments. The subsequent mAbs are fully humanized (with the suffix -zumab and -mumab), with the amino acid sequences that make up the antibodies all derived from humans. These mAbs are mainly manufactured by phage display screening, 58 , 59 yeast surface display, 60 , 61 human hybridoma technology and single B-cell antibody preparation technology, 62 or even metabolic strategy like glycoengineering. 63 Meanwhile, these mAbs have a 100 percent human component and reduced immunogenicity, although they may still have immunogenicity due to anti-idiotype antibodies.

The mAbs are the major component of cancer immunotherapy. 64 mAbs have various mechanisms of action and each type of antibody has multiple mechanisms of action in parallel, mobilizing multiple aspects and components of immunity to ultimately kill tumor cells. The mAbs, when combined with their targets, can kill cancer cells in two ways (Fig. 2a ): (i) direct induction of apoptosis through programmed cell death (PCD); 65 (ii) immune-mediated mechanisms, mainly including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent macrophage-mediated phagocytosis due to the binding of Fc and FcγR (Fc gamma receptor). 65 , 66 , 67 , 68 , 69 , 70

Mechanisms of action of four kinds of immunotherapy drugs. a The monoclonal antibodies (mAbs), when combined with their targets, can kill cancer cells by direct induction of apoptosis through programmed cell death, antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, and antibody-dependent macrophage-mediated phagocytosis. b The BiTE ((bispecific T cell engager) molecule usually targets one CD3 molecule and one tumor antigen simultaneously. Thus, in addition to the anti-cancer role of the tumor antigen-targeted antibody, it can promote the activation and recruitment of CD3 + T cells. c After bound to the tumor surface antigen, the antigen undergoes endocytosis and the antibody-drug conjugates (ADCs) will be internalized into the tumor cell and subsequently transported to the lysosome to release the cytotoxic payload, which can induce apoptosis and kill surrounding cancer cells through bystander effects. d The blockade of PD-1 or its ligands PD-L1 and PD-L2 can help to restore the anti-tumor immunity of the body and simultaneously enhance the lysis effect of cytotoxic T cells to achieve the effect of tumor eradication. CTLA-4 inhibitors can block the binding between CTLA-4 molecule and B7 during T cell activation, increase the level of the recognition of T cells to tumor-associated antigens (TAAs) and enhance the anti-tumor responses of the body’s immune effector cells

Rituximab is a first-generation anti-CD20 mAb. Ofatumumab is one kind of second-generation, fully-humanized anti-CD20 mAb that binds to a different site from rituximab and was approved by the FDA for the treatment of CLL in 2009, as well as in combination with chlorambucil for the treatment of CLL in 2014. 71 , 72 Obinutuzumab is another second-generation anti-CD20 mAb and was approved by the FDA in combination with chlorambucil for the treatment of CLL in 2013 and in combination with bendamustine for the treatment of R/R FL in 2016. 73 , 74 Daratumumab is an anti-CD38 mAb that was FDA-approved for the treatment for patients with MM. 24 Elotuzumab is an anti-CS1 mAb that was approved by FDA in combination with lenalidomide and dexamethasone for the treatment of R/R MM in November 2015. 20 Furthermore, the FDA-approved mAbs, such as daratumumab, 75 , 76 , 77 , 78 elotuzumab, 79 , 80 , 81 and isatuximab, 82 , 83 , 84 have already revolutionized the standard of care for treatment of MM, or even in the front-line therapeutic setting. Up to now, as presented in Table 1 , many kinds of mAbs have been developed for the treatment of hematologic malignancies with their targets involving CD20, CD19, CD22, CD38, CS1 (SLAMF7), CD52, CD40, CD80, CD74, and CD33. 25 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114

In complex disease pathogenesis, multiple mediators facilitate the stimulation of different signaling pathways or promote overlapping signaling cascades, which limits the therapeutic efficacy of the targeting of a single molecule. 115 Therefore, the bsAbs, which combine the binding sites of two mAbs in the same molecule, were developed and transformed into immunotherapy. 116 The emerging bsAbs, exemplified by BiTEs, which promote the activation and recruitment of CD3 + T cells, have facilitated the fast development of cancer immunotherapy in hematologic malignancies. 117 , 118 , 119 , 120 Similar as mAbs, the targeted antigens of bsAbs must be selected from tumor-associated antigens (TAAs) with high specificity and high correlation with the malignant phenotype of the tumor. 120 , 121 The bsAbs are mainly divided into three categories according to their targets: (i) antibodies that target two different tumor antigens; (ii) antibodies that target one tumor antigen and one immune-related molecule, such as CD3 for BiTE; and (iii) antibodies that target two immune-related molecules. 117 Because the BiTE molecule usually targets one CD3 molecule and one tumor antigen simultaneously, it belongs to the second category of bsAbs (Fig. 2b ). 117 BiTEs are the main patterns by which bsAbs work in hematologic malignancies, such as blinatumomab (anti-CD19/CD3 bsAb) approved by the FDA for R/R ALL, 26 , 122 , 123 , 124 , 125 , 126 AFM11 for B-ALL, 127 anti-CD19/CD3 or anti-CD20/CD3 bsAbs for B-NHL, 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 anti-CD33/CD3, CD123/CD3, WT1/CD3, or CLEC12A (C-type lectin domain family 12 member A)/CD3 bsAbs for AML or MDS, 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 and anti-BCMA (B cell maturation antigen)/CD3 or CD38/CD3 bsAbs for MM. 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 In addition, the anti-GPRC5D (G protein-coupled receptor, family C, group 5, member D)/CD3 and anti-FcRH5 (Fc receptor homolog 5)/CD3 bsAbs were also used for the treatment of MM. 168 , 169 Table 1 presents the bsAbs currently developed for hematologic malignancies. Although BiTEs have been proven to be efficient in many R/R hematologic malignancies, several patients still show no responsiveness to BiTE therapy. It is not only due to defects in the structure itself but also the immune escape, involving the aspects of loss of target antigen expression, disrupted trafficking of the target antigens and extramedullary lesions. 170 , 171 , 172 , 173 , 174 Based on this fact, bsAbs and trispecific antibodies (tsAbs) engaging NK cells have also been explored in pre-clinical and/or clinical studies. 175 , 176 , 177 , 178 , 179 Ross et al. reported the NK-cell mediated lysis of BCMA-positive MM cell lines induced by AFM26 (anti-BCMA/CD16A bsAb). 175 Moreover, the anti-CD19/CD22/CD3 tsAb that site-specifically fuses anti-CD19 scFv (single chain variable fragment) and anti-CD22 nanobody to CD3 antigen-binding fragment, was designed for treating patients with B-ALL. 177 It demonstrated enhanced anti-tumor efficacy and the capacity to overcome immune evasion when compared with the corresponding bsAbs alone or multiple antibodies in combination. 177 The therapeutic effects provide a new direction for the development of bispecific and even multi-specific antibodies.

The mAbs have the advantage of a longer plasma half-life, yet they are not inherently cytotoxic. In contrast, small molecule cytotoxic agents commonly utilized in chemotherapy have high cytotoxicity and relatively low costs of production, but they are poorly targeted to cancer cells and have a plasma half-life of only a few hours. 180 , 181 , 182 The concept of utilizing the specific binding properties of mAbs as a mechanism to selectively deliver cytotoxic agents to tumor cells is an appealing approach to overcome the challenges of increasing the therapeutic potentials of cytotoxic agents. All three components of an ADC, the antibody, cytotoxic payload, and the linker chemistry that joins them together, are important for the design of an effective anticancer agent. Mechanistically, ADC differs from the previously mentioned mAb and bsAb in that after it binds to the tumor surface antigen, the antigen undergoes endocytosis and ADC will be internalized into the tumor cell and subsequently transported to the lysosome to release the cytotoxic payload (Fig. 2c ). The released toxic payload can induce apoptosis and kill surrounding cancer cells through bystander effects (Fig. 2c ). 183 Perhaps the most essential aspect of developing an effective molecule is the selection of the targeted antigen to which the ADC will bind. 184 , 185 , 186 Advances in related technology, improvements in the selection of cytotoxic agents and the use of smaller conjugates have all dramatically enhanced the potential clinical benefits of ADCs. Several ADCs have been designed and used for clinical use in hematologic malignancies and their targets include CD22, 187 , 188 , 189 , 190 , 191 , 192 , 193 CD30, 181 , 194 , 195 , 196 , 197 CD33, 198 , 199 , 200 , 201 , 202 CD19, 203 , 204 , 205 , 206 , 207 , 208 CD79, 191 , 209 , 210 BCMA, 211 , 212 CD37, 213 , 214 , 215 CD138, 216 CD56, 217 CD74, 218 GPRC5D, 219 CD123, 220 and CD25, 221 (Table 1 ). The initial excitement for ADCs has risen and then fallen with the approval and subsequent withdrawal of gemtuzumab ozogamicin in the years 2000 and 2010, respectively. 20 With effectiveness in the treatment of R/R HL and SALCL, brentuximab vedotin, an anti-CD30 antibody linked to a microtubule inhibitor monomethyl auristatin E (MMAE), received FDA approval for cancer treatment in 2011 and for post-autologous HSCT consolidation in 2015. 196 , 222 Inotuzumab ozogamicin is comprised of a humanized anti-CD22 mAb conjugated to calicheamicin, a cytotoxic antibiotic agent and was as monotherapy for the treatment of CD22-positive B-ALL in 2017. 180 , 223 , 224 Vadastuximab talirine (SGN-CD33A, 33A), a novel ADC consisting of pyrrolobenzodiazepine dimers linked to a mAb targeting CD33, has demonstrated activity and a tolerable safety profile as a single agent in patients with AML. 199 Belantamab mafodotin 225 targeting BCMA is currently the only ADC approved by the FDA for MM. Furthermore, other TAAs expressed highly on MM cells are also designed as targets of ADCs. Clinical trials of lorvotuzumab mertansine (anti-CD56 ADC), 217 indatuximab ravtansine (anti-CD138 ADC), 216 milatuzumab doxorubicin (anti-CD74 ADC), 218 and the first anti-GPRC5D ADC, LM-305, 219 are ongoing in present.

Although more ICIs have been developed already, 226 , 227 anti-CTLA-4 (ipilimumab), PD-1 (pembrolizumab, nivolumab, pidilizumab) and PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been the focus of current clinical consideration of checkpoint inhibitors. 32 PD-1 is a prominent immunosuppressive trans-membrane molecule that is expressed on the surface of T cells. 228 In the tumor microenvironment (TME), T cells express high levels of PD-1 molecules, which can bind to PD-L1 on tumor cells or other immune cells and PD-L2 on macrophages and dendritic cells (DCs). This will inhibit the intracellular signaling transduction of T cells, reduce effector T cell activity, induce T cell apoptosis, negatively regulate the anti-tumor immune response and ultimately cause tumor cells to undergo immune escape. 229 , 230 , 231 , 232 , 233 In addition to surface PD-L1 molecule, tumors can also secrete soluble PD-L1, which more readily binds to PD-1 on T cells. 234 , 235 Furthermore, immune cells in TME sometimes are accomplices as well. Despite the direct suppression of T cells, Treg-expressed CTLA-4 can deplete CD80/CD86 by trogocytosis to release free PD-L1 on antigen-presenting cells. 236 Presence of PD-L1-expressing DCs and macrophages in TME may play a dominant role in mediating T-cell immunosuppression. 234 The use of mAbs or inhibitors targeting PD-1 or its ligands PD-L1 and PD-L2 can selectively block PD-1 and ligand binding between tumor cells and T cells, thereby helping to restore the anti-tumor immunity of the body and simultaneously enhance the lysis effect of cytotoxic T cells to achieve the effect of tumor eradication (Fig. 2d ). 237 Once the “Cancer-Immunity Cycle” is established, it can produce long-lasting anti-tumor effects. PD-1 inhibitors also enhance the efficacy through the activation of other immune cells within the TME. 238 A robust anti-tumor T-cell response is induced in tumor-draining lymph nodes by blocking PD-L1-mediated inhibition of host antigen-presenting cells (APCs) at off-tumor sites. 239 A further opinion has been recently expressed that the activity of ICI is not limited to TME. PD-1 blockade drives the expansion of a subset of PD-1 low CD8+ progenitor cells with self-renewal properties, resulting in the mobilization of stem-like precursor CD8 + T cells that reside outside the tumor. 240 CTLA-4 molecule is normally expressed on the surface of CD4+ and CD8 + T cells and can bind with high affinity to B7 ligands on APCs, producing signals that inhibit T cell activation, reduce cytokine production and decrease the anti-tumor immune response. 241 , 242 CTLA-4 inhibitors block the co-stimulatory signal between CTLA-4 molecule and Fc on the surface of regulatory T cells, which can induce regulatory T cell death; in addition, this can also block the binding between CTLA-4 molecule and B7 during T cell activation, increase the level of T cell recognition to TAAs and enhance the anti-tumor responses of the immune cells (Fig. 2d ). 243 , 244 , 245 T cell dysfunction, the metabolic profile of CD8 + T cells and immunosuppressive factors lead to resistance of ICIs. 246 , 247 , 248 , 249 The use of PD-1 blockade can also induce anti-PD-1 resistance by induction of dysfunctional PD-1+CD38 high CD8+ cells. 250 Therefore, combination therapy of ICIs is emerging in the treatment of hematologic malignancies. 251 , 252 , 253

ACT is a kind of immunotherapy in which autologous or allogeneic immune effector cells, activated and expanded in vitro, are infused into the patient. Such therapies are divided into non-specific and specific cellular therapies. Non-specific cellular therapy includes the direct infusion of cytokine-induced killer (CIK) cells, tumor-infiltrating lymphocytes (TIL), γ/δ T cells and NK cells, some of which have been used for hematologic malignancies. 254 , 255 , 256 , 257 , 258 The mechanism by which non-specific cellular therapy alleviates tumor symptoms is to boost the immunity of the entire body, leading to limited efficacy. Therefore, specific cellular therapies, particularly CAR-T cells, have become more popular in clinical studies. 259 , 260 An incredible area of immunotherapy for hematologic malignancies is the development and refinement of CAR-T cell therapy. Such therapies involve not only targeting tumor antigens but also augmenting these targeted immune effectors. CAR-T cells are designed to express CAR that aims to target specific tumor surface antigens with antigen specificity and HLA independence and is therefore not dependent on MHC (major histocompatibility complex) expression. CAR-NK cells, not only recognize tumor antigens specifically via the CAR but also eliminate tumors by the NK cell receptor itself. NK cell activity depends on the balance of stimulatory and inhibitory signals and is antigen non-specific. Targeted lysis of CAR-NK cells is based on CAR-dependent and NK receptor-dependent mechanisms and this lysis effect is also indicated for antigen-negative cancer cells. 34 , 261 , 262 The main sources of CAR-NK cells are usually peripheral blood, cord blood, induced pluripotent stem cells (iPSCs) and NK92 cell lines. Since CAR-T therapy has the largest number of clinical trials and the widest range of applications in the field of cell therapy in hematologic malignancies, especially for multi-line therapy-refractory patients, we will focus on CAR-T therapy in the following sections.

The design of the CAR is the pivotal issue and has undergone several updates throughout the evolution of CAR-T therapy (Fig. 3a ). Eshhar et al. were the first to construct the CAR-T cells for the expression of antigen receptors. 263 The intracellular structural domain of first-generation CAR-T cells contains only the signal transduction structural domain CD3-ζ, so that CAR-T cells have poor proliferative abilities and a short survival time in vivo, due to the absence of co-stimulatory signaling and cytokine signaling, such as interleukin-2 (IL-2). 264 , 265 The co-stimulatory structural domain CD28 or 4-1BB (also known as CD137) were integrated with the CD3-ζ molecule in the design of the second-generation CAR-T cells, which allowed CAR-T cells to continuously proliferate and induce enhanced anti-tumor activity. 266 , 267 The second-generation CAR-T cells, which are the most widely used in clinical practice, were able to exert anti-tumor effects even in the absence of exogenous costimulatory molecules. 268 Two different costimulatory domains (CD28/4-1BB or ICOS/4-1BB) are present in third-generation CAR-T cells. 269 , 270 , 271 The fourth-generation CAR-T cells incorporate cytokines or co-stimulatory ligands to further enhance T-cell responses, or suicide genes to enable CAR-T cells to self-destruct when needed. 272 , 273 The fifth-generation CAR-T cell is also derived from the second-generation and includes a shortened cytoplasmic IL-2 receptor β chain domain (IL-2Rβ) and a STAT3 binding moiety. 274 This design enables the fifth-generation CAR-T cells to enhance the T cell receptor (TCR) and cytokine-driven JAK-STAT signaling pathways to promote the proliferation and activation of the bioengineered T cells. 274 In addition to improvements through co-stimulatory domains and cytokines, more important is the design of the antigen-binding region scFv of CARs. The earliest scFv targeting CD19 was also of murine origin (FMC63) and it would generate murine-derived mAbs, namely anti-CAR immune responses. Moreover, this response has also been shown to affect CAR-T efficacy and even lead to late relapse. 275 , 276 Therefore, researchers are continuously working on humanizing scFv fragments and directly design fully human CAR fragments to reduce the occurrence of this response and its impact on efficacy. 277 , 278 , 279 Besides, more novel types of CAR-T cells are being developed to improve the flexibility of CAR target recognition. To address the problem of wait for a long time, the “off-the-shelf” CAR-T cells, in which all T cells are derived from healthy donors, have been developed. 280 , 281 The universal CAR-T cells replace scFv extracellular structural domain used in previous generations of CAR T cells with an adapter-specific recognition structural domain which binds to an adaptor molecule specific to a tumor target. This design enables CAR-T cells to recognize multiple antigens by separating the antigen-targeting structural domain from the T-cell signaling unit.

The evolution of CAR design and the process of CAR-T therapy in clinic. a The design of the CAR has undergone several updates throughout the evolution of CAR-T therapy. To date, there have been five generations of CAR structures. b CAR-T cell therapy is a multi-step process that involves selecting eligible patients, collecting cells, manufacturing CAR-T cells, lymphodepletion and infusion of CAR-T cells and subsequent longitudinal follow-up

CAR-T cell therapy is a multi-step process that involves selecting eligible patients, collecting cells, manufacturing CAR-T cells, lymphodepletion, infusion of CAR-T cells, and subsequent longitudinal follow-up (Fig. 3b ). The eligibility of patients depends on their disease status, previous treatment regimens, risk factors, co-morbidities, performance status and social factors. 282 The patient’s peripheral blood mononuclear cells (PBMCs) are collected by leukapheresis and CD3 + T cells are further purified and isolated. T cell subpopulations are genetically modified to express the CAR of interest, then expanded in vitro. The expanded CAR T cells are frozen and stored for future use and ultimately reinfused into the patients after lymphodepletion-directed chemotherapy. CAR T-cell therapy generally requires hospitalization and the patient’s physical reactions, especially the possibility of AEs, should be closely monitored for several weeks after infusion.

CAR-T cell immunotherapy has gradually become the main therapeutic option for malignant hematological diseases, with impressive results to date. From Kymriah and Yescarta, which were the first to be approved by the FDA for the treatment of leukemia and lymphoma in August and October 2017, respectively, to the latest advances such as CB-010 therapy, they all play a pivotal role in treating malignancies, especially in cases of R/R patients. CAR-T cell immunotherapy has already achieved notable successes in the treatment of B-cell malignancies such as ALL, CLL, and DLBCL. Meanwhile, the most commonly utilized CAR targets for B-cell malignancies are CD19, CD20, and CD22. 283 Of these, CD19 is the most commonly used target and is highly expressed in the majority of B-cell malignancies. CD7 is an important target in T-cell ALL and T-cell lymphoma. 284 , 285 , 286 CD30 is usually expressed on tumor cells of HL, 287 and CD33 is a favorable target for AML. 288 Two CAR T-cell products, idecabtagene vicleucel and ciltacabtagene autoleucel, are the currently FDA-approved BCMA-targeting therapies. In addition to BCMA, many other investigational CAR T-cell therapies for MM are being studied, including cell products targeting SLAMF7, CD19, CD38, TACI (transmembrane activator and CAML interactor), GPRC5D (G protein-coupled receptor, class C, group 5, member D), and CD138. 282 , 289 , 290 , 291 However, the application of CAR-T therapy has been limited by relapse, resistance and toxicity. 292 , 293 , 294 , 295 , 296 , 297 , 298 Researchers have used diverse approaches to improve CAR-T therapy. In terms of target selection, new targets have been diligently searched for, 299 , 300 and even dual-target and even multi-antigen-targeted CAR-T have been introduced 291 , 301 , 302 , 303 , 304 , 305 , 306 to prevent subpopulations of tumors from being ignored. 307 For T-ALL, patients’ own T cells are difficult to make CAR-T, thus healthy donor T cells are used to prepare CAR-T. 281 Recently CAR-NK and CAR-macrophage cells have also become new popular products and novel CARs are designed to overcome treatment failure. 308 , 309 , 310 Despite these advancements in CAR-T cell therapy, there are still several unanswered questions. For example, the optimal CAR T cell design and engrafting technique, the ideal intracellular costimulatory domain or the generation of CARs, the appropriate CD4:CD8 T cell ratio in infusion products and even factors such as the dominance of effector versus central memory cells and the influence of Tregs are unknown. The best timing for the engraftment of CAR-T cells is also not yet clear and may vary depending on the type of malignancies. In addition, the impact of TME may be an additional critical factor in CAR T-cell therapy. Although these questions remain unanswered, CAR T-cell therapy will be an essential strategy for the treatment of hematologic malignancies. As more research is conducted on this breakthrough therapeutic approach, it will be improved in its efficacy and applicability.

Tumor vaccines

Tumor vaccines, one of the hot topics in research in recent years, are immunotherapeutic modalities in which tumor antigens are infused into patients in various forms to generate tumor-specific lymphocytes in the patient and kill the tumor. 311 It consists of molecular vaccines and cellular vaccines, among which molecular vaccines include tumor-associated proteins or peptides and gene vaccines expressing tumor antigens. Cellular vaccines, on the other hand, are tumor cells, which are genetically modified to express MHC molecules and then injected into patients. Tumor vaccines can enhance the immunogenicity of the tumor, activate the patient’s immune system, induce the body’s cellular and humoral immune response and also override the immunosuppressive state caused by the tumor. It is designed to not only induce tumor regression, but also to eliminate minimal residual disease (MRD), establish long-lasting anti-tumor memory and avoid non-specific or adverse reactions. Such vaccines have been developed for B-cell leukemia and lymphoma, ranging from commonly-mutated genes to DC vaccines. 312 , 313 Vaccines targeting immunoglobulin light chain and EBV antigens are also available. 314 , 315 As clinical trials have been conducted, 316 , 317 , 318 although not yet widely used, the prospects are promising.

How immunotherapies work: to promote “Cancer-Immunity Cycle”

The generation of anti-cancer immunity is a cyclical process that can be self-perpetuating, with the accumulated immunostimulatory factors that should, in principle, boost the T cell immune response. This cycle can also be interrupted by suppressive stimuli, which result in immunomodulatory feedback mechanisms that impede the generation of anti-cancer immunity. 6 Generally, the “Cancer-Immunity Cycle” can be divided into multiple steps. First, the neoantigens that are produced during tumorigenesis are released and then captured by the DCs for processing. This must be accompanied by immune-specific signals so as not to induce peripheral immune tolerance to the tumor antigens. Then, DCs deliver antigens that are captured on MHC molecules to T cells, leading to the priming and activation of effector T cells. Subsequently, through the interaction between the TCR and the cognate antigen bound to MHC-I, these activated effector T cells traffic towards and infiltrate into the tumor, where they specifically recognize and bind to the cancer cells and kill them. Noteworthy, the killing of these targeted cancer cells also leads to the release of more TAAs. This in turn extends the breadth and depth of the immune response in subsequent cycles of rotation. 6 Dysregulation of the “Cancer-Immunity Cycle” is the consequence of tumorigenesis and treatment failure. Meanwhile, the TME may also suppress these effector cells engaged in the “Cancer-Immunity Cycle” and resultant cancer immune evasion. 6 , 7 Therefore, cancer immunotherapy requires initiating and promoting the self-sustainability of the “Cancer-Immunity Cycle” so that it can normally amplify and spread, but not to the point of generating an unrestrained autoimmune inflammatory response. In the meantime, cancer immunotherapy also needs to be carefully tailored to counteract these negative feedback mechanisms. 8 , 9 , 10 Numerous factors that play a part in any step of the “Cancer-Immunity Cycle” offer a wide range of potential therapeutic targets (Fig. 4 ): (i) promoting antigen release, presentation and recognition; (ii) priming and activating the immune response; (iii) overcoming immune evasion; (iv) targeting immune suppression in the TME.

How immunotherapies work? To promote “Cancer-Immunity Cycle”. The “Cancer-Immunity Cycle” can be divided into multiple steps. 6 Dysregulation of the “Cancer-Immunity Cycle” is the consequence of tumorigenesis and treatment failure. Meanwhile, the TME may also suppress these effector cells engaged in the “Cancer-Immunity Cycle” and resultant cancer immune evasion. Numerous factors that play a part in any step of this cycle offer a wide range of potential therapeutic targets: (i) promoting antigen release, presentation and recognition; (ii) priming and activating the immune response; (iii) overcoming immune evasion; (iv) targeting immune suppression in the TME

Promote antigen release, presentation and recognition

Although not established as immunotherapies, chemotherapy, radiotherapy and targeted therapies (e.g., mAbs, bsAbs, and ADCs) can kill large numbers of cancer cells, then promote antigen release and T cell activation. The majority of tumor vaccines are therapeutic vaccines, which are based on the principle that tumor antigens are introduced into the patient’s body to improve immunogenicity, activate the immune system and elicit cellular and humoral immune responses to control or eliminate the tumor. 311 Theoretically, it is feasible to promote the activation of the immune system through the specific proteins of cancer cells so as to eliminate cancer cells. Nevertheless, tumor antigens are heterogeneous thus the primary problem in tumor vaccine development is to find the universal or specific antigens expressed on the surface of tumor cells. 319 , 320 CD40 agonist antibodies are used to promote the maturation and antigen-presenting ability of DCs by mimicking CD40L cross-linking CD40, inducing the expansion of tumor antigen-specific cytotoxic T cells and thus eradicating tumors. 105 , 321 , 322 CAR T-cell therapy is the process of transferring genetic material with specific antigen recognition structural domain and T cell activation signal into T cells through genetic modification. In this way, the modified T cells can be activated in an MHC-independent manner by directly binding with specific tumor antigens and directly killing the tumor cells by releasing perforin, granzyme B, etc. and also by secreting cytokines to recruit human endogenous immune cells to help to kill tumor cells.

Priming and activation of immune response

CTLA-4, an inhibitory receptor that is expressed primarily on T cells, has a suppressive function on T cell activation and is upregulated upon T cell activation. Antibodies targeting the immunomodulatory receptor CTLA-4 have two putative mechanisms of action: direct inhibition of CLTA-4 binding to its cognate ligand and depletion of immunosuppressive regulatory T (Treg) cells via Fc-mediated immune-mediated mechanisms, mainly including ADCC and CDC. 245 More importantly, the BiTEs are able to redirect T cells to specific tumor antigens and to directly activate the T cells. 323 Because T cells lack Fcγ receptors, natural antibodies cannot directly recruit these T cells. The BiTE molecule typically targets a tumor antigen and a CD3 molecule at the same time. The CD3 molecule associates non-covalently with the T cell receptor (TCR) and participates in antigen-specific signal transduction that can induce T cell activation. In addition, directly expanding and making available increased numbers of functionally competent immune cells represents an intuitively desirable therapeutic concept. 19 HSCT refers to the transplantation of hematopoietic stem cells from a donor into a recipient to rebuild or restore the recipient’s immune system. Cellular immunotherapy stimulates the body’s anti-tumor immune response by isolating autologous or allogeneic immune effector cells, activating them in vitro and then injecting them into the body. As with CAR-T cell therapy, the scFv recognizes specific TAAs, including the proteins, glycoproteins and other components. CD3-ζ is typically a signaling region containing three ITAMs (immunoreceptor tyrosine-based activation motifs). Upon scFv recognition and binding to TAA, phosphorylation of the ITAM triggers ZAP70 signal transduction and subsequent signaling to initiate and prime the T cell immune responses. 324 This is a principle similar to antigen-antibody complementarity, which can bypass the MHC-dependent antigen presentation and enable the TAA to directly stimulate the activation of CAR-T cells.

Overcoming immune evasion

An important mechanism by which tumor immune evasion occurs is by suppressing the function of effector immune cells. Immune checkpoints are a class of molecules that have a negative effect on immune cell function and are most expressed in immune cells. They can regulate the degree of activation of the immune system, resulting in them playing an important role in the prevention of autoimmune effects. However, these molecules are susceptible to being hijacked by tumor cells, which means the tumor cells can bind to the corresponding ligand/receptor on the immune cell, activating the inhibitory pathway and preventing immune cells from killing the tumor, thus enabling the immune escape of the tumor. 3 ICIs aim to block the corresponding immune checkpoints to prevent the activation of the relevant immunosuppressive pathways and have been widely used in various types of solid and hematologic malignancies. 325 , 326 Moreover, T cell exhaustion occurs due to a multi-factorial etiology resulting from sustained exposure to tumor antigens, the loss of stimulation/secretion of effector cytokines, the involvement of immunosuppressive cell types and immunophenotypic alterations including increased expression of inhibitory receptors and checkpoints such as LAG3 (lymphocyte-activation gene 3), TIGIT (T cell immune receptor with Ig and ITIM domains), TIM3 (T cell immunoglobulin mucin 3). Therefore, T cell exhaustion may be reversed and the anti-tumor immune response enhanced by inhibitors targeting these inhibitory receptors and checkpoints.

Targeting immune suppression in TME

The TME is the internal environment in which tumor cells survive and develop and immune cells in the TME have different mechanisms of pro- or anti-tumor immune action in tumor growth and progression. Tregs suppress T cell activity either directly or by secreting suppressor cytokines such as IL-10 and TGF-β; myeloid-derived suppressor cells (MDSCs) suppress T cell activity and modulate the intrinsic immune response to suppress the immune response. Therefore, targeting the TME is another important mechanism of cancer immunotherapy. For example, overexpression of indoleamine 2,3-dioxygenase (IDO) in tumors inhibits T cell proliferation and promotes regulatory T cell differentiation and IDO inhibitors can effectively improve the immunosuppressive microenvironment of tumors and enhance the anti-tumor immune response.

Representative clinical trials and outcomes

Numerous clinical trials have validated the elimination of hematologic malignancies through transplantation. 327 , 328 , 329 Transplantation-related clinical trials mainly involve two aspects: (i) exploration of peripheral blood stem cell transplantation (PBSCT) and RIST; (ii) comparison of allogeneic HSCT with HLA genotype identical sibling donors (ISD) and haploidentical donors (HID). Around the beginning of the 21st century, several clinical trials were conducted to investigate the efficacy and safety of PBSCT. 330 , 331 These results confirmed the advantage of PBSCT in terms of hematopoietic system reconstitution. Meanwhile, it makes HSCT less harmful to the donor. To expand the application, RIST has been raised for those who can’t tolerate allo-HSCT. And relevant clinical trials were designed to discover the appropriate chemotherapy regimen and compared RIST with high-dose conventional conditioning. A 7-year clinical trial showed that 8 out of 12 patients who received RIST were still alive after 1 year, while only 3 out of 13 patients who received high-dose chemotherapy were still alive. 332 Fludarabine-melphalan as a preparative regimen for RIST is associated with a significant reduction in transplant-related mortality according to an update from the MD Anderson Center. 333 The study in Europe has also shown a reduction in the non-relapse mortality rate in RIST. 334 To date, more clinical trials are ongoing to evaluate RIST in elderly patients with AML and MDS. 335 , 336 , 337 Haplo-HSCT is now being used regularly for patients. However, it was not until 2015 that the technology became more mature and clinical trials comparing it to the ISD-HSCT were conducted. 338 , 339 The results of haplo-HSCT performed in patients who were in remission did not differ significantly from those of ISD-HSCT. In later studies, both transplantation methods were applied to patients not in remission, where haplo-HSCT showed better efficacy. 340 Although there may be a higher rate of GVHD, it has the potential to be used in high-risk child patients. 341 In addition, haplo-HSCT can be followed by adoptive T-cell therapy and the results of such trials have shown that T-cell infusion can be beneficial in reconstituting the immune system and preventing relapse. 342 , 343

The most representative mAb used in the treatment of lymphoma is none other than Rituximab. There is a pivotal phase II trial of rituximab monotherapy that was conducted in 166 patients with R/R low-grade NHL, in which the ORR was 48 and 6% of the patients achieved the complete response. 344 The stage was set for the approval of rituximab with these and subsequent results. 345 However, an increasing number of clinical trials have opted to use rituximab in combination with other chemotherapy regimens to improve efficacy. In 2001, one phase II trial of the first-line R-CHOP regimen was initiated in 33 patients with aggressive NHL. The results were surprising with an ORR of 94% and a CRR (complete response rate) of 61%, demonstrating for the first time the feasibility and safety of the R-CHOP regimen in these patients. 86 Clinical trials of R-CHOP in MCL were then conducted. As implied by the results of a prospective randomized trial conducted by the German Low-Grade Lymphoma Study Group (GLSG), R-CHOP was significantly superior to CHOP as first-line therapy in terms of ORR (94%), CRR (34%) and time to treatment failure (21 months), although no differences were observed in progression-free survival (PFS). 346 Currently, R-CHOP has been designated as the first-line treatment agent for NHL by the National Comprehensive Cancer Network (NCCN), while there are numerous clinical trials to validate the efficacy of R-CHOP as a treatment to overcome relapse or refractory of NHL. 347 It is approved in Europe and the United States for use in combination with chemotherapy to treat patients with previously untreated or R/R CLL. 348 For example, a phase II trial evaluated the efficacy of the addition of rituximab to first-line chemotherapy with fludarabine and cyclophosphamide. And the chemo-immunotherapy group achieved a better clinical outcome, with 65% of patients free of disease progression at 3 years after the randomization. 349 Venetoclax-rituximab was also proved to be able to be applied in R/R CLL with significantly higher rates of PFS(84.9%) at 2 years. 88

The development of new mAbs is ongoing and clinical trials are being conducted. Ofatumumab, a fully human mAb, has been used as a single-agent CD20 immunotherapy in R/R CLL and FL in international clinical trials and has been shown to be an active, well-tolerated treatment with significant clinical improvements. 71 , 90 , 350 There are some clinical trials, such as GAUDI, GAUGUIN and GADOLIN, to investigate the efficacy of obinutuzumab (also called GA101) monotherapy and immunochemical combination with it in treating patients with DLBCL, MCL, FL and CLL. 73 , 92 , 93 , 94 , 95 It has also been used to treat CD20-positive indolent NHL refractory to rituximab. In this study, the median PFS was 25.8 months and OS was also prolonged, demonstrating the clinical benefit of obinutuzumab. 74 , 351 As well, tafasitamab (anti-CD19 mAb) is also approved for the treatment of R/R DLBCL and FL as a novel agent. 23 , 209 , 210 , 352 , 353 Some mAbs which has already been approved in autoimmune disease, such as alemtuzumab (anti-CD52 mAb) and ublituximab (anti-CD20 mAb), also expanded their indications to hematologic malignancies. In the GENUINE trial, ublituximab plus ibrutinib achieved encouraging efficacy in high-risk CLL and the ORR was 83%. 354 Alemtuzumab combined with CHOP similarly showed better outcomes with an ORR of 72% and CRR of 60% in the phase 3 trial. 100 In recent years, mAbs have gradually been introduced into the treatment of other hematologic malignancies. Daratumumab, an anti-CD38 mAb, is initially used as monotherapy in R/R MM. In a phase I-II dose-expansion study, daratumumab was administered to patients who had received a median of four prior therapies, including 76% of patients who had received autologous HSCT. The ORR was 36% in the cohort with a dose of 16 mg/kg and 10% in the cohort with a dose of 8 mg/kg. PFS was 5.6 months and 65% of patients who responded had no disease progression at 12 months. 76 The results of the SIRIUS trial were similar and both were favorable in terms of safety and exciting efficacy. 77 Daratumumab was also combined with classical regimens of MM to investigate the efficacy. The phase 3 trial suggested that the ORR was higher in the daratumumab combination group (82.9%) than that in the control group with bortezomib and dexamethasone alone (63.2%). 24 A similar outcome also occurred in the trial that compared the regimen of lenalidomide and dexamethasone, with an ORR of 92.9%. 75 Afterwards, daratumumab plus bortezomib, melphalan and prednisone was also considered as a prior-line therapy for untreated MM patients. And the outcome indicated that the addition of daratumumab resulted in a lower risk of disease progression or death. 78 Another anti-CD38 mAb named isatuximab has improved its effectiveness when combined with classical therapy regimens. Randomized phase 3 trials have been completed for all of thesecombinations. 82 , 83 , 84 Meanwhile, elotuzumab targeted CS1 on MM cells and also indicated encouraging results in serial clinical trials called ELOQUENT that was conducted in R/R and newly diagnosed MM patients. 80 , 81 In a word, mAbs occupy an important position in hematologic cancers and chemoimmunotherapy associated with mAbs has become a popular trend at the present.

In hematologic malignancies, bsAb therapy usually refers to the BiTEs. Blinatumomab is the first bsAb designed for this field. Some early clinical trials were conducted for NHL in the year 2008. Out of 38 patients who received blinatumomab, a response was only observed in 11 patients. And the longest duration of CR is 13 months in one MCL patient. 355 Furthermore, it has been studied in more cases of B-ALL. A phase II trial has demonstrated that blinatumomab is effective in MRD-positive B-ALL patients who are resistant to previous chemotherapy. The drug showed a high response rate, with an ORR of 76% and a relapse-free survival (RFS) rate of 78%. 356 Other studies showed similar results, 26 , 357 , 358 and blinatumomab is also effective in children and young adults with the first relapse of B-ALL. 359 , 360 Therefore, it has already become an approved therapy for R/R B-ALL. Recently, there’re emerging trials to discover the efficacy of the combination therapies of blinatumomab and other regimens for newly diagnosed Philadelphia chromosome (Ph) positive or negative B-ALL. 124 , 361 , 362 , 363 Blinatumomab was also used to treat patients with R/R B-NHL and DLBCL and showed great anti-tumor efficacy. 125 , 126 , 364 , 365 Meanwhile, some novel bsAbs entered the market in 2022, representing the rapid development of this field. Mosunetuzumab, a CD20/CD3 bispecific antibody, was approved for R/R FL based on the results of the multicenter phase II study in which 90 patients with FL received mosunetuzumab and the ultimate CRR was 60%. 131 Glofitamab is also targeted to CD20 but has been shown to induce durable CR in patients with R/R DLBCL. 132 , 133 In the phase I/II study, 52 patients who had previously received CAR-T therapy were enrolled and 35% of them achieved a CR and 78% of CR were sustained at 12 months. 133 Epcoritamab, odronextamab and plamotamab are all anti-CD20/CD3 antibodies and relevant clinical trials have demonstrated that they are competitive in terms of efficacy and safety. 134 , 136 A anti-BCMA/CD3 bsAb, teclistamab, was the first BiTE developed for MM. 150 , 151 , 152 , 153 , 154 In the trial MajesTEC-1, teclistamab demonstrated promising efficacy, with durable responses that deepened over time and was well tolerated in R/R MM patients. 153 Another phase 1–2 study also showed that teclistamab resulted a high rate of deep and durable response in patients with triple-class-exposed R/R MM. 151 The ORR was 63%, the median duration of response was 18.4 months and the median duration of PFS was 11.3 months. 151 Patients enrolled in the trial MajesTEC-2 had received ≥1 prior line of therapy. 152 While in the trial s MajesTEC-4 and MajesTEC-7, newly-diagnosed patients were enrolled and teclistamab was combined with classical regimens for treating MM. 150 , 154 In addition to teclistamab, other anti-BCMA/CD3 bsAbs have emerged currently, including linvoseltamab, elranatamab and alnuctamab and serial trials are being conducted. 155 , 156 , 157 , 158 , 159 , 366 , 367 , 368 In a Phase 2 study, 232 patients received talquetamab (anti- GPRC5D/CD3 bsAb) monotherapy and 70% of those experienced a response and the median duration of response was 10.2 months. 168 A multicenter, open-label, phase 1/2 study of flotetuzumab (MGD006, anti-CD123/CD3 bsAb) was conducted in 88 adults with R/R AML and showed acceptable safety and encouraging evidence of activity in PIF (primary induction failure)/ER (early relapse) patients. 142 JNJ-63709178, another kind of anti-CD123/CD3 bsAb, was found to have limited exposures and clinical activity with an unfavorable safety profile. 145

Over the past several decades, ADCs have been evaluated in many preclinical models and early-phase clinical trials of hematologic malignancies. Gemtuzumab ozogamicin, an anti-CD33 ADC, was once used in AML patients with their first relapse and no history of an antecedent hematologic disorder and a median age of 61 years. This was based on the result of the clinical trial which revealed that 30% of patients who were treated with gemtuzumab ozogamicin achieved a remission, characterized by 5% or fewer blasts in the bone marrow. 369 However, a phase III SWOG S0106 randomized comparative trial did not confirm the clinical benefit of gemtuzumab ozogamic in combination therapy, such as CR rate, disease-free survival (DFS) and OS. Moreover, increased toxicity was observed and probably caused by relatively high instability of the linker in the bloodstream combined with a high recommended dose. 370 Thus, gemtuzumab ozogamicin was withdrawn in 2010 due to its serious toxicities and poor outcomes of survival. 371 , 372 , 373 It has been re-approved until 2017, following adjustments to the dosage and conditions as well as extensive clinical trials. 374 , 375 , 376 , 377 At present, it is believed that the benefit of gemtuzumab ozogamicin can be predicted by some related conditions and this is the reason why gemtuzumab ozogamicin is used in AML with high CD33 expression levels and corresponding mutated genetic profiles (e.g. NPM-1 mutated, KMT2A rearranged). 198 , 378 , 379 Furthermore, gemtuzumab ozogamicin is effective when used in newly diagnosed core binding factor (CBF)-deficient AML in the clinical trial conducted by MD Anderson. 380 In addition, a humanized anti-CD22 ADC called inotuzumab ozogamicin was initially given to patients with R/R B-NHL in a phase 1 clinical trial. Unfortunately, the final ORR was only 39% for the 79 patients enrolled. 187 Later on, inotuzumab ozogamicin has been tried to be used in R/R B-ALL patients. In the phase 2 trial, the ORR was 57% for the 49 patients in the study. 381 To further demonstrate the promise of inotuzumab ozogamicin, it was compared to standard intensive chemotherapy for ALL in a phase 3 trial. In the inotuzumab ozogamicin group, the CR rate was significantly higher (80.7%), the median duration of remission was longer (4.6 months) and the median PFS was also longer (5.0 months). 180 Based on these results, the FDA approved the use of inotuzumab ozogamicin in adult R/R B-ALL. Meanwhile, clinical trials continued to evaluate the efficacy of the combination therapy in Ph(-) ALL and in pediatric patients. 188 , 382 , 383 Another anti-CD22 ADC, called moxetumomab pasudotox, has been developed for the treatment of R/R hairy cell leukemia (HCL). 189 In the long-term follow-up from the pivotal trial, complete responders lasting ≥60 months was 61% and median PFS without the loss of hematologic remission was 71.7 months. Moxetumomab pasudotox fills the gap in R/R HCL where there is no adequate therapy. 384 In 2022, brentuximab vedotin (anti-CD30 ADC) was used in patients with III/IV-stage cHL. Compared with the classical ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) regimen, the combination of brentuximab vedotin plus BVD (bleomycin, vinblastine and dacarbazine) showed better consequences with a 6-year OS of 93.9%. 181 Polatuzumab vedotin has been designed to target CD79b and used for the treatment of R/R B-NHL including DLBCL and FL. 191 , 209 , 210 Polatuzumab vedotin combined with bendamustine and rituximab resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with bendamustine and rituximab in patients with transplantation-ineligible R/R DLBCL. 210 Loncastuximab tesirine (ADCT-402) is a humanized anti-CD19 IgG1 mAb conjugated through a protease-cleavable Val-Ala linker to a pyrrolobenzodiazepines dimer, a DNA crosslinking agent. 203 , 204 A phase 1 study of loncastuximab tesirine in R/R B-cell NHL showed that ORR in evaluable patients was 45.6%, including 26.7% CRs. ORRs in patients with DLBCL, MCL, and FL were 42.3%, 46.7%, and 78.6%, respectively. 185 Further, a multicentre, open-label, single-arm, phase 2 trial (LOTIS-2) was conducted in patients with R/R DLBCL after two or more multiagent systemic treatments with an ORR of 48.3% and a CRR of 24.1%. 203 Belantamab mafodotin chose BCMA as the target and fills the gap of ADC in MM and the serial trials continue to discover its clinical efficacy and durability as monotherapy or combined with other regimens. 211 , 385 , 386 The DREAMM-2, a two-arm, randomized, open-label, phase 2 study, demonstrated that 31% of 97 patients in the 2·5 mg/kg cohort and 34 of 99 patients in the 3–4 mg/kg cohort achieved an overall response. 211 In DREAMM-6 trial, belantamab mafodotin showed a better outcome with an ORR of 75% and a median PFS of 8.6 months. 386 It seems that ADCs have already played an important role and became a new trend in immunotherapy for hematologic malignancies nowadays. These ADC drugs have achieved satisfactory results in clinical trials and have been approved for use in the diseases for which they are intended. 191 , 203 , 204 , 210 , 353 Furthermore, there’re still some novel ADCs waiting for approval and the corresponding clinical trials are ongoing. 199 , 200 , 221

Several clinical trials of ICIs have been conducted in hematologic malignancies, including MM, ALL, AML, NHL and HL. 387 , 388 , 389 , 390 However, only the results of PD-1 blockade in HL are particularly remarkable. Some observations may suggest why HL is uniquely sensitive to PD-1/PD-L1 blockade. 391 First, HL biopsies typically show the Reed-Sternberg (R-S) cells that are surrounded by an extensive immune infiltration, but it is ineffective. Moreover, increased surface expression of PD-L1 was also observed in HL biopsies. Second, HL is characterized by the genetic alterations in 9p24.1 that result in copy gain and overexpression of PD-L1 and PD-L2, with an increase in copy gain or amplification of 9p24.1 in more than 97% of newly diagnosed HL biopsy specimens. 392 , 393 Third, infection with Epstein-Barr virus (EBV) is common in HL patients and also causes PD-L1 to be overexpressed, which is one of the key mechanisms by which the virus could persist in the host. 394 In contrast, NHL does not display a high frequency of 9p24.1 alterations, thus the efficacy of ICI decreased for NHL patients. 395

Table 2 gives a summary of representative clinical trials of ICIs that are already approved by the FDA or some novel ICIs (e.g., dual-target ICI) that are still in the stage of the clinical study. 387 , 396 , 397 , 398 , 399 , 400 , 401 , 402 , 403 , 404 , 405 , 406 , 407 Ipilimumab, a CTLA-4 inhibitor, has been evaluated in clinical trials of the treatment for NHL and HL patients, 396 , 397 , 398 but only showed certain therapeutic effects in HL with an ORR of 76% and CRR of 57%. 398 Since HL has the property of being more sensitive to ICIs targeting PD-1, most of the clinical trials of PD-1 blockades, including nivolumab, pembrolizumab and pidilizumab, were conducted on R/R HL. 194 , 387 , 396 , 398 , 400 , 408 In recent years, nivolumab and pembrolizumab have been used in patients with NHL, CLL 404 , 409 , 410 and even in some lymphomas for which there is no effective therapy, such as PCNSL (primary central nervous system lymphoma) and PMBCL (primary mediastinal large B-cell lymphoma). 402 , 403 , 411 Moreover, there’s a clinical trial of pidilizumab conducted in advanced hematologic malignancies including MM, promoting the wide application of ICIs. 412 In addition to PD-1 blockade, CD47 blockade has emerged as the treatment for R/R NHL, MM and especially for AML/MDS, where PD-1 blockade shows poor efficacy. 413 , 414 , 415 , 416 , 417 To improve the overall response, one phase 1b trial explored the safety and efficacy of combined PD-1 and CTLA-4 blockade in patients with R/R lymphoid malignancies, including HL, NHL, and MM. 399 But it is regrettable that there was no meaningful improvement in the efficacy of the combinations over single-agent nivolumab in the diseases studied. While this combination was active in HL (ORR 74%, CRR 23%), the toxicity of nivolumab /ipilimumab was higher than expected from nivolumab alone.

Our primary focus has been on the large clinical trials of CAR-T cell therapy in various hematologic malignancies. Table 3 gives a summary of representative clinical trials and outcomes of CAR-T cell monotherapy for blood cancers. Tisagenlecleucel, axicabtagene ciloleucel and lisocabtagene maraleuecel are the most representative anti-CD19 CAR-T cell products and they have been studied in a large number of clinical trials. For tisagenlecleucel, ELIANA has indicated its efficacy in pediatric patients with B-ALL. 418 Other clinical trials with tisagenlecleucel are predominantly focused on B-NHL. Among them, JULIET investigated the CAR-T therapeutic efficacy in R/R DLBCL, 419 BELINDA raised tisagenlecleucel as second-line treatment, 420 and ELARA enrolled patients with R/R FL. 421 The clinical trials for axicabtagene ciloleucel are called ZUMA 422 , 423 , 424 , 425 , 426 , 427 and cover the treatment of R/R LBCL, B-ALL, and MZL. The most recent one, ZUMA-12, demonstrated the high response rate of axicabtagene ciloleucel as first-line therapy for untreated high-risk LBCL. 427 Lisocabtagene maraleuecel has fewer trials in comparison with the two products above, but the 2022 TRANSCEND CLL 004 study showed surprising results suggesting an ORR of 82% in patients with R/R CLL and small lymphocytic lymphoma (SLL). 428 However, the antigen expression of tumor cells still limits the efficacy of CAR-T therapy. Since CD19 may not cover all types of lymphoma subclones, 428 , 429 , 430 CAR-T cells targeting other highly-specific antigens and dual targets, 302 , 431 , 432 , 433 , 434 , 435 , 436 , 437 such as CD22, CD19/CD20, and CD30, have been developed as well. The anti-CD30 CAR-T cells have also been developed in HL, 435 , 436 , 437 and more clinical trials are being conducted to verify their efficacy.

In addition to lymphoma and leukemia, CAR-T cells have also made great progress in treatment of MM. 278 , 438 , 439 , 440 , 441 , 442 , 443 , 444 , 445 , 446 Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have already been approved by the FDA based on responses and safety demonstrated in the KarMMa and CARTITUDE-1 trials. 439 , 440 , 442 Meanwhile, more companies have launched CAR-T cell products for MM, such as orva-cel, P-BCMA-101. 443 , 444 , 446 , 447 , 448 , 449 CAR-T cell products against the new target, GPRC5D, have also been developed without delay. Usually, patients enrolled in CAR-T clinical trials have a good baseline condition. This is to prevent them from not being able to tolerate side effects such as CRS. However, the first clinical trial of the GPRC5D target was conducted in patients with poor baseline conditions who had received multiple lines of therapy. 299 The clinical results also showed a high level of safety and efficacy, taking the development of CAR-T to a new level. In other types of hematological malignancies, CAR-T therapy is still in the exploratory phase of development. A single-center, single-arm, phase 2 trial assessed the activity and safety of a combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with R/R MM and confirmed that this combined infusion is feasible with ORR of 95% and CRR of 43%. 450 As for AML, CAR-T therapy seems to be less effective due to the lack of appropriate tumor targets and is still being explored in preclinical and clinical studies. 289 , 451 , 452 , 453 The difficulty of manufacturing cell products using autologous T cells is the major problem facing CAR-T therapy in T-ALL. As a result, several institutions have developed donor-derived CAR-T cells and have conducted clinical trials to confirm the efficacy and safety of these CAR-T cells. 281 , 284 , 454 The donor-derived CAR-T cells suggested encouraging effects, especially in those patients who received allo-HSCT. 455

The universal CAR-T cells, also known as “off-the-shelf”, can overcome the problem of long period of manufacturing and enable those patients whose T cells are under poor condition to receive CAR-T therapy. Due the heterologous nature of allogeneic CAR-T cells, many products are designed to knock out of the TCR or edit the CD52 gene to overcome GVHD and HVGD (host versus graft disease). It is slao essential to examine the safety and in vivo persistence of universal CAR-T cells through clinical trials. 446 , 456 , 457 , 458 , 459 , 460 Anti-CD19 universal CAR-T cells, like PBCAR0191 and bispecific universal CAR-T CTA101, also showed high rates of CR (60% and 83.3%). 301 , 461 81.8% of patients showed OR after RD13-01 infusion (CRR 63.6%) without GVHD and severe CRS. 458 A phase 1 UNIVERSAL trial reported a first-in-class, allogeneic, anti-BCMA CAR-T cell therapy (ALLO-715) engineered to abrogate GVHD and minimize CAR-T rejection. ALLO-647 (anti-CD52 antibody) was used for lymphodepletion with fludarabine and/or cyclophosphamide before ALLO-715 infusion. There was obvious expansion in 83.3% of patients yet 63.3% of patients showed undetectable levels of CAR-T cells by the day 28. 446 Overall, universal CAR-T cells have made some progress, but the clinical safety, efficacy and the duration of response of these products still requires further observation.

Although CAR-T cell therapy has achieved outstanding results when used as a monotherapy, there are still certain patients who do not benefit from it and further research is urgently needed to improve and prolong the efficacy of CAR-T therapy. Therefore, researchers are focusing on the combination of other immunotherapies with CAR-T cell therapy. The immune checkpoint molecule PD-1 on the surface of CAR-T cells has been reported to be overexpressed due to T-cell overactivation and thus blocking the PD-1/PD-L1 pathway might effectively restore the function of CAR-T cells. 462 Clinical trials have been performed with the combination of PD-1 blockers and CAR-T therapy and the results have been encouraging. A phase II clinical trial of anti-CD30 CAR-T treatment in combination with PD-1 inhibitor in R/R CD30-positive lymphoma has been conducted. Among the 12 patients who were evaluated for response, the ORR was 91.7% and the CRR was 50%. And 7 patients maintained their response until the end of the follow-up. 463 Additionally, the combination of CD19 CAR-T cells and PD-1 blockade was proven to reduce intracranial tumor burden in a patient with centrally-invasive lymphoma. 464 However, some researchers have chosen to construct endogenous PD-1 dominant-negative receptors (DNRs) within CAR-T cells to allow them to bind both TAA and PD-1 on tumor cells, ensuring that CAR-T function is not inhibited. 465 , 466 In combination with CAR-T cell therapy, HSCT is also a popular alternative. Bridging therapy with donor CAR-T cells after allogeneic transplantation can have shown a prolonged effect on the efficacy of the transplant. 467 , 468 According to the results from a retrospective study, haplo-HSCT with pre-transplant negative MRD after CAR-T cell therapy can significantly improve LFS (leukemia-free survival) and OS in patients with R/R B-ALL. 469 This finding was confirmed in subsequent clinical trials. In the subgroups of patients who achieved MRD-negative CR after CAR-T cell therapy, event-free survival (EFS), and RFS were significantly prolonged by allo-HSCT. 470 As a result, CAR-T therapy followed by transplantation can improve survival in a similar manner and is a viable option for achieving a durable remission of the disease.

Currently, CAR-NK is also a hot topic of research, with the major advantage that NK cells are able to be produced from healthy donor-derived PBMC, core blood, or iPSCs (induced pluripotent stem cells) without any appreciable toxicity. 11 patients were treated in a phase 1/2 study with anti-CD19 CAR-NK derived from core blood. Among them, 8 patients experienced a response and 7 of them experienced a CR. The infused CAR-NK cells proliferated and persisted in vivo at low levels for at least 12 months. 471 Although it was not effective in B-ALL patients unfortunately, NKX019 showed a favorable efficacy in R/R B-NHL patients and the ORR was 83% and CRR was 50% in the higher-dose group. 472 Besides, NKX101 targeted NKG2D (natural killer cell group 2 member D) and achieved an ORR of 47% in all R/R AML patients enrolled. 473 For R/R MM, FT576 was proved to be safe and tolerates without CRS, GVHD, or neurotoxicity and was determined a recommended dose in a phase 1 trial. 474 In addition, more researches on CAR-NK cells are still in the pre-clinical stage or early clinical trials. 308 , 475 Further research is also needed to perfect the design and manufacturing to improve the efficacy and durability of CAR-NK cells. 476 , 477

AEs and toxicity management

The era of immunotherapy has brought revolutionary breakthroughs for hematologic malignancies. These therapies are designed to stimulate the immune system to recognize and attack cancer cells, thereby extending survival and improving outcomes. However, immunotherapy poses new clinical problems and challenges for hematologists due to its toxicity, which is different from traditional chemotherapy, depending on the specific mechanism of action. 478 The occurrence of AEs cannot be ignored and can affect almost all organs and systems. These AEs further impede the clinical application of immunotherapy and, in severe cases, even threaten the patient’s life. 478 Therefore, the need for and importance of toxicity management has become increasingly apparent. Treatment of AEs usually depends on the organ involved and the severity of symptoms. These toxicities often require specific management, including steroids and immunomodulatory therapy, for which consensus guidelines have been proposed and published. Here, we summarize the typical AEs associated with various immunotherapies, including HSCT, antibody-based therapies, ICIs, and CAR-T cell therapies, and then discuss their clinical management.

AEs of HSCT

Although HSCT can give some patients a chance at a cure, it is not an easy decision to be made. Transplantation has been a cure for thousands of patients with lethal forms of cancer. However, there can still be life-threatening risks and complications. Most of the side effects that can occur shortly after the transplant are the result of the bone marrow being destroyed by drugs or radiation just before the transplant. Others may be due to side effects of the conditioning treatments themselves. A short-term side effect that can occur with chemotherapy and radiation is mucositis. To prevent this, doctors often give anti-nausea medication at the same time as chemotherapy. Patients can easily get serious infections for at least the first six weeks after the transplant until the new stem cells start to produce white blood cells. 479 , 480 , 481 To prevent possible infections, antibiotics are used until the blood counts reach a certain level. It can take about 6 months to 1 year after the transplant for the immune system to take effect. Injuries and bleeding are other potential risk because the conditioning regimen can damage the body’s ability to generate platelets. Pneumonitis is a type of inflammation of the lung tissue that’s most commonly seen in the first 100 days after the transplant. However, some kinds of lung problems can occur much later after a transplant. Pneumonia caused by an infection is more common, but pneumonitis can also be caused by radiation, GVHD, or chemotherapy, rather than by the infection itself. Pneumonitis can be particularly severe if the patient has received total body irradiation with chemotherapy as part of the pre-transplant regimen. Acute kidney injury (AKI) directly related to stem cell transplant encompasses a wide range of both structural and functional disorders, which may be of the vascular (hypertension, thrombotic microangiopathy), glomerular (albuminuria, nephrotic glomerulopathies), and/or tubulointerstitial type. 482 , 483 , 484 AKI is a common complication following stem cell transplantation, affecting ~10–73% of patients. 482 A serious side effect in which tiny veins and other blood vessels in the liver become blocked is a hepatic veno-occlusive disease (VOD). 485 It is very rare and is only seen in people who have had an allogeneic transplant. 485 , 486 The onset of VOD is usually about 3 weeks after transplantation. It is more common in older patients who have had liver disease before the transplant and in patients who have acute GVHD. The symptoms are yellow skin and eyes, dark urine, tenderness under the rib cage and a rapid increase in body mass. 485 It is life-threatening, so it is very important to recognize and diagnose VOD at an early stage. 487 , 488

GVHD is a leading contributor to mortality and morbidity after allo-HSCT. 489 , 490 The donated immune cells may also attack some of the organs, most typically the skin, the gastrointestinal tract and the liver. As a result, there may be some changes in the functioning of the body’s organs and an elevated risk of infections. 491 GVHD reactions are very common and can range in severity from barely noticeable to life-threatening. 39 , 492 , 493 Acute GVHD can occur between 10 and 90 days after the transplant and lasts for a short period of time. Chronic GVHD has a later onset and longer duration. The patient may experience one or both types of GVHD, or neither type of GVHD. Acute GVHD develops in approximately one-third to one-half of allogeneic transplant recipients. It is less frequent in the younger patients and the ones with a more closely matched HLA. A rash, burning and redness of the skin on the palms and the soles of the feet are usually the first symptoms. The rash may spread to the rest of the body. Other symptoms may include nausea, vomiting, stomach cramps, decreased appetite, jaundice, abdominal pain, and weight loss. Medications that can suppress the immune system may be given to prevent acute GVHD, such as steroids (glucocorticoids), methotrexate, cyclosporine, tacrolimus, or some types of mAbs. 492 , 494 These are administered before acute GVHD begins to occur. The risk of acute GVHD can also be reduced by the removal of immune cells from the donor stem cells prior to transplantation. However, this also increases the risk of viral infection, leukemic recurrence and graft failure. Researchers are exploring new ways to remove allo-activated T cells from donor transplants, which would reduce the severity of GVHD while still allowing donor T cells to destroy any remaining cancer cells. Mild cases of GVHD can usually be treated with topical steroid medications. More severe cases of GVHD may need to be treated with oral steroid medications or intravenous steroid medications. Chronic GVHD, which can lead to significant morbidity and mortality, usually occurs within one year of allo-HSCT. 495 When engrafted immune cells attack host cells, it causes inflammation and fibrosis in various types of tissues and multiple organ systems, such as the esophagus, gastrointestinal tract, neuromuscular system, genitourinary tract, liver, lungs, mouth, eyes, muscles, and joints. 495 , 496 Symptoms of chronic GVHD may include dry eyes, raised or discolored rash, thickened skin, swollen abdomen, yellowing of the skin and eyes, dry mouth, breathlessness, difficulty swallowing, fatigue, muscle weakness, and joint stiffness. Chronic GVHD can also be treated with immunosuppressive drugs, but these drugs increase the risk of infection. Most patients who have chronic GVHD will be able to stop taking the immunosuppressive medication if their symptoms are getting better.

Secondary cancers

It is possible for the original type of cancer to come back and for a second type of cancer to develop after the transplant. 497 , 498 , 499 The cancers that can develop are solid tumors in various organs, leukemia and MDS. They tend to occur a few years or even longer after engraftment. 500 , 501 Post-transplant lymphoproliferative disorder (PTLD) is an out-of-control growth of lymphocytes that can occur following alloHSCT. 502 , 503 Normally, T cells assist the body in getting rid of virally infected cells. The pretransplant treatment compromises the immune system, enabling EBV infections to get out of control. PTLD after allo-HSCT is relatively rare and generally occurs within one to six months. The symptoms of PTLD consist of swollen lymph nodes, fever and chills. 503 Although there is no standard treatment, the usual management is to reduce the use of immunosuppressive drugs and encourage the patient’s immune system to fight back. Other options involve infusing lymphocytes to boost the immune response and the administration of antiviral drugs. 503 , 504 , 505 , 506

AEs of antibody-based therapies

Antibody-based drugs have been generally considered to be less toxic than cytotoxic chemotherapeutics used for cancer therapy, while some of these elements may be recognized as foreign substances and thereby cause hyperactivation of immune and innate reactions. A wide spectrum of AEs to antibodies is observed, necessitating efforts to identify, manage and minimize side effects. Some toxicities result from the binding of a therapeutic antibody to its target antigen on normal cells, which refers to the “on-target, off-tumor” toxicity. Therefore, the manifestations of such toxicities are dependent on the target of antibody drugs. For example, rituximab can cause profound first-dose toxicity related to the rapid lysis of normal and malignant B cells that bear the target antigen, CD20. 507 Acute reactions can be caused by a variety of mechanisms, including acute IgE-mediated hypersensitivity and anaphylactoid reactions against the antibodies, serum sickness, tumor lysis syndrome (TIS) and CRS. 508 , 509 Clinical manifestations include local skin reactions at the injection site, fever and influenza-like syndrome and potentially fatal acute anaphylaxis and systemic inflammatory response syndrome (SIRS). Hypersensitivity reactions may be severe enough to require aggressive management and discontinuation of therapy. Meanwhile, these antibodies have immunomodulatory effects thus they can also induce various autoimmune diseases. AEs are also common in patients receiving bsAbs, with the majority of them being grade 3 or higher-grade AEs. A phase II study which included R/R B-ALL patients revealed that the common AEs during blinatumomab therapy included pyrexia (81%), fatigue (50%), headache (47%), tremor (36%), and leukopenia (19%), and most of the AEs occurred during the first cycle of administration. 357 In another trial, patients in the blinatumomab group suffered more AEs but the rate of serious AEs in the blinatumomab group was lower than that in the chemotherapy group. 510 The T-cell activation induced by BiTE poses the risk of unique complications such as CRS, neurotoxicity and TIS. 511 Moreover, severe CRS and neurological toxicity are the main reasons for the interruption of BiTE therapy, which can be controlled by close clinical monitoring and timely preventive or therapeutic intervention.

More importantly, the immunogenicity of antibodies is not only related to the percentage of homology, as specific amino acid changes at some positions can also affect immunogenicity. Drug-induced immunogenicity has been recognized as a major challenge in the development of antibodies, resulting in adverse effects and loss of efficacy. Drug administration to patients may induce humoral immune responses, causing the formation of anti-drug antibodies (ADAs). ADAs can complex with circulating therapeutic antibodies, making it difficult to achieve efficacious levels of circulating therapeutic antibodies. ADAs may not only inactivate the drug and cause a loss of targeting and/or increased clearance of ADA-drug complexes but also induce increased toxicity caused by the immune response that accompanies ADA formation, loss of drug targeting, or formation of highly immunogenic complexes. 508 , 512 Therefore, ADA assays should be rationally designed to allow an understanding of the characteristics and consequences of the detected ADAs.

Both the cytotoxic molecules and the antibody portion of ADCs can affect normal cells, resulting in “off-tumor” toxicities. 513 These “off-tumor” toxicities can be divided into “on-target” and “off-target” toxicities. The “on-target” toxicity is caused by ADCs killing normal tissues that express the target antigen, while “off-target” toxicity refers to the killing of ADCs in tissues that do not express the target antigen. Based on clinical observations, “on-target toxicity” caused by small molecule toxins is the major source of adverse effects of ADCs. Both antibody-mediated ADCC and CDC effects can occur in normal cells expressing the target antigen and lead to adverse reactions such as secondary kidney injury. In addition, like mAbs and bsAbs, ADCs can block the signaling of target antigens in normal cells, resulting in adverse reactions such as lung injury and liver toxicity. The “off-target toxicity” can be caused by the shedding of cytotoxic molecules into the circulation, bystander effect on normal cells and endocytosis and uptake of ADC by normal cells, causing normal cells to suffer damage from cytotoxic molecules. 514 The main victims are lymphocytes, granulocytes, and platelets in the bloodstream, followed by kidneys, lungs, nerves, skin and other tissues, causing clinically observed side effects similar to those of chemotherapeutic drugs. 513 Common AEs include fever, nausea, infection, vomiting, and stomatitis. Severe side effects were low blood counts, liver damage including hepatic VOD, infusion-related reactions and hemorrhage. Treatment discontinuation should be considered for patients who develop obvious signs or symptoms of anaphylaxis, including severe respiratory symptoms or clinically significant hypotension. Premedication with a corticosteroid, antihistamine and acetaminophen is recommended about one hour prior to the administration of ADC agent. 515

Immune-related adverse effects during ICI therapy

AEs linked to the use of ICIs are referred to as immune-related AEs (irAEs). These primarily include immune-related skin toxicity, endocrinopathies, hepatotoxicity, gastrointestinal toxicity, pulmonary toxicity, hematologic toxicity, central nervous system toxicity, cardiovascular toxicity, rheumatologic toxicity, immunotoxicity, renal toxicity, ocular toxicity, etc.). The incidence of irAEs with single-agent ICIs varies depending on the single agent, the tumor type and the disease setting. 478 Grading of irAEs is in accordance with the Common Terminology Criteria for AEs (CTCAE). Recommendations for the monitoring, diagnosis and treatment of irAEs are available in consensus guidelines from the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the NCCN and the Society for Immunotherapy of Cancer (SITC). 516 , 517 , 518 , 519 , 520 In principle, there are four sequential steps in the management of irAE: (i) diagnosing and grading irAEs, (ii) ruling out differential diagnoses and workup before immunosuppression, (iii) selecting the appropriate immunosuppression strategy for grade ≥2 cases, and (iv) actively evaluating at 72 h to make treatment adjustments. 521 While the management depends on the affected organ system, in general, ICI therapy should be followed with close monitoring for grade 1 toxicities, except for some neurologic, hematologic and cardiovascular toxicities. 521 ICI therapy may be discontinued for the majority of grade 2 toxicities. Consideration should be given to resuming ICI therapy if symptoms revert ≤grade 1. Suspension of ICIs and initiation of high-dose corticosteroids is generally warranted for grade 3 toxicities. Corticosteroids should be tapered over the course of a minimum of 4 to 6 weeks. For grade 4 toxicities, permanent discontinuation of ICIs is generally recommended. This does not apply to endocrinopathies that have been controlled with hormone replacement therapy. 521 , 522

Immune-related skin toxicity

Dermatologic toxicity seems to be one of the most commonly occurring AEs during treatment with ICIs. 523 , 524 , 525 , 526 , 527 Maculopapular eruption and pruritus are the most common symptoms. Serious dermatologic toxicities, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS) and acute febrile neutrophilic dermatosis (Sweet syndrome) and systemic symptoms, are rare. 524 Although serious cutaneous AEs are rare, cutaneous side events can have a significant impact on the quality of life, reduce patient compliance and lead to dose adjustments or even discontinuation of treatment. 525 , 528 The question of whether ICIs can be resumed after grade 3 skin toxicity has been reduced to grade 1 or less with hormonal therapy should be discussed with the dermatologist. ICIs should be discontinued permanently and patients referred to a dermatologist if severe (grade 4) herpetic dermatoses occur. 516 , 517 , 518 , 519 , 520

Immune-related endocrinopathies

Immune-related endocrinopathies involving the thyroid gland (hypothyroidism or thyrotoxicosis), pituitary hypophysitis, adrenal glands (adrenal insufficiency), and pancreas (diabetes mellitus) are a frequent cause of acute and prolonged morbidity and may even be fatal. 529 , 530 , 531 , 532 , 533 Mild symptoms can be managed with continuation of ICI therapy with appropriate hormone replacement therapy; moderate symptoms require immediate discontinuation of ICI therapy and moderate symptoms require oral prednisolone 0.5–1 mg/kg; severe symptoms require intravenous prednisolone 1 mg/kg (methyl) tapered to 5 mg depending on symptom control, but hormone therapy cannot be discontinued. Routine monitoring of blood glucose levels is recommended in patients treated with ICIs and caution is required for the development of life-threatening ketoacidosis. 533 Unlike other irAEs, endocrinopathies are almost always permanent and require lifelong hormone replacement. 520 Due to the relatively vague nature of the symptoms associated with these endocrinopathies, prompt recognition and initiation of treatment can have a dramatic impact on a patient’s health and quality of life.

Immune-related hepatotoxicity

ICI-associated hepatitis is mainly characterized by elevated levels of transaminases with mildly elevated levels of bilirubin. 534 , 535 , 536 The diagnosis of immune-related hepatitis may be aided by laboratory tests, which include viral serologies, liver ultrasound, cross-sectional imaging, and liver biopsy. 534 Serum transaminase and bilirubin levels are recommended for all patients receiving ICI therapy before each treatment cycle to assess liver function. Hepatitis is usually asymptomatic, with some patients presenting with low-grade fever and malaise, which may be associated with transaminase levels. 535 Most patients with immune-related hepatitis respond to corticosteroids, but a substantial fraction require treatment with a secondary immunosuppressive agent. 534 It is also important to be alert to cases in which rebound transaminase levels or even fulminant hepatitis have been observed clinically, even after transaminase levels have been reduced to normal. The patient’s clinical presentation and serologic test results must continue to be monitored after recovery of liver function.

Immune-related gastrointestinal toxicity

Immune-related gastrointestinal toxicity is also a common adverse effect of ICI therapy, mainly manifested as diarrhea, colitis and small bowel inflammation. 537 , 538 , 539 , 540 The risk of gastrointestinal side effects is much higher with anti-CTLA-4 mAbs than with anti-PD-1/PD-L1 mAbs and can occur at any time during treatment, even months after treatment has ended. The median time for gastrointestinal side effects was 3 months. Following the diagnosis of immune-related gastrointestinal adverse events, the clinical selection of treatment options was based on the severity and duration of diarrhea. In addition to discontinuation of ICI, patients with grade 1 diarrhea may be treated with antidiarrheal drugs alone (loperamide, etc.) based on active rehydration and correction of water-electrolyte imbalance; for grade 2 diarrhea and above, glucocorticoids are the first recommended treatment; for grade 3–4 diarrhea or if glucocorticoid therapy is ineffective, immunosuppressive agents (e.g, infliximab, vedolizumab) are also an option.

Immune-related pulmonary toxicity

Immune-related pulmonary toxicity is a heterogeneous group of disorders that includes various clinical manifestations such as interstitial lung disease (ILD) or pneumonitis and rarer presentations such as bronchiolitis or pulmonary sarcoidosis. 519 , 541 , 542 , 543 Immune-related pulmonary toxicity usually appears in the first few months and is accompanied by non-specific clinical manifestations but with suggestive radiologic signs. 544 Exploratory endoscopy, including bronchoalveolar lavage and transbronchial lung biopsies, can further refine the diagnosis by ruling out a lung infection and demonstrating lymphocytic alveolitis. Any new respiratory symptoms, such as upper respiratory tract infection, cough, wheezing and dyspnea, should prompt a chest CT (computerized tomography) scan. Follow-up and monitoring are recommended for those who have imaging changes only and no clinical symptoms (grade 1); prednisolone therapy is suggested for those with mild to moderate symptoms (grade 2) and those with severe or life-threatening symptoms. For grade 2 pneumonia, clinical symptoms should be evaluated every 2–3 days; for grade 3–4 pneumonia, clinical symptoms and imaging should be evaluated after 2 days of treatment and if there is no evidence of improvement, immunosuppressive agents such as infliximab, cyclophosphamide, or mycophenolate mofetil can be considered. 517 , 518 , 519

Other rare immune-related toxicities

Rare immune-related toxicities during ICI treatment mainly include neurotoxicity, cardiotoxicity, rheumatologic immunotoxicity, hematologic toxicity, neuromuscular toxicity, and nephrotoxicity. 545 , 546 , 547 , 548 , 549 , 550 , 551 , 552 , 553 However, they are still reported in 1–12% of cases and are more common in patients receiving combination therapy. As an increasing number of patients with cancer are being treated with checkpoint inhibitors, the balance between clinical benefits and treatment-related toxicities for each patient is becoming more challenging. 554 Rarity is not the same as insignificance and the extent of damage to patients after its occurrence can even lead to death in a short period of time. In general, patients who experience a severe grade 3 or 4 irAE during ICI therapy are at risk of experiencing serious toxicities when rechallenged with checkpoint inhibitors. 555

CAR-T therapy-related toxicities

Cytokine Release Syndrome (CRS) and neurotoxicity are the most common and unique toxicities associated with CAR T-cell therapies, 556 , 557 , 558 , 559 , 560 , 561 , 562 , 563 , 564 , 565 , 566 , 567 and they are completely different from the irAEs that are associated with the treatment of ICIs. CAR-based therapies have the advantage of higher targeting specificity over conventional chemotherapy and radiotherapy. However, like antibody-based therapies, targeted antigens od CAR-T cells are also expressed in normal cells, such as CD19 in the normal B-cell lineage. The “on-target, off-tumor” toxicity is widespread, although a large part of others has not been identified or overlapped with other symptoms. Some toxicities, such as hypogammaglobulinemia, are a direct consequence of the “on-target, off-tumor” effects of the CAR-T cells and others may be an indirect result of the immunosuppressed state of the host. 565 For early recognition of potential toxicities and timely intervention, clinical monitoring before, during and after CAR-T cell therapy is critically required. Perhaps more importantly, with the appropriate management strategies, some of these toxicities associated with CAR-T therapies can be reversed with appropriate monitoring and management (Table 4 ). 559 , 568 , 569 , 570

CRS is the most common life-threatening adverse event associated with CAR T-cell therapy. Variable incidence of CRS has been reported with different CAR T-cell therapies due to differences in grading scales used to assess CRS severity, CAR T-cell design and generation and clinical trial design. 565 , 571 The typical time to the onset of CRS ranges from 2 to 3 days, with a persistent duration of 7 to 8 days, although CRS can occur within a few hours or as late as 10 to 15 days after CAR-T cell infusion. The onset of CRS is usually characterized by fever and constitutional symptoms such as malaise and anorexia. In severe cases, CRS also manifests with features of a systemic inflammatory response. These include hypotension, hypoxia, cytopenia, coagulopathy and even organ dysfunction. The organ dysfunction may be the secondary effect of hypotension or hypoxia, but it may also be a direct result of the release of cytokines. Organ dysfunction can be prevented or even reversed in the majority of patients if the symptoms and signs of CRS are recognized and addressed in a prompt and timely manner. 564 CAR-T cell-mediated cancer elimination was also the trigger for the systemic inflammatory response, which is the hallmark of CRS. 556 , 558 , 572 Thus, from a clinical standpoint, the most important management to overcome CRS is to block the feedback loop of cytokines. 573 Cytokines and markers of inflammation that have been implicated in more severe CRS are C-reactive protein (CRP), ferritin, interferon (IFN)-γ, IL-1, IL-2, soluble IL2-Rα, IL-4, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, granzyme B, granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein-1α (MIP-1α), and monocyte chemoattractant protein-1 (MCP-1). 564 , 574 , 575 , 576 , 577 A number of risk factors for severe CRS have been implicated, although these vary between different studies and likely between different indications. In general, these include an increased CAR-T cell expansion and a higher tumor burden. 578 , 579 Moreover, bone marrow (BM) suppression is also considered a determinant of the occurrence and evolution of CRS. 579 Because the management of CRS depends on the severity of the disease, several institutions had independently developed different CRS grading systems prior to the publication of consensus guidelines. These guidelines have contributed to the standardization of CRS management. Both direct targeting and non-specific immunosuppressive strategies to counteract overactive immune cells and elevated cytokine are used to control CRS in patients receiving CAR T-cell therapy. IL-6 has been implicated as an activating signal for CAR-T cells and is considered a pivotal mediator of CRS. The empirical testing of various blocking antibodies soon identified IL-6 as a critical driver of CRS. Tocilizumab, a monoclonal antibody that blocks signaling through the IL-6 receptor (IL-6R), became a cornerstone of CRS management. 564 , 580 , 581 , 582 , 583 In general, patients with grade 1 CRS should be given broad-spectrum antibiotics along with supportive care. This may vary depending on the end-organ toxicities that are observed. Intravenous tocilizumab should be administered for a maximum of 4 doses to patients with grade ≥2 CRS. In cases of grade ≥3 CRS and in cases of grade 2 toxicity with sustained hypotension after anti-IL-6 therapy, the addition of corticosteroids should be considered. 518 To prevent the progression of CRS, emergent intervention is warranted. However, other potential causes of the inflammatory response, including infection and malignant progression, should be ruled out. If there is no improvement in CRS after treatment with tocilizumab and steroids, an examination for infection should be performed and managed as necessary. In addition to siltuximab and anakinra, other agents may be considered for patients who are refractory to both tocilizumab and corticosteroids. These agents include the Janus-associated kinase inhibitor, cyclophosphamide, extracorporeal cytokine adsorption with continuous renal replacement therapy, intravenous IgG (IVIG) and anti-thymocyte globulin. Data in support of the use of any of these agents are mostly from anecdotal reports or small case series.

Neurotoxicity

Neurotoxicity is another adverse event that has been a concern in clinical trials of various immune effector cell therapies. 577 , 584 , 585 Neurologic toxicity may occur concurrently with CRS. However, in some cases, neurologic toxicity may not occur simultaneously but may occur before or days after CRS. Like CRS rates, neurotoxicity incidence rates across clinical trials vary considerably. Neurologic toxicities are diverse and may include temporary working memory loss, delirium, seizures and rarely, acute cerebral edema. 564 Neurotoxicity associated with CAR T-cell therapies has been referred to as immune effector cell-associated neurotoxicity syndrome (ICANS). It is characterized by a pathologic process involving the central nervous system following any immunotherapy that results in the activation or engagement of endogenous or infused T cells and other immune effector cells. The time to the onset of neurotoxicity is typically 4–10 days after the administration of CAR-T cells, with a duration of 14–17 days. For BCMA-directed CAR T-cell therapies, the duration may be somewhat shorter. CRS is considered to be a potent risk factor for ICANS and the severity of CRS is highly correlated with that of ICANS. The development of neurotoxicity is associated with a higher pre-treatment disease burden, a higher peak CAR T-cell expansion, a higher baseline inflammatory status, an earlier and higher elevation of pro-inflammatory cytokines in the blood and cerebrospinal fluid and the presence of pre-existing neurological comorbidities. 563 Pro-inflammatory cytokines were accumulated in the cerebrospinal fluid during severe neurotoxicity, with a disproportionately high level of IL-6, IL-8, and MCP1, suggesting a production that is specific to the central nervous system. 563 IL-1, derived from monocytes, has recently been highlighted as a key driver of neurotoxicity. 556 Gust et al. also described the endothelial dysfunction and increased permeability of the blood-brain barrier (BBB) during neurotoxicity following adoptive immunotherapy with CD19 CAR-T cells, which may help to identify risk predictors for neurotoxicity. 585 Increased BBB permeability may enable inflammatory cytokines and immune cells to migrate into the central nervous system and potentially contribute to inflammation of the nervous system. 585 , 586 As in the case of CRS, the risk factors and the incidence of CRS are reported with variability between studies. CD19-directed CAR is more likely than BCMA-directed CAR to be accompanied by high-grade ICANS. The grade of ICANS determines the management of neurotoxicity. Consensus guidelines with recommended grading of ICANS have been issued by the American Society for Transplantation and Cellular Therapy (ASTCT). It’s recommended that clinicians use this scale to grade any CAR-T cell-related neurotoxicity. 587 , 588 Along with careful monitoring and supportive care, corticosteroids are the cornerstone of ICANS management. Since tocilizumab may exacerbate ICANS, 575 for patients with grade 1 CRS (fever only) and higher grade ICANS, corticosteroids alone may be preferred. The NCCN consensus panel does not recommend treating patients receiving CAR T-cell therapy for neurotoxicity with tocilizumab unless they have concurrent CRS. 518

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome

Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) is regarded as a serious immunologic syndrome that is triggered by out-of-control immune activation, which includes the hyperactivation of macrophages and lymphocytes, increased production of pro-inflammatory cytokines, infiltration of lymphocytes and histiocytes into tissues and organs and multi-organ failure. 569 , 584 , 589 , 590 In contrast to primary HLH/MAS, CAR T-cell therapy-induced HLH/MAS is thought to be a type of secondary HLH/MAS because it is initiated by an immune trigger. 558 In a recent study, it was estimated that HLH/MAS occurs in 3.5% of the patients who receive CAR T-cell therapy. 591 Nevertheless, the actual incidence of HLH/MAS has been disputed, in part because of the close overlap in symptoms between CRS and HLH/MAS. The definitive diagnosis of HLH/MAS after CAR T-cell therapy can be challenging as the clinical features and laboratory abnormalities overlap substantially with the CRS. 558 , 591 The majority of patients with moderate-to-severe CRS exhibit the typical laboratory abnormalities of HLH/MAS, such as elevated levels of CRP, cytopenia, hyperferritinemia, hypofibrinogenemia, coagulopathy, and increased levels of several serum cytokines, in particular IL-6, INF-γ and GM-CSF. 478 , 569 , 584 , 589 The clinical manifestations related to CAR T cell-induced HLH/MAS typically comprise fever, multi-organ dysfunction and central nervous system disorders and occasionally hepatosplenomegaly or hemophagocytosis in the bone marrow or other organs. 589 , 591 Suppressing the overactive immune cells that are contributing to symptoms is the ultimate goal of clinical management of HLH/MAS. In some cases, resistance to tocilizumab may also lead to late-onset HLH/MAS-like lesions. Corticosteroids, anakinra, or intrathecal cytarabine should be considered in such cases. 584 , 589 , 590 However, there is still a lack of data to support the use of such drugs in this setting.

Hypogammaglobulinemia

Hypogammaglobulinemia is another potential risk related to CAR T-cell therapy. Hypogammaglobulinemia has been reported in up to 53% of patients who have been treated with CAR-T cells in clinical studies. 592 , 593 Hypogammaglobulinemia is a disorder that is characterized by decreased levels of antibodies in the blood and an increase in the risk of infection. Hypogammaglobulinemia is the consequence of an extremely small number of B cells or plasma cells, termed B cell aplasia or plasma cell aplasia, respectively. 593 Even in patients in CR after CAR T-cell therapy, long-term hypogammaglobulinemia may still occur. The recommendations are made based on experts’ opinions, institution-specific experience and infection prevention approaches and strategies from other contexts due to the lack of randomized, controlled clinical trials for the treatment of hypogammaglobulinemia. 593 Hypogammaglobulinemia can be controlled with either intravenous or subcutaneous immunoglobulin G, a product of fractionated blood derived from the pooled plasma of many individuals. 592 , 593 , 594 , 595 Immunoglobulin offers broad protection from opportunistic infections because it contains antibodies against a variety of infectious agents. 592

Patients receiving CAR T-cell therapy are also at high risk for developing hematologic toxicities, particularly sustained cytopenia such as neutropenia, thrombocytopenia, anemia and/or leukopenia. 596 , 597 , 598 Cytopenia may appear following CAR-T infusion and always presents at an early stage (<30 days), frequently for a prolonged period (30–90 days) and sometimes persists or appears at a late stage (>90 days). 597 The onset and duration of cytopenia are often correlated with the severity of CRS and ICANS, the burden of the tumor, the number of prior therapies, baseline blood counts, peak levels of CRP and ferritin, as well as the CAR construct. 596 , 597 , 599 , 600 Bone marrow biopsy is critical for the evaluation of both primary disease and secondary bone marrow neoplasm in patients with persistent or late-onset cytopenia. The management options for cytopenia are somewhat limited and need to be individualized based on the likely underlying etiology. These options may include growth factors, thrombopoietin receptor agonists, stem cell enhancement, transfusion support and the elimination of infectious risk. 597 , 601 , 602

Coagulopathy

The typical time to onset of CAR-T therapy-associated coagulopathy (CARAC) is often 6 to 10 days after CAR-T cell infusion and closely follows the elevation of IL-6 and other cytokines and gradually relieves as the CRS is controlled. 503 CARAC, including disseminated intravascular coagulation (DIC), prolonged prothrombin time/activated partial thromboplastin time, and hypofibrinogenemia, often occurs in patients with severe CRS. 603 Over half of the patients experienced thrombocytopenia or at least one abnormal coagulation parameter after CAR-T therapy. Clinically bleeding events occurred in about 19.6% of patients with coagulopathy and 14 to 50% of patients with coagulopathy developed DIC; 6.7 to 42.9% of patients with DIC died. 503 Monitoring of patients with CARAC is imperative to avoid the potential for bleeding events and even life-threatening hemorrhage. Since the severity of CARAC is highly associated with that of CRS, the management of CRS is of great importance. As bleeding is the main feature of CARAC, replacement therapy can decrease the risk of bleeding and control active bleeding, including the transfusion of platelet, fresh frozen plasma and prothrombin complex concentrates and fibrinogen, and cryoprecipitate. More importantly, anticoagulant therapy and/or antifibrinolytic therapy should be used as appropriate for patients with high-grade CRS. 503

Infectious complications following CAR T-cell therapy are very common. They have been reported in up to ~70% of recipients. 604 , 605 , 606 The majority of infections develop shortly following infusion and can be attributed to several causes, such as the depletion of normal B cells or plasma cells resulting from the direct action of the CAR-T cells, the depletion of lymphocytes and granulocytes caused by conditioning chemotherapy, anti-cytokine, or corticosteroid therapies given for CRS or neurologic toxicity and immunocompromise induced by the patient’s underlying malignancy. 604 , 607 Infections, including bacterial, viral and fungal infections, have been reported following CAR T-cell therapy and can be life-threatening. 604 An increased likelihood of acute infections may also be linked to the seriousness of CRS. The control of infections is generally with agents that are selective for the source of the infection. Risk stratification should be performed based on patient characteristics such as prior suppressive therapy, history of infection, etc. when determining whether to provide antibacterial or antifungal prophylaxis. 604 For certain patients with concurrent severe or recurrent infections and hypogammaglobulinemia, the NCCN guidelines suggest IVIG as a replacement treatment. 518

Since CAR is an exogenous sequence, it has certain immunogenicity which leads to ADA production by humoral immunity after infusion. Early-generation CAR-T cells were constructed from murine-derived scFv and the species difference resulted in the generation of a HAMA. 276 Even though humanized CAR circumvented immunogenicity to a certain extent, some patients were still reported to have ADA in clinical trials of CD19 and BCMA, which eventually affected the efficacy or led to earlier relapse. 278 , 608 Therefore, monitoring of ADA has become an important part of current CAR-T clinical trials. Although with large individual variability, the factors related to the production of ADA are currently thought to be the use of CAR-T with murine scFv and multiple infusions of the same CAR-T product. 275 , 609 There is no targeted method to solve the problem of ADA, but it should be monitored by ELISA (enzyme-linked immunosorbent assay) and flow cytometry, to understand the reason for drug resistance or recurrence in patients in time, 610 , 611 and to reduce the impact of ADA on secondary reinfusion by replacing the target and strengthening lymphodepletion. 609 , 612

Challenges and future prospects

Each immunotherapy strategy has achieved varying degrees of encouraging results in hematologic malignancies. Different immunotherapeutic approaches have their advantages but also shortcomings that need to be addressed (Table 5 ). Further clinical exploration will be needed to further improve the prognosis of patients with hematologic malignancies. The allo-HSCT remains the primary treatment for hematologic malignancies with a potentially curative outcome. The haplo-HSCT modality can best address the limited source of allo-HSCT donors, but it’s still necessary to further explore how to minimize the severity of GVHD and transplant-related death while improving anti-tumor effects, especially for patients with R/R hematologic cancers. The future direction of transplantation will be toward personalization, in which a combination therapy strategy is very essential. R/R patients can be pre-treated with CAR-T therapy or other targeted therapies to achieve remission before bridging to HSCT. Patients, who still have residual disease after incomplete remission with various treatments such as chemotherapy, targeted therapy and immunotherapy, can be treated with donor CAR-T combined with allo-HSCT. For patients with positive MRD after transplantation, CAR-T therapy can also be recommended. The second direction is to optimize donor selection, especially for familial donors and to avoid selecting donors who carry the same genetic defect as the patient. Molecular testing can be used to detect HLA loss and guide the search for donors for patients who need a second transplantation. In addition, anti-tumor therapy needs to be considered along with GVHD prevention and thus individualized management should be conducted after transplantation to balance the anti-GVHD and anti-tumor benefits. The mAbs, bsAbs, and ADC-based agents have also improved the treatment of cancer patients to some extent, but the clinical toxicities remain unavoidable. Meanwhile, some patients have demonstrated little or no responsiveness to such treatments. Ideal tumor antigens need to be screened for these antibody-based therapies to improve the anti-tumor effects and reduce the incidence of “off-tumor, on-target” effects. The technical threshold for the development of bsAbs is more difficult compared to single-target mAbs. Selecting the best target combination is only the first step, followed by a rational structural design based on the receptor structure as well as the biological mechanism of the disease. In addition, inappropriate clinical design and dosing regimens will result in higher toxicity in patients, which can be improved by optimizing treatment strategy, dose and timing to reduce side effects to some extent. The payload and linker in ADC drugs can also directly affect effectiveness and safety. In addition, how to solve the complexity of pharmacokinetics, enhance drug stability, improve drug efficacy and reduce drug resistance are also urgent to be explored. The bsADC (bispecific antibody-drug conjugate) combines the advantages of bsAbs and ADCs and is a major challenge for the future. Compared to mAbs, bsADCs can target tumor cells more specifically through two antibodies, overcoming drug resistance while increasing the safety. Meanwhile, novel therapeutic agents, such as bifunctional checkpoint-inhibitory T cell engager (CiTE), 613 simultaneous multiple interaction T cell engager (SMITE), 614 trispecific killer engager (TriKE) and BiTE-expressing CAR-T cells, are being designed to integrate various immune functions into one molecule or a single cellular vector and thereby enhance efficacy without compromising safety. 172 ICIs have shown superior efficacy mainly in HL and primary mediastinal large B-cell lymphoma, but has limited efficacy in other hematologic cancers. Serious irAEs may also occur with ICI therapy, which will impede its application in the clinic. The exploration of more-effective and rational combinatorial approaches is an area of great interest in improving the efficacy of ICI therapy. The emergence of ACTs, especially CAR T-cell therapy, offers a new therapeutic avenue and hope for R/R patients with hematologic malignancies. However, these therapeutic approaches are usually accompanied by serious complications such as CRS, ICANS, and “off-target” effects, while achieving remarkable results. Challenges remain in the optimization of CAR design and cell products, improvement of remission rates, prolongation of remission duration, reduction of toxicity and expansion of this therapeutic modality to other cancer types. To further improve patient outcomes, innovative strategies are needed to enhance the therapeutic efficacy and in vivo persistence of CAR-T cells and to mitigate tumor cell resistance. Elucidation of mechanisms of resistance and immune escape has long been a big challenge. Epigenetic mechanisms play an important role in both tumor development and anti-tumor immune regulation and epi-drugs represented by DNA methylation inhibitors and histone deacetylation inhibitors can coordinate, potentiate and reduce immune escape effects in several aspects by regulating tumor killing and enhancing the anti-tumor immunity. 615 , 616 , 617 Therefore, a deeper and broader exploration of epi-immunotherapy will further advance the understanding of this emerging concept and bring more creative breakthroughs in immunotherapy. Allogeneic CAR-T cells also have the potential to overcome many of the manufacturing limitations of traditional autologous CAR T-cell therapies. Universal CAR-T cells will undoubtedly be the future direction of CAR-T therapy. While there are still concerns about host-versus-graft and graft-versus-host reactions caused by CAR-T cells in the allogeneic environment, the risks and side effects are being reduced through gene knockout technology and the safety of universal CAR-T cells will be further enhanced. Universal CAR-T therapies are expected to bring less expensive and more immediately available “off-the-shelf” therapies to patients with malignant hematologic cancers. However, there are many challenges with universal CAR-T cells and clinical studies are still in the early stages. Tumor vaccines take advantage of tumor-associated antigens or tumor-specific antigens to stimulate the immune system but are currently in their infant stage and there is still much space for refinement to discover their full potential.

The current status quo in cancer treatment is that immunotherapy is generally used as a second-, third-, or even last-line treatment option when patients have no better options. Based on promising results in terms of efficacy and safety, immunotherapy is expected to become the first line of treatment in the future, while conventional treatment will be relegated to the second line. 618 Treatment regimens for patients with hematologic cancers typically include 3–4 or even 5 cytotoxic drugs and the addition of immunotherapy drugs can reduce the use of these chemotherapy agents. Several clinical trials have confirmed that the combination of immunotherapy with reduced chemotherapy regimens has improved rather than suppressed therapeutic effects. Therefore, one of the major trends in cancer treatment is that immunotherapy will become increasingly prominent. 618 Combination immunotherapy is an exciting area of research that may further enhance our ability to utilize the immune system against hematologic malignancies. Currently, HSCT remains a fundamental treatment option and combining HSCT with novel immunotherapies is a promising direction for our future. Many clinical questions remain to be answered. Which immunotherapy works best in the context of HSCT? Which immunotherapy is better suited as a bridge to HSCT or as a preferred option after HSCT relapse? Which immunotherapy approach is more appropriate for patients who are ineligible for HSCT? With the continuous development and advancement of molecular biology and immunology technologies, immunotherapy is expected to further change the existing treatment paradigm of hematological cancers. The detailed information generated by multidimensional omics technologies, single-cell sequencing and others will not only provide insights into the complex determinants of efficacy and toxicity of immunotherapies but also help identify predictive biomarkers and develop new treatment strategies. As future research helps to address these challenges, these advanced technologies may eventually become the standard and necessary tool in the field of immunotherapy, revealing the relationship between key drivers of cancer phenotypes and enabling clinicians to better predict and monitor patient responses, thereby facilitating more comprehensive and realistic personalized treatments for cancer patients. 619 , 620 , 621 , 622 , 623 , 624 , 625 , 626 , 627 , 628 , 629 , 630 , 631 , 632

Malignant hematologic cancers are major diseases that pose a serious threat to human health. The past and present are very exciting eras for immunotherapy of hematologic malignancies, but the future looks quite incredible and we are rapidly moving in that direction. Although the various immunotherapies aim to treat cancer patients through different mechanisms of action, the core is to restart and maintain the “Cancer-Immunity Cycle” and restore normal anti-tumor immunity. Multiple categories of immunotherapies have been developed for the treatment of blood cancers and are being further evaluated in clinical trials. More importantly, some of these immunotherapies have been approved by the FDA for the treatment of blood cancers or have even entered the commercialization stage. At present, immunotherapy for blood cancers still faces a series of challenges. The most important of these is safety, where different therapies are accompanied by varying degrees of treatment-related side effects, thus emphasizing the importance of early detection and intervention of toxicities. As mentioned above, clinical experts have been developing guidelines for the management of toxicities based on clinical trials and real-world clinical experience. The establishment of these guidelines has provided a solid foundation for improving the safety and widespread use of immunotherapy. In addition, they are gaining experience in managing the unique complications associated with novel immunotherapies and establishing practice guidelines that will be critical to expanding their use worldwide. Another notable issue is treatment failure due to resistance and relapse. This illustrates the striking difference in the ability of each patient to respond to immunotherapy, highlighting the potentially urgent need for and importance of personalized cancer treatment.

Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450 , 903–907 (2007).

CAS   PubMed   Google Scholar  

von Locquenghien, M., Rozalén, C. & Celià-Terrassa, T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J. Clin. Invest . 131 , e143296 (2021).

Vinay, D. S. et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35 , S185–s198 (2015).

PubMed   Google Scholar  

Zitvogel, L., Tesniere, A. & Kroemer, G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6 , 715–727 (2006).

Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 , 137–148 (2004).

Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39 , 1–10 (2013).

Motz, G. T. & Coukos, G. Deciphering and reversing tumor immune suppression. Immunity 39 , 61–73 (2013).

CAS   PubMed   PubMed Central   Google Scholar  

McNutt, M. Cancer immunotherapy. Science 342 , 1417 (2013).

Couzin-Frankel, J. Breakthrough of the year 2013. Cancer immunotherapy. Science 342 , 1432–1433 (2013).

Couzin, J. Cancer immunotherapy. select T cells, given space, shrink tumors. Science 297 , 1973 (2002).

Pui, C. H. & Evans, W. E. Acute lymphoblastic leukemia. N. Engl. J. Med. 339 , 605–615 (1998).

Döhner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373 , 1136–1152 (2015).

Kayser, S. & Levis, M. J. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica 108 , 308–320 (2023).

Armitage, J. O., Gascoyne, R. D., Lunning, M. A. & Cavalli, F. Non-Hodgkin lymphoma. Lancet 390 , 298–310 (2017).

Wang, H. W., Balakrishna, J. P., Pittaluga, S. & Jaffe, E. S. Diagnosis of hodgkin lymphoma in the modern era. Br. J. Haematol. 184 , 45–59 (2019).

Ansell, S. M. Hodgkin lymphoma: diagnosis and treatment. Mayo Clin. Proc. 90 , 1574–1583 (2015).

van de Donk, N., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397 , 410–427 (2021).

Kennedy, J. A. & Ebert, B. L. Clinical implications of genetic mutations in myelodysplastic syndrome. J. Clin. Oncol. 35 , 968–974 (2017).

Bachireddy, P., Burkhardt, U. E., Rajasagi, M. & Wu, C. J. Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat. Rev. Cancer 15 , 201–215 (2015).

Im, A. & Pavletic, S. Z. Immunotherapy in hematologic malignancies: past, present, and future. J. Hematol. Oncol. 10 , 94 (2017).

PubMed   PubMed Central   Google Scholar  

Salles, G. et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv. Ther. 34 , 2232–2273 (2017).

Tilly, H. et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26 , v116–v125 (2015).

Salles, G. et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 21 , 978–988 (2020).

Palumbo, A. et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375 , 754–766 (2016).

Feldman, E. J. et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J. Clin. Oncol. 23 , 4110–4116 (2005).

Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16 , 57–66 (2015).

Connors, J. M. et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N. Engl. J. Med. 378 , 331–344 (2018).

Horwitz, S. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393 , 229–240 (2019).

Oka, Y. et al. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis. Int. J. Hematol. 78 , 56–61 (2003).

Oka, Y. et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA . 101 , 13885–13890 (2004).

Xu-Monette, Z. Y., Zhou, J. & Young, K. H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131 , 68–83 (2018).

Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev. Pathol. 16 , 223–249 (2021).

Sebestyen, Z. et al. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat. Rev. Drug Discov. 19 , 169–184 (2020).

Wang, W., Jiang, J. & Wu, C. CAR-NK for tumor immunotherapy: clinical transformation and future prospects. Cancer Lett. 472 , 175–180 (2020).

Xu, Z. & Huang, X. Cellular immunotherapy for hematological malignancy: recent progress and future perspectives. Cancer Biol. Med. 18 , 966–980 (2021).

Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature 602 , 503–509 (2022).

Holstein, S. A. & Lunning, M. A. CAR T-cell therapy in hematologic malignancies: a voyage in progress. Clin. Pharmacol. Ther. 107 , 112–122 (2020).

Holtick, U. et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst. Rev . Cd010189 (2014).

Penack, O. et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol. 7 , e157–e167 (2020).

Du, J. et al. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Netw. Open. 4 , e219807 (2021).

Cornelissen, J. J. & Blaise, D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood 127 , 62–70 (2016).

Gagelmann, N. et al. Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis. Blood Adv. 6 , 1222–1231 (2022).

Kato, K., Khaled, Y. & Mineishi, S. Reduced-intensity stem cell transplantation for hematological malignancies: current status and the future. Curr. Stem Cell Res. Ther. 2 , 149–162 (2007).

Cohen, S. et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 7 , e134–e145 (2020).

Huang, X. J. et al. Combined transplantation of G-CSF primed allogeneic bone marrow cells and peripheral blood stem cells in treatment of severe aplastic anemia. Chin. Med. J. 117 , 604–607 (2004).

Luznik, L. et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol. Blood Marrow Transpl. 14 , 641–650 (2008).

CAS   Google Scholar  

Kanakry, C. G., Fuchs, E. J. & Luznik, L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat. Rev. Clin. Oncol. 13 , 132 (2016).

Chang, Y. J. et al. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J. Clin. Oncol. 34 , 1855–1863 (2016).

Gooley, T. A. et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N. Engl. J. Med. 363 , 2091–2101 (2010).

Kanakry, C. G., Fuchs, E. J. & Luznik, L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat. Rev. Clin. Oncol. 13 , 10–24 (2016).

Ciurea, S. O. et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 126 , 1033–1040 (2015).

Tomita, M. & Tsumoto, K. Hybridoma technologies for antibody production. Immunotherapy 3 , 371–380 (2011).

Buist, M. R., Kenemans, P., van Kamp, G. J. & Haisma, H. J. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol. Immunother. 40 , 24–30 (1995).

Klee, G. G. Human anti-mouse antibodies. Arch. Pathol. Lab. Med. 124 , 921–923 (2000).

Legouffe, E. et al. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin. Exp. Immunol. 98 , 323–329 (1994).

Arakawa, F. et al. Cloning and sequencing of the VH and V kappa genes of an anti-CD3 monoclonal antibody, and construction of a mouse/human chimeric antibody. J. Biochem. 120 , 657–662 (1996).

Nishimura, Y. et al. Recombinant human-mouse chimeric monoclonal antibody specific for common acute lymphocytic leukemia antigen. Cancer Res. 47 , 999–1005 (1987).

Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228 , 1315–1317 (1985).

Saw, P. E. & Song, E. W. Phage display screening of therapeutic peptide for cancer targeting and therapy. Protein Cell 10 , 787–807 (2019).

Chao, G. et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 1 , 755–768 (2006).

Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15 , 553–557 (1997).

Glukhova, X. A. et al. Updates on the production of therapeutic antibodies using human hybridoma technique. Curr. Pharm. Des. 22 , 870–878 (2016).

Buettner, M. J. et al. Improving immunotherapy through glycodesign. Front. Immunol. 9 , 2485 (2018).

Tsao, L. C., Force, J. & Hartman, Z. C. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 81 , 4641–4651 (2021).

Mossner, E. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115 , 4393–4402 (2010).

Tipton, T. R. et al. Anti-mouse FcγRIV antibody 9E9 also blocks FcγRIII in vivo. Blood 126 , 2643–2645 (2015).

Herter, S. et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab In vitro and in xenograft models. Mol. Cancer Ther. 12 , 2031–2042 (2013).

Overdijk, M. B. et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7 , 311–320 (2015).

Krejcik, J. et al. Daratumumab depletes CD38(+) immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128 , 384–394 (2016).

Moreno, L. et al. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clin. Cancer Res. 25 , 3176–3187 (2019).

Wierda, W. G. et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28 , 1749–1755 (2010).

Hillmen, P. et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 385 , 1873–1883 (2015).

Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 370 , 1101–1110 (2014).

Sehn, L. H. et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 17 , 1081–1093 (2016).

Dimopoulos, M. A. et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375 , 1319–1331 (2016).

Lokhorst, H. M. et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373 , 1207–1219 (2015).

Lonial, S. et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387 , 1551–1560 (2016).

Mateos, M. V. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 378 , 518–528 (2018).

Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373 , 621–631 (2015).

Dimopoulos, M. A. et al. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol. 9 , e403–e414 (2022).

Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J. Clin. Oncol. 41 , 568–578 (2023).

Moreau, P. et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. Lancet 397 , 2361–2371 (2021).

Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394 , 2096–2107 (2019).

Goldschmidt, H. et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 9 , e810–e821 (2022).

Coiffier, B. et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92 , 1927–1932 (1998).

Vose, J. M. et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin’s lymphoma. J. Clin. Oncol. 19 , 389–397 (2001).

Salles, G. et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377 , 42–51 (2011).

Seymour, J. F. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N. Engl. J. Med. 378 , 1107–1120 (2018).

Morschhauser, F. et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial. J. Clin. Oncol. 31 , 1977–1983 (2013).

Coiffier, B. et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 111 , 1094–1100 (2008).

Morschhauser, F. et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin’s lymphoma: phase I/II results. J. Clin. Oncol. 27 , 3346–3353 (2009).

Morschhauser, F. A. et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J. Clin. Oncol. 31 , 2912–2919 (2013).

Radford, J. et al. Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000). Blood 122 , 1137–1143 (2013).

Salles, G. et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119 , 5126–5132 (2012).

Salles, G. A. et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J. Clin. Oncol. 31 , 2920–2926 (2013).

Morschhauser, F. et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann. Oncol. 21 , 1870–1876 (2010).

Forero-Torres, A. et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma. Clin. Cancer Res. 18 , 1395–1403 (2012).

Ganjoo, K. N. et al. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma. Leuk. Lymphoma 56 , 42–48 (2015).

Cheney, C. M. et al. Ocaratuzumab, an Fc- engineered antibody demonstrates enhanced antibody- dependent cell- mediated cytotoxicity in chronic lymphocytic leukemia. Mabs 6 , 748–754 (2014).

PubMed Central   Google Scholar  

Wulf, G. G. et al. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. Leukemia 35 , 143–155 (2021).

Cortelezzi, A. et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. Leukemia 23 , 2027–2033 (2009).

Ansell, S. et al. Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s disease (HD) and anaplastic large cell lymphoma (ALCL). Blood 102 , 181–182 (2003).

Google Scholar  

Ansell, S. M. et al. Phase I/II, open-label, dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma. Blood 104 , 721 (2004).

Hussein, M. et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95 , 845–848 (2010).

Advani, R. et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin’s lymphoma. J. Clin. Oncol. 27 , 4371–4377 (2009).

Fayad, L. et al. Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk. Lymphoma 56 , 2569–2578 (2015).

Stein, R. et al. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. Clin. Cancer Res. 15 , 2808–2817 (2009).

Alinari, L. et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117 , 4530–4541 (2011).

Smith, M. R., Jin, F. & Joshi, I. Milatuzumab and veltuzumab induce apoptosis through JNK signalling in an NF-κB dependent human transformed follicular lymphoma cell line. Br. J. Haematol. 165 , 151–153 (2014).

Hertlein, E. et al. Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells. Blood 116 , 2554–2558 (2010).

Vasu, S. et al. A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. Haematologica 107 , 770–773 (2022).

Ohmachi, K. et al. A multicenter phase I study of inebilizumab, a humanized anti-CD19 monoclonal antibody, in Japanese patients with relapsed or refractory B-cell lymphoma and multiple myeloma. Int. J. Hematol. 109 , 657–664 (2019).

Czuczman, M. S. et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann. Oncol. 29 , 2271 (2018).

Leonard, J. P. et al. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin’s lymphoma. J. Clin. Oncol. 23 , 5044–5051 (2005).

Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 , 1011–1027 (2005).

Viardot, A. & Bargou, R. Bispecific antibodies in haematological malignancies. Cancer Treat. Rev. 65 , 87–95 (2018).

Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 14 , 75 (2021).

Wang, Z. et al. Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity. J. Hematol. Oncol. 14 , 204 (2021).

Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot, D. J. A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol. Ther. 201 , 103–119 (2019).

Velasquez, M. P., Bonifant, C. L. & Gottschalk, S. Redirecting T cells to hematological malignancies with bispecific antibodies. Blood 131 , 30–38 (2018).

Li, H., Er Saw, P. & Song, E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell. Mol. Immunol. 17 , 451–461 (2020).

Nagorsen, D., Kufer, P., Baeuerle, P. A. & Bargou, R. Blinatumomab: a historical perspective. Pharmacol. Ther. 136 , 334–342 (2012).

Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376 , 836–847 (2017).

Advani, A. S. et al. SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia. J. Clin. Oncol. 40 , 1574–1582 (2022).

Goebeler, M. E. et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J. Clin. Oncol. 34 , 1104–1111 (2016).

Viardot, A. et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood 127 , 1410–1416 (2016).

Reusch, U. et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs 7 , 584–604 (2015).

Falchi, L., Vardhana, S. A. & Salles, G. A. Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities. Blood 141 , 467–480 (2023).

Sun, L. L. et al. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci. Transl. Med. 7 , 287ra270 (2015).

Bock, A. M., Nowakowski, G. S. & Wang, Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr. Treat. Options Oncol. 23 , 155–170 (2022).

Budde, L. E. et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 23 , 1055–1065 (2022).

Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39 , 1959–1970 (2021).

Dickinson, M. J. et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 387 , 2220–2231 (2022).

Hutchings, M. et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet 398 , 1157–1169 (2021).

Thieblemont, C. et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J. Clin. Oncol. 41 , 2238–2247 (2023).

Bannerji, R. et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 9 , e327–e339 (2022).

Patel, K. et al. A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin’s lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis. Blood 140 , 9470–9472 (2022).

Patel, K. et al. Phase 2 randomized, open-label, multicenter study to evaluate the efficacy and safety of plamotamab combined with tafasitamab (Tafa) plus lenalidomide (Len) Vs Tafa plus Len in relapsed or refractory DLBCL. Blood 140 , 12066–12067 (2022).

Yeung, Y. A. et al. An optimized full-length FLT3/CD3 bispecific antibody demonstrates potent anti-leukemia activity and reversible hematological toxicity. Mol. Ther. 28 , 889–900 (2020).

Reusch, U. et al. Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin. Cancer Res. 22 , 5829–5838 (2016).

Campagne, O. et al. Integrated pharmacokinetic/pharmacodynamic model of a bispecific CD3xCD123 DART molecule in nonhuman primates: evaluation of activity and impact of immunogenicity. Clin. Cancer Res. 24 , 2631–2641 (2018).

Uy, G. L. et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood 137 , 751–762 (2021).

Aigner, M. et al. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct. Leukemia 27 , 1107–1115 (2013).

Cheng, P. et al. Immunodepletion of MDSC by AMV564, a novel bivalent, bispecific CD33/CD3 T cell engager, ex vivo in MDS and melanoma. Mol. Ther. 30 , 2315–2326 (2022).

Boyiadzis, M. et al. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin. Transl. Sci. 16 , 429–435 (2023).

Rettig, M. P. et al. Preliminary translational results from an ongoing phase 1 study of flotetuzumab, a CD123 x CD3 dart (R), in AML/MDS: rationale for combining flotetuzumab and anti-PD-1/PD-L1 immunotherapies. Blood . 130 , 637–637 (2017).

Ravandi, F. et al. Complete responses in relapsed/refractory acute myeloid leukemia (AML) patients on a weekly dosing schedule of XmAb14045, a CD123 x CD3 T cell-engaging bispecific antibody: initial results of a phase 1 study. Blood 132 , 763 (2018).

van Loo, P. F. et al. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin. Biol. Ther. 19 , 721–733 (2019).

Dao, T. et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat. Biotechnol. 33 , 1079–1086 (2015).

Krishnan, A. Y. et al. MajesTEC-7: a phase 3, randomized study of teclistamab plus daratumumab plus lenalidomide (Tec-DR) versus daratumumab plus lenalidomide plus dexamethasone (DRd) in patients with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant. Blood 140 , 10148–10149 (2022).

Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387 , 495–505 (2022).

Searle, E. et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study. Blood 140 , 394–396 (2022).

Usmani, S. Z. et al. Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398 , 665–674 (2021).

Zamagni, E. et al. MajesTEC-4 (EMN30): a phase 3 trial of teclistamab plus lenalidomide versus lenalidomide alone as maintenance therapy following autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 140 , 7289–7291 (2022).

Zonder, J. A. et al. Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific antibody, in a phase 1/2 first-in-human study in patients with relapsed/refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 22 , S406–S407 (2022).

Ferreri, C. J. et al. Trial in progress: a phase II window of opportunity study of the BCMAxCD3 bispecific antibody REGN5458 in previously untreated patients with symptomatic multiple myeloma. Blood 140 , 10129–10130 (2022).

Fonseca, R. et al. MagnetisMM-9: an open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. J. Clin. Oncol. 40 , TPS8068–TPS8068 (2022).

Landgren, O. et al. Magnetismm-4: an open label, phase 1b/2 umbrella study of elranatamab in combination with other anti-cancer treatments for patients with multiple myeloma. Blood 140 , 10172–10173 (2022).

Wong, S. W. et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study. Blood 140 , 400–402 (2022).

Fayon, M. et al. Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma. Haematologica 106 , 1193–1197 (2021).

Zuch de Zafra, C. L. et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin. Cancer Res . 25 , 3921–3933 (2019).

Topp, M. S. et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J. Clin. Oncol. 38 , 775–783 (2020).

Kumar, S. et al. A phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma. Blood 138 , 900 (2021).

Harrison, S. J. et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE (R) (bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM). Blood 136 , 181 (2020).

Lesokhin, A. M. et al. Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood 136 , 8–9 (2020).

Mohan, S. R. et al. Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM). Blood 140 , 7264–7266 (2022).

Richter, J. R. et al. Phase 1, multicenter, open-label study of single-agent bispecific antibody t-cell engager GBR 1342 in relapsed/refractory multiple myeloma. J. Clin. Oncol. 36 , TPS81 (2018).

Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387 , 2232–2244 (2022).

Vij, R. et al. CAMMA 1: a multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. J. Clin. Oncol. 40 , TPS8069 (2022).

Zhao, Y. et al. Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL. Blood 137 , 471–484 (2021).

Jabbour, E. et al. Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression. Am. J. Hematol. 93 , 371–374 (2018).

Goebeler, M. E. & Bargou, R. C. T cell-engaging therapies - BiTEs and beyond. Nat. Rev. Clin. Oncol. 17 , 418–434 (2020).

Braig, F. et al. Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129 , 100–104 (2017).

Aldoss, I. et al. Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol. 92 , 858–865 (2017).

Ross, T. et al. Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma. Blood 132 , 1927 (2018).

Reusch, U. et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 6 , 728–739 (2014).

Zhao, L. et al. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. Blood 140 , 1790–1802 (2022).

Chan, W. K. et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma. Cancer Immunol. Res. 6 , 776–787 (2018).

Felices, M. et al. CD16-IL15-CD33 trispecific killer engager (TriKE) overcomes cancer-induced immune suppression and induces natural killer cell-mediated control of MDS and AML via enhanced killing kinetics. Blood 128 , 4291 (2016).

Kantarjian, H. M. et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N. Engl. J. Med. 375 , 740–753 (2016).

Ansell, S. M. et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N. Engl. J. Med. 387 , 310–320 (2022).

Chari, R. V., Miller, M. L. & Widdison, W. C. Antibody-drug conjugates: an emerging concept in cancer therapy. Angew. Chem. Int. Ed. Engl. 53 , 3796–3827 (2014).

Jin, Y. et al. Stepping forward in antibody-drug conjugate development. Pharmacol. Ther. 229 , 107917 (2022).

Meyer, S. & Rees, A. R. The antibody molecule: from antitoxins to therapeutic antibodies. Soc. Hist. Med. 29 , hkv119 (2015).

Thomas, A., Teicher, B. A. & Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 17 , e254–e262 (2016).

Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody-drug conjugates. Chem. Soc. Rev. 48 , 4361–4374 (2019).

Advani, A. et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin’s lymphoma: results of a phase I study. J. Clin. Oncol. 28 , 2085–2093 (2010).

Brivio, E. et al. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study). Blood 137 , 1582–1590 (2021).

Kreitman, R. J. et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 30 , 1822–1828 (2012).

Short, N. J. et al. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br. J. Haematol. 182 , 442–444 (2018).

Morschhauser, F. et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol. 6 , e254–e265 (2019).

Wayne, A. S. et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin. Cancer Res. 16 , 1894–1903 (2010).

Kreitman, R. J. et al. Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia. J. Clin. Oncol. 25 , 7095 (2007).

Kuruvilla, J. et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 22 , 512–524 (2021).

Horwitz, S. et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann. Oncol. 33 , 288–298 (2022).

Pro, B. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J. Clin. Oncol. 30 , 2190–2196 (2012).

Prince, H. M. et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 390 , 555–566 (2017).

Pollard, J. A. et al. Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children’s oncology group trial AAML0531. J. Clin. Oncol. 39 , 3149–3160 (2021).

Stein, E. M. et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood 131 , 387–396 (2018).

Fathi, A. T. et al. A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132 , 1125–1133 (2018).

Kovtun, Y. et al. IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML. Mol. Cancer Ther. 17 , 1271–1279 (2018).

Cortes, J. E. et al. Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia. Blood 132 , 26 (2018).

Caimi, P. F. et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 22 , 790–800 (2021).

Hamadani, M. et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 137 , 2634–2645 (2021).

Carol, H. et al. The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia. Clin. Cancer Res. 19 , 1795–1805 (2013).

Ribrag, V. et al. A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 20 , 213–220 (2014).

Jones, L. et al. Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts. Pediatr. Blood Cancer 66 , e27765 (2019).

Schindler, J. et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br. J. Haematol. 154 , 471–476 (2011).

Diefenbach, C. et al. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematol. 8 , e891–e901 (2021).

Sehn, L. H. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol. 38 , 155–165 (2020).

Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21 , 207–221 (2020).

Figueroa-Vazquez, V. et al. HDP-101, an anti-BCMA antibody-drug conjugate, safely delivers amanitin to induce cell death in proliferating and resting multiple myeloma cells. Mol. Cancer Ther. 20 , 367–378 (2021).

Stathis, A. et al. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest. New Drugs 36 , 869–876 (2018).

Pereira, D. S. et al. AGS67E, an anti-CD37 monomethyl auristatin E antibody-drug conjugate as a potential therapeutic for B/T-cell malignancies and AML: a new role for CD37 in AML. Mol. Cancer Ther. 14 , 1650–1660 (2015).

Pereira, D. S. et al. Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin’s lymphoma, chronic lymphocytic leukemia and acute myeloid leukemia. Cancer Res. 74 , 2650 (2014).

Kelly, K. R. et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 8 , e794–e807 (2021).

Ailawadhi, S. et al. A phase I study to assess the safety and pharmacokinetics of single-agent lorvotuzumab mertansine (IMGN901) in patients with relapsed and/or refractory CD-56-positive multiple myeloma. Clin. Lymphoma Myeloma Leuk. 19 , 29–34 (2019).

Govindan, S. V. et al. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers. Mol. Cancer Ther. 12 , 968–978 (2013).

Huang, W. T. et al. Preclinical activity of LM-305 targeting G-protein-coupled receptor class 5 member D (GPRC5D) antibody drug conjugate for the treatment of multiple myeloma. Cancer Res. 82 , 6020 (2022).

Daver, N. et al. Broad activity for the pivekimab sunirine (PVEK, IMGN632), azacitidine, and venetoclax triplet in high-risk patients with relapsed/refractory acute myeloid leukemia (AML). Blood 140 , 145–149 (2022).

Hamadani, M. et al. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Lancet Haematol. 8 , e433–e445 (2021).

Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J. Clin. Oncol. 30 , 2183–2189 (2012).

Lamb, Y. N. Inotuzumab ozogamicin: firstg global approval. Drugs 77 , 1603–1610 (2017).

Mori, J., Tsuda, K. & Tanimoto, T. Inotuzumab ozogamicin for acute lymphoblastic leukemia. N. Engl. J. Med. 375 , 2100 (2016).

Leong, S., Lam, H. P. J., Kirkham, Z. & Popat, R. Antibody drug conjugates for the treatment of multiple myeloma. Am. J. Hematol. 98 , S22–s34 (2023).

Bartok, O. et al. Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature 590 , 332–337 (2021).

Röhrig, U. F. et al. Inhibition mechanisms of indoleamine 2,3-dioxygenase 1 (IDO1). J. Med. Chem. 62 , 8784–8795 (2019).

Ahmadzadeh, M. et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 , 1537–1544 (2009).

Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8 , 1069–1086 (2018).

Qin, G. et al. NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer. Nat. Commun. 11 , 1669 (2020).

Fang, W. et al. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8(+) T cell exclusion. J. Exp. Clin. Cancer Res. 40 , 4 (2021).

Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545 , 495–499 (2017).

Juneja, V. R. et al. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J. Exp. Med. 214 , 895–904 (2017).

Patsoukis, N., Wang, Q., Strauss, L. & Boussiotis, V. A. Revisiting the PD-1 pathway. Sci. Adv. 6 , eabd2712 (2020).

Mahoney, K. M. et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J. Immunother. Cancer 10 , e003527 (2022).

Tekguc, M. et al. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc. Natl Acad. Sci. USA 118 , e2023739118 (2021).

Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170 , 1120–1133.e1117 (2017).

Garris, C. S. et al. Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12. Immunity 49 , 1148–1161.e1147 (2018).

Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12 , eaav7431 (2020).

Budimir, N., Thomas, G. D., Dolina, J. S. & Salek-Ardakani, S. Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol. Res. 10 , 146–153 (2022).

Walker, L. S. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11 , 852–863 (2011).

Wing, K., Yamaguchi, T. & Sakaguchi, S. Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation. Trends Immunol. 32 , 428–433 (2011).

Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14 , 561–584 (2015).

Mayes, P. A., Hance, K. W. & Hoos, A. The promise and challenges of immune agonist antibody development in cancer. Nat. Rev. Drug Discov. 17 , 509–527 (2018).

Romano, E. et al. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc. Natl Acad. Sci. USA . 112 , 6140–6145 (2015).

Vesely, M. D., Zhang, T. & Chen, L. Resistance mechanisms to anti-PD cancer immunotherapy. Annu. Rev. Immunol. 40 , 45–74 (2022).

Chen, L. et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 8 , 1156–1175 (2018).

Banta, K. L. et al. Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses. Immunity 55 , 512–526.e519 (2022).

Strauss, L. et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci. Immunol. 5 , eaay1863 (2020).

Verma, V. et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1(+)CD38(hi) cells and anti-PD-1 resistance. Nat. Immunol. 20 , 1231–1243 (2019).

Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8(+) T cell exhaustion program. Nature 610 , 173–181 (2022).

Vari, F. et al. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood 131 , 1809–1819 (2018).

Yi, M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol. Cancer 21 , 28 (2022).

Zhang, L. et al. Immunotherapy for advanced hepatocellular carcinoma, where are we? Biochim. Biophys. Acta Rev. Cancer 1874 , 188441 (2020).

Sommaggio, R. et al. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. Oncoimmunology 9 , 1777046 (2020).

Krishna, S. et al. Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science 370 , 1328–1334 (2020).

Lopez, R. D. et al. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96 , 3827–3837 (2000).

Laskowski, T. J., Biederstädt, A. & Rezvani, K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat. Rev. Cancer 22 , 557–575 (2022).

Ping, Y., Liu, C. & Zhang, Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell 9 , 254–266 (2018).

Zhang, X. et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front. Immunol. 13 , 927153 (2022).

Tanaka, J. Recent advances in chimeric antigen receptor natural killer cell therapy for overcoming intractable hematological malignancies. Hematol. Oncol. 39 , 11–19 (2021).

Yilmaz, A., Cui, H., Caligiuri, M. A. & Yu, J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. J. Hematol. Oncol. 13 , 168 (2020).

Gross, G., Waks, T. & Eshhar, Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA . 86 , 10024–10028 (1989).

Heuser, C. et al. T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells. Gene Ther. 10 , 1408–1419 (2003).

Jensen, M. C. et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol. Blood Marrow Transplant. 16 , 1245–1256 (2010).

Locke, F. L. et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol. Ther. 25 , 285–295 (2017).

Abramson, J. S. et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396 , 839–852 (2020).

van der Stegen, S. J., Hamieh, M. & Sadelain, M. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 14 , 499–509 (2015).

Bôle-Richard, E. et al. CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm. Leukemia 34 , 3228–3241 (2020).

Wang, J. et al. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J. Hematol. Oncol. 11 , 7 (2018).

Roselli, E. et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J. Immunother. Cancer 9 , e003354 (2021).

Liu, Z. et al. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol. Cancer 22 , 3 (2023).

Zhou, X. et al. Phase I trial of fourth-generation anti-CD19 chimeric antigen receptor T cells against relapsed or refractory B cell non-Hodgkin lymphomas. Front. Immunol. 11 , 564099 (2020).

Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24 , 352–359 (2018).

Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126 , 2123–2138 (2016).

Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1 , 26–31 (2013).

Gu, R. et al. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia. J. Hematol. Oncol. 13 , 122 (2020).

Wang, D. et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma. Blood 137 , 2890–2901 (2021).

Song, F. et al. Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL. J. Immunother. Cancer 11 , e005701 (2023).

Depil, S. et al. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19 , 185–199 (2020).

Hu, Y. et al. Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study. Cell Res. 32 , 995–1007 (2022).

Parikh, R. H., Lonial, S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA: A Cancer J. Clin. 73 , 275–285 (2023).

Hay, K. A. & Turtle, C. J. Chimeric antigen receptor (CAR) T Cells: lessons learned from targeting of CD19 in B-cell malignancies. Drugs 77 , 237–245 (2017).

Pan, J. et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J. Clin. Oncol. 39 , 3340–3351 (2021).

Zhang, M. et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma. Clin. Cancer Res. 28 , 2830–2843 (2022).

Freiwan, A. et al. Engineering naturally occurring CD7- T cells for the immunotherapy of hematological malignancies. Blood 140 , 2684–2696 (2022).

Gruss, H. J. et al. Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines. Blood 83 , 2045–2056 (1994).

Walter, R. B., Appelbaum, F. R., Estey, E. H. & Bernstein, I. D. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 119 , 6198–6208 (2012).

Cui, Q. et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J. Hematol. Oncol. 14 , 82 (2021).

Zhang, M. et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 10 , e107–e116 (2023).

Mei, H. et al. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J. Hematol. Oncol. 14 , 161 (2021).

Zhang, Z. et al. Point mutation in CD19 facilitates immune escape of B cell lymphoma from CAR-T cell therapy. J. Immunother. Cancer 8 , e001150 (2020).

Samur, M. K. et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat. Commun. 12 , 868 (2021).

Ruella, M. et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat. Med. 24 , 1499–1503 (2018).

Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568 , 112–116 (2019).

Nian, Z. et al. Rapamycin pretreatment rescues the bone marrow AML cell elimination capacity of CAR-T cells. Clin. Cancer Res. 27 , 6026–6038 (2021).

Jain, M. D. et al. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood 137 , 2621–2633 (2021).

Shen, Y. et al. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr. Res. Transl. Med. 71 , 103378 (2023).

Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387 , 1196–1206 (2022).

Smith, E. L. et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci. Transl. Med. 11 , eaau7746 (2019).

Hu, Y. et al. CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. Clin. Cancer Res. 27 , 2764–2772 (2021).

Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 136 , 1632–1644 (2020).

He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135 , 713–723 (2020).

Li, K. X. et al. A novel approach for relapsed/refractory FLT3(mut+) acute myeloid leukaemia: synergistic effect of the combination of bispecific FLT3scFv/NKG2D-CAR T cells and gilteritinib. Mol. Cancer 21 , 66 (2022).

Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35 , 75–89 (2021).

Han, X., Wang, Y., Wei, J. & Han, W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J. Hematol. Oncol. 12 , 128 (2019).

Rabilloud, T. et al. Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy. Nat. Commun. 12 , 865 (2021).

Shao, L. et al. Genome-wide profiling of retroviral DNA integration and its effect on clinical pre-infusion CAR T-cell products. J. Transl. Med. 20 , 514 (2022).

Xie, G. et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine 59 , 102975 (2020).

Pan, K. et al. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J. Exp. Clin. Cancer Res. 41 , 119 (2022).

Pao, S. C., Chu, M. T. & Hung, S. I. Therapeutic vaccines targeting neoantigens to induce T-cell immunity against cancers. Pharmaceutics 14 , 867 (2022).

Keilholz, U. et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113 , 6541–6548 (2009).

Van Tendeloo, V. F. et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc. Natl Acad. Sci. USA . 107 , 13824–13829 (2010).

Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21 , 360–378 (2021).

Smith, C. et al. Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood 113 , 6148–6152 (2009).

Frank, M. J. et al. Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. J. Exp. Med. 217 , e20191712 (2020).

Neelapu, S. S. et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat. Med. 11 , 986–991 (2005).

Maslak, P. G. et al. Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. Blood Adv. 2 , 224–234 (2018).

Hu, Z., Ott, P. A. & Wu, C. J. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat. Rev. Immunol. 18 , 168–182 (2018).

Tay, B. Q. et al. Evolution of cancer vaccines-challenges, achievements, and future directions. Vaccines (Basel) . 9 (2021).

French, R. R., Chan, H. T., Tutt, A. L. & Glennie, M. J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5 , 548–553 (1999).

Sotomayor, E. M. et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5 , 780–787 (1999).

Nagorsen, D. & Baeuerle, P. A. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp. Cell Res. 317 , 1255–1260 (2011).

Lu, J. & Jiang, G. The journey of CAR-T therapy in hematological malignancies. Mol. Cancer 21 , 194 (2022).

Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 , 252–264 (2012).

Postow, M. A., Callahan, M. K. & Wolchok, J. D. Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 , 1974–1982 (2015).

Baker, K. S. et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin’s disease in children and adolescents. J. Clin. Oncol. 17 , 825–831 (1999).

Eckert, C. et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J. Clin. Oncol. 31 , 2736–2742 (2013).

Pession, A. et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 122 , 170–178 (2013).

Vose, J. M. et al. Autologous transplantation for aggressive non-Hodgkin’s lymphoma: results of a randomized trial evaluating graft source and minimal residual disease. J. Clin. Oncol. 20 , 2344–2352 (2002).

Majolino, I., Pearce, R., Taghipour, G. & Goldstone, A. H. Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin’s and non-Hodgkin’s lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J. Clin. Oncol. 15 , 509–517 (1997).

Bertz, H., Illerhaus, G., Veelken, H. & Finke, J. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens. Ann. Oncol. 13 , 135–139 (2002).

Anderlini, P. et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin’s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica 93 , 257–264 (2008).

Sureda, A. et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin’s lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 97 , 310–317 (2012).

Beelen, D. W. et al. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am. J. Hematol. 97 , 1023–1034 (2022).

Russell, N. H. et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica 107 , 1518–1527 (2022).

Nakamura, R. et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J. Clin. Oncol. 39 , 3328–3339 (2021).

Wang, Y. et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood 125 , 3956–3962 (2015).

Wang, Y. et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin. Cancer Res. 22 , 3467–3476 (2016).

Lu, Y. et al. Unmanipulated haplo-identical donor transplantation compared with identical sibling donor had better anti-leukemia effect for refractory/relapsed acute myeloid leukemia not in remission status. Ann. Hematol. 99 , 2911–2925 (2020).

Zheng, F. M. et al. Haploidentical- versus identical-sibling transplant for high-risk pediatric AML: a multi-center study. Cancer Commun. 40 , 93–104 (2020).

Zhou, X. et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood 123 , 3895–3905 (2014).

Martelli, M. F. et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood 124 , 638–644 (2014).

McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16 , 2825–2833 (1998).

Foran, J. M. et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol. 18 , 317–324 (2000).

Lenz, G. et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23 , 1984–1992 (2005).

Mounier, N. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101 , 4279–4284 (2003).

Eichhorst, B. et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 32 , 23–33 (2021).

Hallek, M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376 , 1164–1174 (2010).

Hagenbeek, A. et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 111 , 5486–5495 (2008).

Cheson, B. D. et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J. Clin. Oncol. 36 , 2259–2266 (2018).

Jurczak, W. et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann. Oncol. 29 , 1266–1272 (2018).

Tilly, H. et al. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study. Lancet Oncol. 20 , 998–1010 (2019).

Sharman, J. P. et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 8 , e254–e266 (2021).

Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321 , 974–977 (2008).

Topp, M. S. et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J. Clin. Oncol. 29 , 2493–2498 (2011).

Topp, M. S. et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 32 , 4134–4140 (2014).

Klinger, M. et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119 , 6226–6233 (2012).

Brown, P. A. et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325 , 833–842 (2021).

Locatelli, F. et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA 325 , 843–854 (2021).

Jabbour, E. et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 9 , e878–e885 (2022).

Jabbour, E. et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol. 10 , e24–e34 (2023).

Foà, R. et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N. Engl. J. Med. 383 , 1613–1623 (2020).

Coyle, L. et al. Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk. Lymphoma 61 , 2103–2112 (2020).

Katz, D. A. et al. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL. Leuk. Lymphoma 63 , 2063–2073 (2022).

Grosicki, S. et al. Elranatamab in combination with daratumumab for patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the phase 3 magnetismm-5 study safety lead-in cohort. Blood 140 , 4407–4408 (2022).

Lesokhin, A. et al. Magnetismm-3: an open-label, multicenter, non-randomized phase 2 study of elranatamab (PF-06863135) in patients with relapsed or refractory multiple myeloma. Blood 138 , 1674 (2021).

Mateos, M. V. et al. MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant. Clin. Lymphoma Myeloma Leuk. 22 , S45–S45 (2022).

Sievers, E. L. et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol. 19 , 3244–3254 (2001).

Petersdorf, S. H. et al. A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121 , 4854–4860 (2013).

Löwenberg, B. et al. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 115 , 2586–2591 (2010).

Hasle, H. et al. Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004. Blood 120 , 978–984 (2012).

Amadori, S. et al. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17). J. Clin. Oncol. 31 , 4424–4430 (2013).

Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379 , 1508–1516 (2012).

Burnett, A. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J. Clin. Oncol. 30 , 3924–3931 (2012).

Gamis, A. S. et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J. Clin. Oncol. 32 , 3021–3032 (2014).

Olombel, G. et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Blood 127 , 2157–2160 (2016).

Fournier, E. et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood 135 , 542–546 (2020).

Schlenk, R. F. et al. Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study. J. Clin. Oncol. 38 , 623–632 (2020).

Borthakur, G. et al. Retrospective comparison of survival and responses to fludarabine, cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patients. Am. J. Hematol. 97 , 1427–1434 (2022).

Kantarjian, H. et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 13 , 403–411 (2012).

Jabbour, E. et al. Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial. JAMA Oncol. 4 , 230–234 (2018).

Kantarjian, H. et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 19 , 240–248 (2018).

Kreitman, R. J. et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J. Hematol. Oncol. 14 , 35 (2021).

Trudel, S. et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 19 , 1641–1653 (2018).

Quach, H. et al. Safety and clinical activity of belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-6 arm-A interim analysis. Clin. Lymphoma Myeloma Leuk. 22 , S423–S424 (2022).

Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372 , 311–319 (2015).

Younes, A. et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 17 , 1283–1294 (2016).

Schnorfeil, F. M. et al. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J. Hematol. Oncol. 8 , 93 (2015).

Armand, P. et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 31 , 4199–4206 (2013).

Armand, P. Immune checkpoint blockade in hematologic malignancies. Blood 125 , 3393–3400 (2015).

Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116 , 3268–3277 (2010).

Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34 , 2690–2697 (2016).

Green, M. R. et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 18 , 1611–1618 (2012).

Merryman, R. W., Armand, P., Wright, K. T. & Rodig, S. J. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma. Blood Adv. 1 , 2643–2654 (2017).

Bashey, A. et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 113 , 1581–1588 (2009).

Ansell, S. M. et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 15 , 6446–6453 (2009).

Diefenbach, C. S. et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 7 , e660–e670 (2020).

Armand, P. et al. A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. Leukemia 35 , 777–786 (2021).

Mei, M. G. et al. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood 139 , 3605–3616 (2022).

Deng, Q. et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat. Med. 26 , 1878–1887 (2020).

Nayak, L. et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood 129 , 3071–3073 (2017).

Zinzani, P. L. et al. Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II checkMate 436 study. J. Clin. Oncol. 37 , 3081–3089 (2019).

Ansell, S. M. et al. Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study. J. Clin. Oncol. 37 , 481–489 (2019).

Chen, R. et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J. Clin. Oncol. 35 , 2125–2132 (2017).

Westin, J. R. et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 15 , 69–77 (2014).

Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379 , 1711–1721 (2018).

Armand, P. et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J. Clin. Oncol. 34 , 3733–3739 (2016).

Younes, A. et al. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. Lancet Haematol. 6 , e67–e78 (2019).

Ding, W. et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood 129 , 3419–3427 (2017).

Zinzani, P. L. et al. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood 130 , 267–270 (2017).

Berger, R. et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14 , 3044–3051 (2008).

Hawkes, E. et al. First-in-human (FIH) study of the fully-human kappa-lambda CD19/CD47 bispecific antibody TG-1801 in patients (pts) with B-cell lymphoma. Blood 140 , 6599–6601 (2022).

Mehta, A. et al. Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non- Hodgkin’s lymphoma: initial clinical results. Blood 138 , 3542 (2021).

Qi, J. Y. et al. A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results. Blood 136 , 30–31 (2020).

Stadtmauer, E. et al. Lemzoparlimab (TJ011133), an anti-CD47 antibody, with/without dexamethasone plus anti myeloma regimens for relapsed/refractory multiple myeloma: a phase 1b dose escalation and expansion study. J. Immunother. Cancer 9 , A476 (2021).

Garcia-Manero, G. et al. Evorpacept (ALX148), a CD47-blocking myeloid checkpoint inhibitor, in combination with azacitidine: a phase 1 / 2 study in patients with myelodysplastic syndrome (ASPEN-02). Blood 138 , 2601 (2021).

Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378 , 439–448 (2018).

Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380 , 45–56 (2019).

Bishop, M. R. et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N. Engl. J. Med. 386 , 629–639 (2022).

Fowler, N. H. et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat. Med. 28 , 325–332 (2022).

Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 20 , 31–42 (2019).

Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382 , 1331–1342 (2020).

Shah, B. D. et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet 398 , 491–502 (2021).

Jacobson, C. A. et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 23 , 91–103 (2022).

Locke, F. L. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N. Engl. J. Med. 386 , 640–654 (2022).

Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. 28 , 735–742 (2022).

Siddiqi, T. et al. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood 139 , 1794–1806 (2022).

Kamdar, M. et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399 , 2294–2308 (2022).

Sehgal, A. et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 23 , 1066–1077 (2022).

Cheng, Q. et al. CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma. Cytotherapy 24 , 1026–1034 (2022).

Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24 , 20–28 (2018).

Spiegel, J. Y. et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat. Med. 27 , 1419–1431 (2021).

Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26 , 1569–1575 (2020).

Ramos, C. A. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol. 38 , 3794–3804 (2020).

Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J. Clin. Investig. 127 , 3462–3471 (2017).

Wang, C. M. et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial. Clin. Cancer Res. 23 , 1156–1166 (2017).

Raje, N. et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N. Engl. J. Med. 380 , 1726–1737 (2019).

Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384 , 705–716 (2021).

Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388 , 1002–1014 (2023).

Raje, N. et al. Updated clinical and correlative results from the Phase I CRB-402 study of the BCMA-targeted CAR T cell therapy bb21217 in patients with relapsed and/or refractory multiple myeloma. Clin. Lymphoma Myeloma Leuk. 22 , S4–S5 (2022).

Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398 , 314–324 (2021).

Costello, C. L. et al. Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM) (PRIME). Blood 134 , 3184 (2019).

Mailankody, S. et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J. Clin. Oncol. 38 , 8504 (2020).

Kumar, S. K. et al. Results from Lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T cells (CT053) in patients with relapsed and/or refractory multiple myeloma. Blood 136 , 28–29 (2020).

Mailankody, S. et al. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat. Med. 29 , 422–429 (2023).

Zhao, W. H. et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J. Hematol. Oncol. 11 , 141 (2018).

Bal, S. et al. Clinical activity of BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed and/or refractory (R/R) multiple myeloma (MM): first results from a phase 1, multicenter, open-label study. Blood 140 , 883–885 (2022).

Shi, D. et al. USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer. Nat. Commun. 13 , 5644 (2022).

Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6 , e521–e529 (2019).

Baumeister, S. H. et al. Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol. Res. 7 , 100–112 (2019).

Jin, X. et al. First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia. J. Hematol. Oncol. 15 , 88 (2022).

Sallman, D. A. et al. Ameli-01: a phase I trial of UCART123v1.2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD123+acute myeloid leukemia (AML). Blood 140 , 2371–2373 (2022).

Lu, P. et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood 140 , 321–334 (2022).

Zhang, Y. et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer J. 13 , 61 (2023).

Lekakis, L. J. et al. ALPHA2 Study: ALLO-501A allogeneic CAR T in LBCL, updated results continue to show encouraging safety and efficacy with consolidation dosing. Blood 138 , 649 (2021).

Jain, N. et al. Preliminary results from the Flu/Cy/alemtuzumab arm of the phase I BALLI-01 trial of UCART22, an antiCD22 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R/R) CD22+B-cell acute lymphoblastic leukemia (B-ALL). Blood 138 , 1764 (2021).

Ni, J. J. et al. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol. Sin. 44 , 288–307 (2022).

McGuirk, J. P. et al. CTX110 allogeneic CRISPR-Cas9-engineered CAR T cells in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 1 dose escalation carbon study. Blood 140 , 10303–10306 (2022).

Shah, B. D. et al. Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+NHL. J. Clin. Oncol. 39 , 7516 (2021).

Jain, N. et al. Preliminary safety and efficacy of PBCAR0191, an allogeneic ‘off-the-shelf’ CD19-directed CAR-T for patients with relapsed/refractory (R/R) CD19+B-ALL. Blood 138 , 650 (2021).

Scott, D. W. & Gascoyne, R. D. The tumour microenvironment in B cell lymphomas. Nat. Rev. Cancer 14 , 517–534 (2014).

Sang, W. et al. Anti-PD-1 therapy enhances the efficacy of CD30-directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma. Front. Immunol. 13 , 858021 (2022).

Chen, X. et al. A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma. Immunotherapy 12 , 681–696 (2020).

Zhang, J. et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 609 , 369–374 (2022).

Liu, H. et al. CD19-specific CAR T Cells that express a PD-1/CD28 chimeric switch-receptor are effective in patients with PD-L1-positive B-cell lymphoma. Clin. Cancer Res. 27 , 473–484 (2021).

Cruz, C. R. et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122 , 2965–2973 (2013).

Wang, X. et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127 , 2980–2990 (2016).

Zhao, H. et al. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. J. Hematol. Oncol. 13 , 42 (2020).

Jiang, H. et al. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial. Am. J. Hematol. 94 , 1113–1122 (2019).

Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382 , 545–553 (2020).

Mickinso, M. et al. A phase 1 study of NKX019, a CD19 chimeric antigen receptor natural killer (CAR NK) cell therapy, in subjects with B-cell malignancies. Blood 138 , 3868 (2021).

Bachier, C. et al. A phase 1 study of NKX101, an allogeneic CAR natural killer (NK) cell therapy, in subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS). Blood 136 , 42–43 (2020).

Dhakal, B. et al. Interim phase I clinical data of FT576 as monotherapy and in combination with daratumumab in subjects with relapsed/refractory multiple myeloma. Blood 140 , 4586–4587 (2022).

Roex, G. et al. Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. J. Transl. Med. 20 , 124 (2022).

Christodoulou, I. et al. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities. J. Immunother. Cancer 9 , e003894 (2021).

Gong, Y. et al. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. J. Hematol. Oncol. 14 , 73 (2021).

Kennedy, L. B. & Salama, A. K. S. A review of cancer immunotherapy toxicity. CA Cancer J. Clin. 70 , 86–104 (2020).

Fontana, L. & Strasfeld, L. Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient. Infect. Dis. Clin. North Am. 33 , 523–544 (2019).

Misch, E. A. & Andes, D. R. Bacterial infections in the stem cell transplant recipient and hematologic malignancy patient. Infect. Dis. Clin. North Am. 33 , 399–445 (2019).

Nathan, S. & Ustun, C. Complications of stem cell transplantation that affect infections in stem cell transplant recipients, with analogies to patients with hematologic malignancies. Infect. Dis. Clin. North Am. 33 , 331–359 (2019).

Renaghan, A. D. et al. Acute kidney injury and CKD associated with hematopoietic stem cell transplantation. Clin. J. Am. Soc. Nephrol. 15 , 289–297 (2020).

Kemmner, S., Verbeek, M. & Heemann, U. Renal dysfunction following bone marrow transplantation. J. Nephrol. 30 , 201–209 (2017).

Abramson, M. H. et al. Acute kidney injury in the modern era of allogeneic hematopoietic stem cell transplantation. Clin. J. Am. Soc. Nephrol. 16 , 1318–1327 (2021).

Mahadeo, K. M. et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 7 , e61–e72 (2020).

Bonifazi, F. et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front. Immunol. 11 , 489 (2020).

Kammersgaard, M. B. et al. Assessment of the proposed EBMT pediatric criteria for diagnosis and severity grading of sinusoidal obstruction syndrome. Bone Marrow Transpl. 54 , 1406–1418 (2019).

Dignan, F. L. et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br. J. Haematol. 163 , 444–457 (2013).

Markey, K. A., MacDonald, K. P. & Hill, G. R. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 124 , 354–362 (2014).

Ferrara, J. L. & Deeg, H. J. Graft-versus-host disease. N. Engl. J. Med. 324 , 667–674 (1991).

Sacirbegovic, F. et al. Graft-versus-host disease is locally maintained in target tissues by resident progenitor-like T cells. Immunity 56 , 369–385.e366 (2023).

Khoury, H. J. et al. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica 102 , 958–966 (2017).

Zhao, X. S. & Huang, X. J. Seeking biomarkers for acute graft-versus-host disease: where we are and where we are heading? Biomark. Res. 7 , 17 (2019).

Gooptu, M. & Koreth, J. Better acute graft-versus-host disease outcomes for allogeneic transplant recipients in the modern era: a tacrolimus effect? Haematologica 102 , 806–808 (2017).

Müller, A. M. S. Chronic GVHD on the move. Blood 140 , 2660–2661 (2022).

Kong, X. et al. Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD. Blood 140 , 2740–2753 (2022).

Nelson, A. S. et al. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy. Leukemia 29 , 441–447 (2015).

Goyal, A. et al. Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, And End Results analysis. J. Am. Acad. Dermatol. 83 , 404–411 (2020).

André, M. et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin’s disease. Blood 92 , 1933–1940 (1998).

Tichelli, A. et al. Evaluation of second solid cancers after hematopoietic stem cell transplantation in European patients. JAMA Oncol. 5 , 229–235 (2019).

Sirohi, B. et al. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin’s lymphoma. Ann. Oncol. 19 , 1312–1319 (2008).

Duignan, S. et al. Post-transplant lymphoproliferative disorder presenting as supraglottitis following pediatric heart transplantation treated with EBV-specific cytotoxic T-lymphocytes. J. Heart Lung Transpl. 41 , 708–711 (2022).

Zimmermann, H. et al. Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial. Leukemia 36 , 2468–2478 (2022).

Thieme, C. J. et al. In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. Kidney Int . 102 , 1392–1408 (2022).

Trappe, R. et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol. 13 , 196–206 (2012).

Burns, D. M. et al. Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant. Transplantation 104 , 2582–2590 (2020).

Byrd, J. C. et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J. Clin. Oncol. 17 , 791–795 (1999).

Hansel, T. T. et al. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9 , 325–338 (2010).

Baldo, B. A. Adverse events to monoclonal antibodies used for cancer therapy: Focus on hypersensitivity responses. Oncoimmunology 2 , e26333 (2013).

Duell, J. et al. Functionally defective T cells after chemotherapy of B-cell malignancies can be activated by the tetravalent bispecific CD19/CD3 antibody AFM11. J. Immunother. 42 , 180–188 (2019).

Salvaris, R., Ong, J. & Gregory, G. P. Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas. J. Pers. Med . 11 (2021).

van Brummelen, E. M. et al. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist 21 , 1260–1268 (2016).

Zhu, Y., Liu, K., Wang, K. & Zhu, H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer 129 , 283–295 (2023).

Nguyen, T. D., Bordeau, B. M. & Balthasar, J. P. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers 15 , 713 (2023).

Wolska-Washer, A. & Robak, T. Safety and tolerability of antibody-drug conjugates in cancer. Drug Saf. 42 , 295–314 (2019).

Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2019. J. Natl Compr. Canc. Netw. 17 , 255–289 (2019).

Haanen, J. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28 , iv119–iv142 (2017).

Thompson, J. A. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J. Natl Compr. Cancer Netw. 16 , 594–596 (2018).

Haanen, J. et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 29 , iv264–iv266 (2018).

Puzanov, I. et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5 , 95 (2017).

Schneider, B. J., Lacchetti, C. & Bollin, K. Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. JCO Oncol. Pract. 18 , 431–444 (2022).

Martins, F. et al. New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol. 20 , e54–e64 (2019).

Belum, V. R. et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur. J. Cancer 60 , 12–25 (2016).

Geisler, A. N. et al. Immune checkpoint inhibitor-related dermatologic adverse events. J. Am. Acad. Dermatol. 83 , 1255–1268 (2020).

Ellis, S. R. et al. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J. Am. Acad. Dermatol. 83 , 1130–1143 (2020).

Kumar, V. et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8 , 49 (2017).

Villadolid, J. & Amin, A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl. Lung Cancer Res. 4 , 560–575 (2015).

Phillips, G. S. et al. Treatment outcomes of immune-related cutaneous adverse events. J. Clin. Oncol. 37 , 2746–2758 (2019).

de Filette, J. et al. A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm. Metab. Res. 51 , 145–156 (2019).

Wright, J. J., Powers, A. C. & Johnson, D. B. Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17 , 389–399 (2021).

Grouthier, V. et al. Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO vigiBase report analysis. Oncologist 25 , 696–701 (2020).

Muir, C. A. et al. Thyroid immune-related adverse events following immune checkpoint inhibitor treatment. J. Clin. Endocrinol. Metab. 106 , e3704–e3713 (2021).

de Filette, J. M. K. et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur. J. Endocrinol. 181 , 363–374 (2019).

Reynolds, K., Thomas, M. & Dougan, M. Diagnosis and management of hepatitis in patients on checkpoint blockade. Oncologist 23 , 991–997 (2018).

De Martin, E. et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J. Hepatol. 68 , 1181–1190 (2018).

Zen, Y. & Yeh, M. M. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod. Pathol. 31 , 965–973 (2018).

Abdel-Rahman, O., ElHalawani, H. & Fouad, M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Immunotherapy 7 , 1213–1227 (2015).

Geukes Foppen, M. H. et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open 3 , e000278 (2018).

Collins, M. et al. Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. Ann. Oncol. 28 , 2860–2865 (2017).

Samaan, M. A. et al. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat. Rev. Gastroenterol. Hepatol. 15 , 222–234 (2018).

Naidoo, J. et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 35 , 709–717 (2017).

Nishino, M. et al. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2 , 1607–1616 (2016).

Naidoo, J. et al. Chronic immune checkpoint inhibitor pneumonitis. J. Immunother. Cancer 8 , e000840 (2020).

Delaunay, M. et al. Management of pulmonary toxicity associated with immune checkpoint inhibitors. Eur. Respir. Rev. 28 , 190012 (2019).

Zhang, X. T., Ge, N., Xiang, Z. J. & Liu, T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell Int. 22 , 363 (2022).

Solimando, A. G. et al. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int. J. Mol. Sci . 21 , 3054 (2020).

Wu, L. et al. Unravelling checkpoint inhibitor associated autoimmune diabetes: from bench to bedside. Front. Endocrinol. 12 , 764138 (2021).

Kramer, R. et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur. J. Cancer 147 , 170–181 (2021).

Herrmann, S. M. & Perazella, M. A. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int. Rep. 5 , 1139–1148 (2020).

Sprangers, B. et al. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat. Rev. Nephrol. 18 , 794–805 (2022).

Meraz-Muñoz, A. et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J. Immunother. Cancer 8 , e000467 (2020).

Awadalla, M. et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J. Am. Coll. Cardiol. 75 , 467–478 (2020).

Leaf, R. K. et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am. J. Hematol. 94 , 563–574 (2019).

Haanen, J. et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J. Immunother. Cancer 8 , e000604 (2020).

Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39 , 4073–4126 (2021).

Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24 , 739–748 (2018).

Sandler, R. D. et al. Diagnosis and management of secondary HLH/MAS folowing HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front. Immunol. 11 , 524 (2020).

Lichtenstein, D. A. et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood 138 , 2469–2484 (2021).

Schubert, M. L. et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann. Oncol. 32 , 34–48 (2021).

Si, X. et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective. Cancer Lett. 550 , 215920 (2022).

Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18 , 843–851 (2010).

Gust, J., Taraseviciute, A. & Turtle, C. J. Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs 32 , 1091–1101 (2018).

Santomasso, B. D. et al. Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 8 , 958–971 (2018).

Brudno, J. N. & Kochenderfer, J. N. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 34 , 45–55 (2019).

Thompson, J. A. et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 20 , 387–405 (2022).

Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22 , 85–96 (2022).

Freyer, C. W. & Porter, D. L. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. J. Allergy Clin. Immunol. 146 , 940–948 (2020).

Schmidts, A., Wehrli, M. & Maus, M. V. Toward better understanding and management of CAR-T cell-associated toxicity. Annu. Rev. Med. 72 , 365–382 (2021).

Santomasso, B. D. et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J. Clin. Oncol. 39 , 3978–3992 (2021).

Jain, M. D., Smith, M., Shah, N. N. How I treat refractory CRS and ICANS following CAR T-cell therapy. Blood . 141 , 2430–2442 (2023).

Frey, N. & Porter, D. Cytokine release syndrome with chimeric antigen receptor T cell therapy. Biol. Blood Marrow Transplant. 25 , e123–e127 (2019).

Giavridis, T. et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24 , 731–738 (2018).

Staedtke, V. et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature 564 , 273–277 (2018).

Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric sntigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6 , 664–679 (2016).

Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124 , 188–195 (2014).

Boyiadzis, M. M. et al. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. J. Immunother. Cancer 6 , 137 (2018).

Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377 , 2531–2544 (2017).

Mueller, K. T. et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin. Cancer Res . 24 , 6175–6184 (2018).

Wei, J. et al. The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. Signal Transduct. Target Ther. 5 , 134 (2020).

Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368 , 1509–1518 (2013).

Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371 , 1507–1517 (2014).

Le, R. Q. et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23 , 943–947 (2018).

Chen, H. et al. Management of cytokine release syndrome related to CAR-T cell therapy. Front. Med. 13 , 610–617 (2019).

Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15 , 47–62 (2018).

Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7 , 1404–1419 (2017).

Taraseviciute, A. et al. Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discov. 8 , 750–763 (2018).

Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and nurologic toxicity associated with immune efector clls. Biol. Blood Marrow Transpl. 25 , 625–638 (2019).

Santomasso, B. D., Gust, J. & Perna, F. How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity. Blood 141 , 2443–2451 (2023).

Major, A. et al. Management of hemophagocytic lymphohistiocytosis (HLH) associated with chimeric antigen receptor T-cell (CAR-T) therapy using anti-cytokine therapy: an illustrative case and review of the literature. Leuk. Lymphoma 62 , 1765–1769 (2021).

Schram, A. M. & Berliner, N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood 125 , 2908–2914 (2015).

Sandler, R. D. et al. Diagnosis and management of secondary HLH/MAS following HSCT and CAR-T cell therapy in adults; a review of the literature and a survey of practice within EBMT centres on behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front. Immunol. 11 , 524 (2020).

Doan, A. & Pulsipher, M. A. Hypogammaglobulinemia due to CAR T-cell therapy. Pediatr. Blood Cancer https://doi.org/10.1002/pbc.26914 (2018).

Wat, J. & Barmettler, S. Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: characteristics, management, and future directions. J. Allergy Clin. Immunol. Pract. 10 , 460–466 (2022).

Garcia-Lloret, M., McGhee, S. & Chatila, T. A. Immunoglobulin replacement therapy in children. Immunol. Allergy Clin. North Am. 28 , 833–849 (2008).

Radinsky, S. & Bonagura, V. R. Subcutaneous immunoglobulin infusion as an alternative to intravenous immunoglobulin. J. Allergy Clin. Immunol. 112 , 630–633 (2003).

Rejeski, K. et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138 , 2499–2513 (2021).

Jain, T., Olson, T. S., Locke, F. L. How I treat cytopenias after CAR T-cell therapy. Blood 141 , 2460–2469 (2023).

Du, M. et al. Case report: ITP treatment after CAR-T cell therapy in patients with multiple myeloma. Front. Immunol. 13 , 898341 (2022).

Fried, S. et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 54 , 1643–1650 (2019).

Nahas, G. R. et al. Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT). Leuk. Lymphoma 61 , 940–943 (2020).

Jain, T. et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 4 , 3776–3787 (2020).

Baur, R. et al. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report. J. Immunother. Cancer 9 , e002721 (2021).

Buechner, J. et al. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 5 , 593–601 (2021).

Gudiol, C., Lewis, R. E., Strati, P. & Kontoyiannis, D. P. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol. 8 , e216–e228 (2021).

Wang, Y. et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J. Clin. Oncol. 41 , 2594–2606 (2023).

Hill, J. A. et al. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131 , 121–130 (2018).

Gill, S. & Brudno, J. N. CAR T-cell therapy in hematologic malignancies: clinical role, toxicity, and unanswered questions. Am. Soc. Clin. Oncol. Educ. Book 41 , 1–20 (2021).

Shi, M. et al. Safety and efficacy of a humanized CD19 chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic leukemia. Am. J. Hematol. 97 , 711–718 (2022).

Holland, E. M. et al. Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation. J. Immunother. Cancer 10 , e004483 (2022).

Lamers, C. H. et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117 , 72–82 (2011).

Xu, J. et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc. Natl Acad. Sci. USA 116 , 9543–9551 (2019).

Wagner, D. L. et al. Immunogenicity of CAR T cells in cancer therapy. Nat. Rev. Clin. Oncol. 18 , 379–393 (2021).

Herrmann, M. et al. Bifunctional PD-1 × αCD3 × αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia. Blood 132 , 2484–2494 (2018).

Correnti, C. E. et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32 , 1239–1243 (2018).

Li, X. et al. Decitabine priming increases anti-PD-1 antitumor efficacy by promoting CD8+ progenitor exhausted T cell expansion in tumor models. J. Clin. Invest. 133 , e165673 (2023).

Wang, Y. et al. Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming. Nat. Commun. 12 , 409 (2021).

Xu, Y. et al. Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials. Cancer Commun. 42 , 493–516 (2022).

Short, N. J. & Kantarjian, H. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past. Lancet Haematol. 10 , e382–e388 (2023).

Yang, J. et al. Advancing CAR T cell therapy through the use of multidimensional omics data. Nat. Rev. Clin. Oncol. 20 , 211–228 (2023).

Svensson, V., Vento-Tormo, R. & Teichmann, S. A. Exponential scaling of single-cell RNA-seq in the past decade. Nat. Protoc. 13 , 599–604 (2018).

Stubbington, M. J. T., Rozenblatt-Rosen, O., Regev, A. & Teichmann, S. A. Single-cell transcriptomics to explore the immune system in health and disease. Science 358 , 58–63 (2017).

Horns, F., Dekker, C. L. & Quake, S. R. Memory B cell activation, broad anti-influenza antibodies, and bystander activation revealed by single-cell transcriptomics. Cell Rep. 30 , 905–913.e906 (2020).

Bode, D., Cull, A. H., Rubio-Lara, J. A. & Kent, D. G. Exploiting single-cell tools in gene and cell therapy. Front. Immunol. 12 , 702636 (2021).

Castellanos-Rueda, R., Di Roberto, R. B., Schlatter, F. S. & Reddy, S. T. Leveraging single-cell sequencing for chimeric antigen receptor T cell therapies. Trends Biotechnol. 39 , 1308–1320 (2021).

Tracy, S. I. et al. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia. Blood 140 , 335–348 (2022).

Jiang, P. et al. Single-cell ATAC-seq maps the comprehensive and dynamic chromatin accessibility landscape of CAR-T cell dysfunction. Leukemia 36 , 2656–2668 (2022).

Charitidis, F. T. et al. Monitoring CAR T cell generation with a CD8-targeted lentiviral vector by single-cell transcriptomics. Mol. Ther. Methods Clin. Dev. 24 , 207–209 (2022).

Bai, Z. et al. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells. J. Immunother. Cancer 9 , e002328 (2021).

Yan, C. et al. Single-cell imaging of T cell immunotherapy responses in vivo. J. Exp. Med. 218 , e20210314 (2021).

Cazaux, M. et al. Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity. J. Exp. Med. 216 , 1038–1049 (2019).

Tian, M. et al. An optimized bicistronic chimeric antigen receptor against GPC2 or CD276 overcomes heterogeneous expression in neuroblastoma. J. Clin. Invest. 132 , e155621 (2022).

Pfeifer, R. et al. A multimodal imaging workflow for monitoring CAR T cell therapy against solid tumor from whole-body to single-cell level. Theranostics 12 , 4834–4850 (2022).

Download references

Acknowledgements

This work was supported by grants from the National Key R&D Program of China (2022YFC2502700), the National Natural Science Foundation of China (81873434; 82100190) and the China Postdoctoral Innovative Talent Support Foundation (BX2021106). All the figures were created by the website tool BioRender ( https://www.biorender.com/ ).

Author information

These authors contributed equally: Lu Tang, Zhongpei Huang

Authors and Affiliations

Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China

Lu Tang, Zhongpei Huang, Heng Mei & Yu Hu

Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, 430022, Wuhan, China

Key Laboratory of Biological Targeted Therapy, the Ministry of Education, 430022, Wuhan, China

Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 430022, Wuhan, China

Heng Mei & Yu Hu

You can also search for this author in PubMed   Google Scholar

Contributions

L.T. and H.M.: conception and offering critical comments. L.T., Z.H., and H.M.: data collection. L.T., Z.H., and H.M.: writing and original draft preparation. L.T. and Z.H.: table and figure preparation and editing. L.T., Y.H., and H.M.: review and editing. All authors contributed to the article have read and approved the submitted version.

Corresponding authors

Correspondence to Heng Mei or Yu Hu .

Ethics declarations

Competing interests.

The authors declare no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ .

Reprints and permissions

About this article

Cite this article.

Tang, L., Huang, Z., Mei, H. et al. Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Sig Transduct Target Ther 8 , 306 (2023). https://doi.org/10.1038/s41392-023-01521-5

Download citation

Received : 29 December 2022

Revised : 31 May 2023

Accepted : 04 June 2023

Published : 18 August 2023

DOI : https://doi.org/10.1038/s41392-023-01521-5

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

This article is cited by

Gmp-manufactured crispr/cas9 technology as an advantageous tool to support cancer immunotherapy.

• S Iacovelli
• Valentina Folgiero

Journal of Experimental & Clinical Cancer Research (2024)

Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology

• Muhammad Hossein Ashoub
• Razieh Razavi
• Mahnaz Amiri

European Journal of Medical Research (2024)

Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy

• Zengzheng Du

Signal Transduction and Targeted Therapy (2024)

Quick links

• Explore articles by subject
• Guide to authors
• Editorial policies

• News Releases

Scientists discover blood proteins that may give cancer warning 7 years before diagnosis

Cancer Research UK

Two Cancer Research UK-funded studies from Oxford Population Health have discovered proteins in the blood that could warn people of cancer more than seven years before it is diagnosed.

Scientists identified 618 proteins linked to 19 different types of cancer, including 107 proteins in a group of people who blood was collected at least seven years before diagnosis.

The team have discovered that these proteins could be involved at the very earliest stages of cancer, where it could be prevented.

They believe that some of these proteins could be used to detect cancer much earlier than is currently possible. In the future, this could help treat the disease at a much earlier stage or prevent it altogether. 

Cancer Research UK is funding researchers to look for the earliest signs of cancer as part of its long-term strategy to prevent cancer through research . In these studies, the team used a powerful technique called proteomics. Proteomics allows scientists to analyse a large set of proteins in tissue samples at a single point in time, to see how they interact with each other and find any important differences in proteins between different tissue samples.

In the first study, scientists analysed blood samples from UK Biobank which were taken from more than 44,000 people, including over 4,900 people who subsequently had a cancer diagnosis.

Using proteomics, the team analysed a set of 1,463 proteins from a single sample of blood from each person. They compared the proteins of people who did and did not go on to be diagnosed with cancer to look for important differences between them and find out which ones were linked to cancer risk. The scientists also identified 182 proteins that differed in the blood three years before a cancer diagnosis took place.

In the second study, the scientists looked at genetic data from over 300,000 cancer cases to do a deep dive into which blood proteins were involved in cancer development and could be targeted by new treatments.

The scientists found 40 proteins in the blood that influenced someone’s risk of getting 9 different types of cancer. While altering these proteins may increase or decrease the chances of someone developing cancer, the scientists also found that in some cases this may lead to unintended side-effects.

However, the team stress that they will need to do further research to find out the exact role these proteins play in cancer development, which of the proteins are the most reliable ones to test for, what tests could be developed to detect the proteins in the clinic and which drugs could target these proteins.

Dr Keren Papier, Senior Nutritional Epidemiologist at Oxford Population Health and joint first author of the first study, said:

"To save more lives from cancer, we need to better understand what happens at the earliest stages of the disease. Data from thousands of people with cancer has revealed really exciting insights into how the proteins in our blood can affect our risk of cancer. Now we need to study these proteins in depth to see which ones could be reliably used for prevention.”

Dr Joshua Atkins, Senior Genomic Epidemiologist at Oxford Population Health and joint first author of the first study, said:

“The genes we are born with, and the proteins made from them, are hugely influential in how cancer starts and grows. Thanks to the thousands of people who gave blood samples to UK BioBank, we are building a much more comprehensive picture of how genes influence cancer development over many years.  

Dr Karl Smith-Byrne, Senior Molecular Epidemiologist at Oxford Population Health and a senior author of the first paper and first author of the second study, said:

 “We’ve predicted how the body might respond to drugs that target specific proteins, including many potential side-effects. Before any clinical trials take place, we have some early indications of which proteins we might avoid targeting because of unintended side-effects.    

“This research brings us closer to being able to prevent cancer with targeted drugs – once thought impossible but now much more attainable.”

Professor Ruth Travis, Senior Molecular Epidemiologist at Oxford Population Health and a senior author of both studies, said:

"To be able to prevent cancer, we need to understand the factors driving the earliest stages of its development. These studies are important because they provide many new clues about the causes and biology of multiple cancers, including insights into what’s happening years before a cancer is diagnosed.”

 “We now have technology that can look at thousands of proteins across thousands of cancer cases, identifying which proteins have a role in the development of specific cancers, and which might have effects that are common to multiple cancer types.

Executive Director of Research and Innovation at Cancer Research UK, Dr Iain Foulkes, said:

“Preventing cancer means looking out for the earliest warning signs of the disease. That means intensive, painstaking research to find the molecular signals we should pay closest attention to.

“Discoveries from this research are the crucial first step towards offering preventative therapies which is the ultimate route for giving people longer, better lives, free from the fear of cancer.”

The papers, titled “Identifying proteomic risk factors for cancer using prospective and exome analyses of 1,463 circulating proteins and risk of 19 cancers in the UK Biobank” and “Identifying therapeutic targets for cancer among 2,074 circulating proteins and risk of nine cancers.” were published today (15 th May) and 29 th April respectively in Nature Communications* .

ENDS  

For media enquiries to Cancer Research UK, contact Graeme Sneddon in the Cancer Research UK press office on 020 3469 5758 or, out of hours, on 020 3469 8301. 

For media enquiries to Oxford Population Health, please contact [email protected] .

Notes to Editor

* The first paper will be available from https://www.nature.com/articles/s41467-024-48017-6 when the embargo lifts. The second paper is available from https://www.nature.com/articles/s41467-024-46834-3 .

About Cancer Research UK: 

• Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research, influence and information. 
• Cancer Research UK’s pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.  
• Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last 50 years.  
• Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK wants to accelerate progress and see 3 in 4 people surviving their cancer by 2034. 
• Cancer Research UK supports research into the prevention and treatment of cancer through the work of over 4,000 scientists, doctors and nurses. 
• Together with its partners and supporters, Cancer Research UK is working towards a world where people can live longer, better lives, free from the fear of cancer. 

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit www.cancerresearchuk.org . Follow us on Twitter and Facebook  

Nature Communications

Method of Research

Observational study

Subject of Research

Human tissue samples

Article Title

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1,463 circulating proteins and risk of 19 cancers in the UK Biobank

Article Publication Date

15-May-2024

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• SAGE Open Med

New approaches and procedures for cancer treatment: Current perspectives

Dejene tolossa debela.

1 Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia

Seke GY Muzazu

2 Enteric Diseases and Vaccines Research Unit, Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka, Zambia

Kidist Digamo Heraro

3 Wachemo University, Hossana, Ethiopia

Maureen Tayamika Ndalama

Betelhiem woldemedhin mesele.

4 Kotebe Metropolitan University, Addis Ababa, Ethiopia

Dagimawi Chilot Haile

5 University of Gondar, Gondar, Ethiopia

Sophia Khalayi Kitui

Tsegahun manyazewal.

Cancer is a global health problem responsible for one in six deaths worldwide. Treating cancer has been a highly complex process. Conventional treatment approaches, such as surgery, chemotherapy, and radiotherapy, have been in use, while significant advances are being made in recent times, including stem cell therapy, targeted therapy, ablation therapy, nanoparticles, natural antioxidants, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-based therapy. Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Stem cell therapy has brought promising efficacy in regenerating and repairing diseased or damaged tissues by targeting both primary and metastatic cancer foci, and nanoparticles brought new diagnostic and therapeutic options. Targeted therapy possessed breakthrough potential inhibiting the growth and spread of specific cancer cells, causing less damage to healthy cells. Ablation therapy has emerged as a minimally invasive procedure that burns or freezes cancers without the need for open surgery. Natural antioxidants demonstrated potential tracking down free radicals and neutralizing their harmful effects thereby treating or preventing cancer. Several new technologies are currently under research in clinical trials, and some of them have already been approved. This review presented an update on recent advances and breakthroughs in cancer therapies.

Introduction

Cancer is a global health problem responsible for one in six deaths worldwide. In 2020, there were an estimated 19.3 million new cancer cases and about 10 million cancer deaths globally. Cancer is a very complicated sequence of disease conditions progressing gradually with a generalized loss of growth control. 1 – 3 There were only a few options of cancer treatment for patients for many decades which include surgery, radiation therapy, and chemotherapy as single treatments or in combination. 4 , 5 But recently, many pathways involved in cancer therapy progression and how they can be targeted has improved dramatically, with combinatorial strategies, involving multiple targeted therapies or “traditional” chemotherapeutics, such as the taxanes and platinum compounds, being found to have a synergistic effect. 6 New approaches, such as drugs, biological molecules, and immune-mediated therapies, are being used for treatment even if the excepted therapy level has not reached that resists the mortality rate and decreases the prolonged survival time for metastatic cancer.

The creation of a new revolution in neoplastic cancer or targeting drugs depends on the pathways and characteristics of different tumor entities. 7 Chemotherapy is considered the most effective and widely used modality in treating cancers as used alone or in combination with radiotherapy. Genotoxicity is how chemotherapy drugs target the tumor cells mainly producing reactive oxygen species that largely destroy tumor cells. 8 Hormonal treatments are also widely used for cancer malignancies and considered as cytostatic because it restricts tumor development by limiting the hormonal growth factors acting through the direction of hypothalamic–pituitary–gonadal axis (HPGA), hormone receptor blockage, and limiting of adrenal steroid synthesis. 9

In this narrative review, a general overview of the most advanced and novel cancer therapies was provided. In addition, also new strategies currently under investigation at the research stage that should overwhelm the drawbacks of standard therapies; different strategies to cancer diagnosis and therapy; and their current status in the clinical context, underlining their impact as innovative anti-cancer approaches.

Cancer treatment modalities

We can see cancer treatment modalities by dividing them into conventional (traditional) and advanced or novel or modern categories. In this era worldwide, over half of all ongoing medical treatment trials are focusing on cancer treatments. 7 Entities, such as the type of cancer, its site, and severity, guide to select treatment options and its progress. The most widely used traditional treatment methods are surgery, chemotherapy, and radiotherapy, while modern modalities include hormone therapy, anti-angiogenic, stem cell therapies, immunotherapy, and dendritic cell-based immunotherapy. 10

Conventional cancer therapies

The most recommended conventional cancer treatment strategies include surgical resection of the tumors followed by radiotherapy with x-rays and/or chemotherapy. 11 Of these modalities, surgery is most effective at an early stage of disease progression. Radiation therapy can damage healthy cells, organs, and tissues. Although chemotherapy has reduced morbidity and mortality, virtually all chemotherapeutic agents damage healthy cells, especially rapidly dividing and growing cells. 12 Drug resistance, a major problem with chemotherapy, is a phenomenon wherein cancer cells that initially were suppressed by an anti-cancer drug develop resistance to the drug. This is caused primarily by reduced drug uptake and increased drug efflux. 13 Limitations of conventional chemotherapeutic modality, such as dosage selection difficulty, lack of specificity, rapid drug metabolism, and mainly harmful side effects. 14

Advanced and innovative cancer therapies

Among the obstacles of cancer, drug resistance and its delivery systems are the most problem in cancer cure and decreasing signs and symptoms; but currently, there are many approved treatment approaches and drugs. The efficiency of conventional cancer is reduced due to tumor pathology and architectural abnormality of tumor tissue blood vessels. 15 The following are the advanced and innovative cancer therapy types with their benefits and challenges.

Stem cells therapy

Stem cells are undifferentiated cells present in the bone marrow (BM) with an ability to differentiate into any type of body cell. Stem cell therapeutic strategy is also one of the treatment options for cancer which are considered to be safe and effective. Application of stem cell is yet in the experimental clinical trial; for example, their use in the regeneration of other damaged tissue is being explored. Mesenchymal stem cells (MSCs) are currently being used in trials that are delivered from the BM, fat tissues, and connective tissues. 16

Pluripotent stem cells

Embryonic stem cells (ESCs) isolated from the uniform inner mass cells of the embryo possess the flexibility to administer rise to any or all kinds of cells except those within the placenta. In 2006, the invention of Yamanaka factors to induce pluripotent stem cells (iPSCs) from physical cells in a culture marked a breakthrough in cell biology. 17 Avoiding ethical issues from embryo destruction, iPSCs and ESCs have the same characteristics. Hematopoietic embryonic stem cells (hESCs) and iPSCs are currently used for the induction of effector T cells and natural killer (NK) cells, 18 and anti-tumor vaccine preparation. 19

Adult stem cells

Adult stem cells (ASCs) groups often used in tumor therapy include hematopoietic stem cells (HSCs), MSCs, and neural stem cells (NSCs). HSCs, located in BM, can form all mature blood cells in the body. Currently, only approved by the Food and Drug Administration (FDA) is the infusion of HSCs derived from cord blood to treat multiple myeloma and leukemia. 20 MSCs are found in many tissues and organs, playing important roles in tissue repair and regeneration into cells, such as osteocytes, adipocytes, and chondrocytes. MSCs have special biological characteristics and are used as complimentary with other approaches in treating tumors. 21 NSCs can self-renew and generate new neurons and glial cells and are used for treating both primary and metastatic breast and other tumors. 22

Cancer stem cells

Cancer stem cells (CSCs) are generated in normal stem cells or precursor/progenitor cells by the epigenetic mutations process. Their role in tumor treatment includes cancer growth, metastasis, and recurrence, so that it could give promise in the treatment of solid tumors. 23 Stem cells have several action mechanisms in treating the tumor. The homing process is one mechanism which is a rapid migration of HSCs into defined stem cell niches in BM after that the transplants undergo the engraftment process before giving rise to specialized blood cells. This mechanism is dependent on the active interaction between stem cell CXCR4 receptors and requires their interaction with endothelial cells through LFA-1, VLA-4/5, CD44, and the secretion of matrix degradable enzyme MMP-2/9. 22 The second mechanism is the tumor-tropic effect in which the migration of MSCs toward tumor microenvironment (TM) after attraction by CXCL16, SDF-1, CCL-25, and IL-6 secreted by tumor cells and differentiation of MSCs within the tumor cells which contributes to tumor stromal development. 24 Stem cells also act by paracrine factor secretion, including extracellular vesicles (EVs) and soluble materials, 25 and their differentiation capacity, such as transplanted HSCs, can give rise to all blood cell types. 26

Generally, cancer treatment using stem cell therapy by various strategies, including transplantation of HSC, 27 MSC infusion, 28 therapeutic carriers, 29 generation of immune effector cells, 30 and vaccine production. 31 The stem cell cancer therapy approach confronted the following side effects: (1) tumorigenesis, (2) adverse events in allogeneic HSC transplantation, (3) drug toxicity and drug resistance, (4) increased immune responses and autoimmunity, and (5) viral infection. 22 Despite several successes, there are challenges, such as therapeutic dose control, low cell targeting, and retention in tumor sites, that should be investigated and overcome in the future. In addition, existing results from stem cell technologies are highly encouraging for tumor treatment but it still needs further efforts to improve the safety and efficacy before they could enter clinical trials. Table 1 summarized the licensed list of stem cell therapies.

Licensed stem cell therapies.

AML: acute myelogenous leukemia; FDA: The US Food and Drug Administration; iPSC: induced pluripotent stem cell; MSC-INβ: mesenchymal stem cells with interferon beta.

Targeted drug therapy

Targeted cancer therapies are drugs or other substances which are sometimes interchangeably used as “molecularly targeted drugs,” “molecularly targeted therapies,” and “precision medicines.” Those drugs’ mechanism of action is by interfering with growth molecules which leads to blocking the growth and spreading of cancer. 34 Tumor initiation and progression are determined by the TM of an atypical tumor which comprises endothelial cells, pericytes, smooth muscle cells, fibroblasts, various inflammatory cells, dendritic cells, and CSCs. There are various signaling mechanisms and pathways that TM-forming cells dynamically interact with the cancerous cells which are suitable for sustaining a reasonably high cellular proliferation. So, it is the area of research interest using TM conditions to mediate effective targeting measures for cancer therapy. 35

Selectively treating cancer cells with conventional chemotherapy is difficult since it is similar to normal cells. So those problems are intervened by cellular mechanisms, such as cell cycle arrest, apoptosis induction, proliferation prevention, and interfering with metabolic reprogramming by targeted drug therapy agents. 36 Modifying TM and targeting TM for drug delivery for effective treatment are two strategies that can be used for the treatment of cancer. 37 Targeted therapy drugs do work in different ways from standard chemotherapy drugs treatment like attacking cancer cells while doing less damage to normal cells which is a programming that sets them apart from normal, healthy cells. 38

Using targeted therapy markedly increased the survival rate for some diseases, for example, from 17% to 24% in patients with advanced pancreatic cancer, the addition of erlotinib to standard chemotherapy. Imatinib has had a dramatic effect on chronic myeloid leukemia, and rituximab, sunitinib, and trastuzumab have revolutionized the treatment of renal cell carcinoma and breast cancer, respectively. 39

We can classify the targeted cell agents based on the mechanism of their work or their target site. Some enzymes serve as signals for cancer cells to grow. Some targeted therapies inhibit enzymes that are signals for cancer cells to grow. These drugs are called enzyme inhibitors. Blocking these cell signals can inhibit cancer from getting bigger and spreading. 40

Some targeted therapies are called apoptosis-inducing drugs because they are aimed right at the parts of the cell that control whether cells live or die. The examples are serine/threonine kinase, protein kinase B (PKB/Akt), which promotes cell survival, and inhibitors of this protein are in the preclinical phase. 41

These agents stop the tumors from making new blood vessels which helps cut off the tumors’ blood supply so that tumors cannot grow. In addition, they arrest tumor growth that involves by curtailing blood supply to the tumor by inhibiting angiogenic factors, such as vascular endothelial growth factor (VEGF) or its receptors. The study showed the survival of patients with advanced colorectal carcinoma extended by months after the use of Avastin (bevacizumab) in combination with 5-fluorouracil-based chemotherapy. 42

Types of target agents

Monoclonal antibodies.

Antibody drugs are man-made versions of immune system proteins administered intravenously to attack certain targets on cancer cells. They contain a more proportion of human components than murine components. 43 Their attack mechanisms of action are recruiting host immune functions to attack the target cell, binding to ligands or receptors thereby interrupting essential cancer cell processes, and carrying a lethal payload, such as radioisotope or toxin, to the target cell. 44 Gemtuzumab is an example of a CD-33-specific monoclonal antibody currently used for AML treatment by conjugating with calicheamicin. 45 In addition, ibritumomab tiuxetan is an anti-CD20, a 90Y metal isotope-based is developed in clinical therapy. 46 Delivery of active therapeutics, prodrug activation enzymes, and chemotherapy toxins are also another use of target agents of monoclonal antibodies. 47

Small molecule inhibitors

These are smaller protein in size (⩽500 Da) than monoclonal antibodies, so that they can simply translocate through plasma membranes and can be taken orally. Their main function is interrupting cellular processes by interfering with the intracellular signaling of tyrosine kinases which leads to the inhibition of tyrosine kinase signaling and initiates a molecular cascade that can lead to the inhibition of cell growth, proliferation, migration, and angiogenesis in malignant tissues. 48 Examples of small molecule inhibitors are gefitinib and erlotinib which inhibit epidermal growth factor receptor (EGFR) kinase and EGFR in non-small cell lung cancer (NSCLC) patients, respectively. There are also lapatinib and sorafenib which act on the inhibition of EGFR/Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2) for ERBB2-positive breast cancer and VEGFR kinase, in renal cancer. 49

Ablation cancer therapy

Ablation is a treatment technique that destroys tumors without removing them mostly indicated for small-size tumors of less than 3 cm and the surgical option is contraindicated. Ablation is also used with embolization for larger tumors. However, this technique might not be indicated for treating tumors near major blood vessels, the diaphragm, or major bile ducts due to destroying some of the normal tissue around the tumor. 50

Thermal ablation

This technique uses extreme hyperthermia or hypothermia to destruct tumor tissue concentrating on a focal zone in and around the tumor. Similar to surgery, thermal ablation removes the tumor and a 5–10 mm thick margin of seemingly normal tissue but the tissue is killed in situ and then absorbed by the body later. The procedure is similar to surgery using an open, laparoscopic, or endoscopic approach but is commonly applied using a percutaneous or non-invasive approach. The type of tumor, site, physician’s choice, and health status determine the approach. 51

Radiofrequency ablation (RFA), microwave ablation, high-intensity focused ultrasound, and cryoablation are currently being used in the clinical setting. Cryoablation uses a hypothermic modality to induce tissue damage by a freeze-thaw process against others. All these treatments operate on the principle of hyperthermia except cryoablation. Of all the ablation techniques, cryoablation demonstrated the highest potential to elicit a post-ablative immunogenic response. 52

Recent studies showed additional to tissue disruption RFA and cryoablation can modulate the immune system that they were applied as therapy on TM and in the systematic circulation. Evidence has shown that ablation procedures affect carcinogenesis due to its local inflammatory response leading to an immunogenic gene signature. 53

The advantage of this procedure over surgery is that it provides a minimal (e.g. percutaneously or laparoscopically) or non-invasive approach to cancer therapy and gets attention as an alternative to standard surgical therapies. 54

Cryoablation

Cryoablation is one of the ablation techniques which ablates the extensive tissue by freezing to lethal temperatures followed by liquid formation, causing extensive tissue. Benign and malignant primary tumors are mostly treated by this therapy. 55 James Arnott reported that the freezing temperatures can impair cancer cell viability after he attempted the usage of cold temperatures by salt and ice solutions for the generation of local numbness before surgical operations in the nineteenth century. He suggested cryoablation as an attractive therapeutic option and increased a patient’s survival. 56

Cryoablation techniques are based on the principle of the Joule–Thomson effect which was studied in the 1930s by many researchers and concluded using liquid CO 2 under high pressure, liquid air, and liquid oxygen to achieve the cooling effect and the subsequent formation of ice crystals so employed to treat lesions, warts, and keratosis. However, after 1950, Allington replaced liquid N 2 for the treatment of various skin lesion disorders. 47

RFA therapy

RFA is a minimally invasive procedure and an image-guided technique using hyperthermic (high-frequency electrical currents) conditions to destroy cancer cells. Imaging techniques, such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI), guide needle electrodes into a tumor cell. Generally, RFA is the most effective approach for treating small-size tumors of less than 3 cm in diameter. RFA can be used in combination with other conventional cancer treatment options. 57 After starting the use of deployable devices or multiple-electrode systems, RFA can treat medium tumors (up to 5 cm diameter). 58

Gene therapy

Gene therapy is the insertion of a normal copy of a defective gene in the genome to cure a specific disorder. The first application dates back to 1990 when a retroviral vector was exploited to deliver the adenosine deaminase (ADA) gene to T cells in patients with severe combined immunodeficiency (SCID). Approximately, about 2900 gene therapy clinical trials are currently ongoing, two-third of which are related to cancer. Strategies, such as expression of proapoptotic and chemosensitizing genes, expression of wild-type tumor suppressor genes, expression of genes able to solicit specific anti-tumor immune responses, and targeted silencing of oncogenes, are under evaluation for cancer gene therapy. 47

Thymidine kinase (TK) gene delivery is effective for the administration of prodrug ganciclovir to activate its expression and induce specific cytotoxicity. 59 The p53 tumor suppressor gene which is vectors carrying has been assessed for the clinical purpose very recently. ONYX-015 has been tested in NSCLC patients and gave a high response rate when given alone or combined with chemotherapy. 60 Gendicine, a recombinant adenovirus carrying wild-type p53-induced complete disease regression in head and neck squamous cell cancer had similar success when combined with radiotherapy. 61

Some challenges that have been faced with gene therapy are the selection of the right conditions and the choice of the best delivery mechanism. Identified drawbacks of this therapy are genome integration, limited efficacy in specific subsets of patients, and high chances of being neutralized by the immune system. Basic research and medical translation used RNA interference (RNAi) as an efficient technology that able to produce targeted gene silencing. 62 RNA-induced silencing complex (RISC) mediates the targeted gene silencing process by cleaving the messenger RNA (mRNA) and interference with protein synthesis. 63 A siRNAs can be designed to block desired targets, involving cell proliferation and metastatic invasion; hence, precise molecular mechanisms are a triggering factor for tumor formation. This method relies on siRNA-mediated gene silencing of anti-apoptotic proteins, transcription factors (i.e. c-myc gene), 64 , 65 or cancer mutated genes (i.e. K-RAS). 66

Advantages of siRNA-based drugs are safety, high efficacy, specificity, few side effects, and low costs of production. 67 However, occasionally, they can induce off-target effects or elicit innate immune responses, followed by specific inflammation. 68 Delivery methods currently under study are chemical modification (insertion of a phosphorothioate at 3’ end, introduction of a 2’ O-methyl group, and modification by 2,4-dinitrophenol) and lipid encapsulation, or conjugation with organic molecules (polymers, peptides, lipids, antibodies, small molecules) efficiently target to spontaneously cross cell membranes of naked siRNAs. 69 Interaction of cationic liposomes with negatively charged nucleic acids facilitates easy transfection by simple electrostatic interactions. 70 They can be constituted by 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and N-[1-(2,3-dioleoyloxy) propyl]-N, Ntrimethylammonium methyl sulfate (DOTMA). 71 Currently, a Phase I clinical trial is recruiting patients for evaluating the safety of Eph receptor A2 (EphA2) targeting 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) encapsulated siRNA (siRNA-EphA2- DOPC) in patients with advanced and recurrent cancer. 72 siRNAs can be concentrated in cationic polymers, such as chitosan, cyclodextrin, and polyethyleneimine (PEI). 73 CALAA-01 is one of the cyclodextrin polymers conjugated with human transferrin is being entered a Phase I clinical trial. PEI has been used as an anti-cancer by forming small cationic nanoparticles and loading with human epidermal growth factor receptor 2 (HER-2 receptor)-specific siRNA. 74 Phase II clinical trial has been started to evaluate Local Drug EluteR (siG12D LODER) directed to mutated Kirsten rat sarcoma (K-RAS) oncogene for the treatment of advanced pancreatic cancer. Conjugating to peptides, antibodies, and aptamers improves stability during circulation and enhances cellular uptake of siRNAs. 75 The introduction of nanocarriers has largely improved siRNAs stability, pharmacokinetics and biodistribution properties, and targeting specificity. Polyallylamine phosphate nanocarriers have been developed to release siRNAs in the cytoplasm after disassembly at low endosomal pH. 76

Dose correction and variabilities between individuals and different stages of disease are challenging issues on clinical translation of the siRNA-based approach. In the future, the needed research is on setting up the best-personalized therapy and toward controlled release to reach only specific targets on treating the tumor. Table 2 summarizes the gene therapy drugs based on their mechanism of action and induction.

Summary of gene therapy approaches.

Natural antioxidants

Day to day, the anatomy undergoes many exogenous insults, such as ultraviolet (UV) rays, pollution, and tobacco smoke, that end in the assembly of reactive species, particularly oxidants and free radicals, liable for the onset of many diseases, together with cancer. These molecules can even be made as a consequence of clinical administration of medication; however, they are additionally naturally created within our cells and tissues by mitochondria and peroxisomes, and from macrophages metabolism, throughout traditional physiological aerobic processes. 47

Oxidative stress and radical oxygen species can significantly change the regulation of transcription factors by damaging the DNA and other bio-macromolecule. 77

Vitamins, polyphenols, and plant-derived bioactive compounds are natural antioxidants used as preventive and therapeutic drugs against these molecules that damage the body due to their anti-inflammatory and antioxidant properties. 78 Studies added to cancer therapy after appreciating their anti-proliferative and proapoptotic properties. Compounds, such as vitamins, alkaloids, flavonoids, carotenoids, curcumin, berberine, quercetin, and others, are examples of natural antioxidants screened in vitro and in vivo. 79

Limited bioavailability and/ or toxicity is one of the challenges of natural drugs while their translation into clinical practice. 47 Curcumin has cytotoxic effects in different kinds of tumors, such as the brain, lung, leukemia, pancreatic, and hepatocellular carcinoma, 80 while sparing normal cells at effective therapeutic doses. The curcumin’s biological properties, treatment duration and efficient therapeutic doses are under study. 80 This day, about 27 clinical trials are done, while 40 are under study on curcumin.

Berberine is an alkaloid compound that has been studied to be effective against different cancers as a chemopreventive agent, modulating many signaling pathways. Different nanotechnological strategies have been developed to facilitate its delivery across cell membranes due to their poorly soluble in water. 81 Six clinical trials are under study and two have been completed.

Quercetin is another natural plant origin agent that is effective alone and also in combination with chemotherapeutic agents in treating many cancers, such as lung, prostate, liver, colon, and breast cancers. 82 Quercetin’s mechanism of action is by binding to cellular receptors and the interference of several signaling pathways. 83 Currently, six clinical trials are under study and seven studies have been completed.

Current clinical trials

In recent years, analysis of cancer medication has taken outstanding steps toward more practical, precise, and fewer invasive cancer treatments in the research of clinical trials ( Figure 1 ).

Current status of clinical trials of innovative and novel strategies of cancer therapy.

Currently, the most frequent entries focusing on cancer therapies in the database of clinical trials ( www.clinicalTrials.gov ) include the terminologies stem cell, targeted therapy, immunotherapy, and gene therapy because they are very promising and effective. Table 3 summarizes the potential advantages and disadvantages of the new treatment approaches.

Comparison of advantageous and disadvantageous of new cancer therapies.

MRI: magnetic resonance imaging.

Table 4 summarizes the approaches to advanced cancer therapies and their respective delivery systems with examples.

Advanced therapy approaches and delivery systems.

Current methods in oncology focus on the development of safe and efficient cancer nanomedicines. Targeted medical care helped rising the biodistribution of recent or already tested chemotherapeutical agents around the specific tissue to be treated; different methods, such as sequence medical care, siRNAs delivery, therapy, and inhibitor molecules, supply new potentialities to cancer patients. Gene therapy acts by direct in situ insertion of exogenous genes into benign tumors. Noticeably, stem cells can be used as regenerative medicine, therapeutic carriers, drug targeting, and generation of immune cells because of having unique biological actions on other cells. 22 On the opposite hand, thermal ablation and magnetic hyperthermia are promising alternatives to the growth surgical process. Finally, radionics and pathomics approaches facilitate the management of huge knowledge sets from cancer patients to enhance prognosis and outcomes. Much progress has been made, but many others are likely to come soon, producing more and more ad hoc personalized therapies. Further development and refinement of drug delivery systems are essential for improving therapeutic outcomes.

Acknowledgments

The authors thank the Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University, for the support rendered.

Author contributions: D.T.D. is a major contributor in writing the manuscript. All others reviewed and approved the manuscript.

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Two decades of studies suggest health benefits associated with plant-based diets

But researchers caution against broad diet recommendations until remaining knowledge gaps are filled.

Vegetarian and vegan diets are generally associated with better status on various medical factors linked to cardiovascular health and cancer risk, as well as lower risk of cardiovascular diseases, cancer, and death, according to a new review of 49 previously published papers. Angelo Capodici and colleagues present these findings in the open-access journal PLOS ONE on May 15, 2024.

Prior studies have linked certain diets with increased risk of cardiovascular disease and cancer. A diet that is poor in plant products and rich in meat, refined grains, sugar, and salt is associated with higher risk of death. Reducing consumption of animal-based products in favor of plant-based products has been suggested to lower the risk of cardiovascular disease and cancer. However, the overall benefits of such diets remain unclear.

To deepen understanding of the potential benefits of plant-based diets, Capodici and colleagues reviewed 48 papers published between January 2000 and June 2023 that themselves compiled evidence from multiple prior studies. Following an "umbrella" review approach, they extracted and analyzed data from the 48 papers on links between plant-based diets, cardiovascular health, and cancer risk.

Their analysis showed that, overall, vegetarian and vegan diets have a robust statistical association with better health status on a number of risk factors associated with cardiometabolic diseases, cancer, and mortality, such as blood pressure, management of blood sugar, and body mass index. Such diets are associated with reduced risk of ischemic heart disease, gastrointestinal and prostate cancer, and death from cardiovascular disease.

However, among pregnant women specifically, those with vegetarian diets faced no difference in their risk of gestational diabetes and hypertension compared to those on non-plant-based diets.

Overall, these findings suggest that plant-based diets are associated with significant health benefits. However, the researchers note, the statistical strength of this association is significantly limited by the many differences between past studies in terms of the specific diet regimens followed, patient demographics, study duration, and other factors. Moreover, some plant-based diets may introduce vitamin and mineral deficiencies for some people. Thus, the researchers caution against large-scale recommendation of plant-based diets until more research is completed.

The authors add: "Our study evaluates the different impacts of animal-free diets for cardiovascular health and cancer risk showing how a vegetarian diet can be beneficial to human health and be one of the effective preventive strategies for the two most impactful chronic diseases on human health in the 21st century."

• Diet and Weight Loss
• Diseases and Conditions
• Colon Cancer
• Endangered Plants
• Veterinary Medicine
• Colorectal cancer
• Ovarian cancer
• Polyphenol antioxidant
• Stomach cancer
• Cervical cancer
• HPV vaccine
• Breast cancer

Story Source:

Materials provided by PLOS . Note: Content may be edited for style and length.

Journal Reference :

• Angelo Capodici, Gabriele Mocciaro, Davide Gori, Matthew J. Landry, Alice Masini, Francesco Sanmarchi, Matteo Fiore, Angela Andrea Coa, Gisele Castagna, Christopher D. Gardner, Federica Guaraldi. Cardiovascular health and cancer risk associated with plant based diets: An umbrella review . PLOS ONE , 2024; 19 (5): e0300711 DOI: 10.1371/journal.pone.0300711

Cite This Page :

Explore More

• High-Efficiency Photonic Integrated Circuit
• Life Expectancy May Increase by 5 Years by 2050
• Toward a Successful Vaccine for HIV
• Highly Efficient Thermoelectric Materials
• Toward Human Brain Gene Therapy
• Whale Families Learn Each Other's Vocal Style
• AI Can Answer Complex Physics Questions
• Otters Use Tools to Survive a Changing World
• Monogamy in Mice: Newly Evolved Type of Cell
• Sustainable Electronics, Doped With Air

Trending Topics

Strange & offbeat.

Local Leukemia & Lymphoma Society holds annual fundraiser for blood cancer research

by Liz Bonis & Megan Burgasser, WKRC

CINCINNATI (WKRC) - The local chapter of the Leukemia and Lymphoma Society held its annual fundraiser to raise money for blood cancer research, and it’s giving patients new hope.

Those who treat blood cancers said progress is being made in research, but more research is needed to have more long-term survivors.

Maddie Havera was diagnosed with acute myeloid leukemia at just two years old. She’s 10 now and doing great.

“You gotta think on the positive,” said Havera.

At the Leukemia and Lymphoma Society event, she was one of several long-term blood cancer survivors.

Kate Schroder was diagnosed more than a decade ago.

“I discovered lymph nodes and lumps on my clavicle, but ignored them for a few weeks,” Schroder said. “I went and got scans. Everything changes when you get the diagnosis.”

Scott Carroll was diagnosed nearly three decades ago.

“In 1996, when my wife was seven months pregnant, I had a bump under my arm. And I went to my father-in-law who’s a doctor and he said don’t worry about it, but to let him know if it doesn't go away in a couple of weeks. And then three days later, a series of bumps came up my neck, literally, and I was diagnosed with Hodgkin’s lymphoma and underwent about nine months of treatment,” said Carroll.

That treatment has changed dramatically in the last few decades thanks in part to money raised for research at walks like Light the Night for Blood Cancer Survivors, and events where some of the top cancer specialists in the country come together to raise blood cancer awareness.

“They help patients get through their treatments by securing funds and helping give back to the community,” said Abbie Ochsner, Director of Infusion Services at St. Elizabeth Health.

Dr. Edward Faber described some of the advancements in cancer drugs.

“We had a few drugs, only two or three. Now, we have eight, 10, 12. A lot of the research that’s very exciting is how do we use what we now have, and how do we organize them together?” said Dr. Faber of the UC Cancer Center.

Dr. Akash Mukherjee described other advancements.

“We're trying to harness the immune system of the patient, genetically modify those products, and give it back to the patient,” said Dr. Mukherjee of Oncology Hematology Care.

Dr. Doug Flora mentioned advancements in precision medicine.

“Each patient’s cancer is individual. And finally, our cancer drugs are individualized, and we're targeting specific receptors, specific mutations, so that the right patient gets the right drugs at the right time,” said Dr. Flora of St. Elizabeth Health.

The goal now is to have more people like Havera, who overcome the odds.

“I want people to look at me and say, 'I can do this,'" said Havera.

To support the Leukemia and Lymphoma Society, families and businesses are needed to raise money and sponsor this year’s Light the Night walk. It’s Oct. 3. For more information, click here.